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ABSTRACT
The resistance of hypoxic cells in poorly vascularised solid tumours to radiotherapy 
and chemotherapy represents the major cause of the local failure of control of many 
cancers. One approach to increase the selectivity of drugs for these hypoxic cells is to 
exploit their lower oxygen concentration, by designing prodrugs which will be 
metabolically activated to inhibitors of poly(ADP-ribose)polymerase (PARP) in this 
environment. PARP uses NAD+ as the source of ADP-ribosyl units for poly(ADP- 
ribosyl)ation of histones near a site of damage in DNA. Thus, inhibition of this enzyme 
will impede DNA repair.
Synthesis and evaluation of heterocyclic analogues of the known inhibitors, 3-amino- 
benzamide and 5-substituted isoquinolinones have been undertaken. A large 
differential is required between the inhibitory activity of the nitro prodrug and the 
active amino metabolite. Series of nitro- and aminothiophenecarboxamides, 
thienopyridinones, thienopyrimidinones and imidazopyrimidinones have been 
synthesised for this approach.
6-Methyl- and 6-phenylthienopyridinones were found to be the most potent PARP 
inhibitors exhibiting >90% inhibition of PARP activity at 10 îM. Although, the 
differential between nitro and aminothiophenes was not sufficient for selectivity in 
hypoxic cells to be achieved, it has been demonstrated that a thiophene may replace a 
benzene ring without an adverse effect on inhibition, contrary to previous literature 
reports.
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1. THE CHALLENGE OF THE TREATMENT OF CANCER.
More than 300,000 people develop cancer each year in the UK, that is over 800 new 
cases every day. It is estimated that 1 in 3 people are at risk of developing cancer 
sometime during their life1. The statistics stress the need for new treatment 
modalities to tackle the ever increasing number of cases.
The treatment of cancer is a multidisciplinary problem involving the use of surgery, 
radiotherapy and chemotherapy as major modalities. However, each of these 
approaches has its limitations. Surgery, which is a major curative modality for 
localised disease, cannot alone cure neoplasms which are widely disseminated or 
which have invaded critical tissues or organs.
Radiation therapy continues to be an important treatment modality for many forms of 
human cancer. Although this therapeutic approach is effective for many cases, there 
are certain clinical situations in which the success of radiotherapy is limited either by 
an extremely radioresistant neoplasm or by a tumour invading a very sensitive normal 
tissue2. In these situations, it may be impossible to deliver a curative dose of 
radiation to a tumour without causing damage to surrounding normal tissue. 
Advances in instrumentation and technology have provided radiotherapists with the 
means of targeting X-rays more precisely and eliminating some of the normal tissue 
damage, but this is not sufficient to eliminate the problem totally3.
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Attempts to develop effective chemotherapeutic agents are restricted by a single 
major constraint, the similarity between cancer cells and normal cells. Cancer cells 
are normal cells that have been transformed and behave aberrantly. The most 
prominent aspect of the aberrant behaviour is rapid, uncontrolled growth and as a 
result cancerous cells quickly invade adjacent tissues and can metastasise to distant 
tissues4. The damaging side effects to the gastrointestinal tract or bone marrow limit 
the administration of chemotherapeutic agents5. Thus multi-agent therapies have 
been developed to circumvent normal tissue toxicity and to avoid the development of 
multidrug resistance.
Significant advances toward the cure of human cancer by chemotherapy have been 
achieved primarily with cytotoxic agents directed towards proliferating cells. Certain 
rapidly growing cancers such as childhood tumours and Hodgkin’s disease respond 
dramatically to chemotherapy2,6. Since the introduction of chemotherapy in the 
1960s, the last thirty years have seen a 60% increase in the survival rate for children 
with acute lymphoid leukaemia, the commonest childhood cancer .
However, these relatively responsive neoplasms represent only a small proportion of 
the malignancies that occur in man. Relatively slow growing solid tumours, such as 
carcinomas of the lung, colon and breast are reported1 to have the largest incidence of 
cancers registered each year. These also represent the major cause of mortality from 
cancer1. The national mortality statistics in 19921 show that for men, cancer of the 
lung is the most common cause of death, constituting 30% of all cancers, with cancer 
of the colon representing 7%. Breast cancer is responsible for 19% of all female
2
cancer deaths, with lung and colon cancers representing 16% and 9% respectively. 
Even when treated curable tumours may relapse and become resistant. Apart from 
breast cancer, which has a 62% five-year relative survival rate, the five-year survival 
rates1 for solid tumours are very low. Thus there is a great need for the development 
of reagents that are more selective for these solid tumours. Ideally, such reagents 
would be extremely toxic to malignant cells and completely harmless to normal cells.
Two main obstacles stand in the path of effective treatment of cancer:
1. the presence of hypoxic cells in solid tumours and their resistance to both radio- 
and chemotherapy8,9,
2. the repair of DNA damaged by radiation10.
The resistance of many tumour cells to the lethal effects of DNA damaging agents 
such as ionising radiation has been attributed to efficient cellular repair of the 
induced damage10. Studies have shown that the enzyme poly(ADP-ribose)polymerase 
(PARP) may regulate or directly participate in the repair of DNA damage11'14, 
therefore enabling the tumour to recur. Thus inhibition of this enzyme provides a 
potentially attractive target to increase the cytotoxic effects of radiotherapy or 
chemotherapy in cancer cells.
Deliberate exploitation of the physiological differences existing between tumour and 
normal tissues for therapeutic gain provides an elegant strategy for the selective 
attack of hypoxic cells. Therefore, the aim is to design pro-drugs which will be 
bioreductively activated to inhibitors of poly(ADP-ribose)-polymerase in hypoxic 
cells by exploiting the low oxygen concentration in this environment. The selectivity
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needed for treatment of hypoxic cells will be achieved without producing a 
concomitant increase in toxicity to normal tissue.
Chapter Two discusses the concept of hypoxia and its resistance to radiotherapy and 
chemotherapy. Chapter Three describes the principle of bioreduction and the existing 
chemical agents which exploit the metabolic characteristics of hypoxic cells. Chapter 
Four outlines the enzyme poly(ADP-ribose)polymerase and its inhibitors. Chapter 




The presence of hypoxic (oxygen deficient) cells in solid tumours has been 
recognised by radiation oncologists for more than a quarter of a century as the major 
factor in limiting the control of these tumours by radiation. Different proliferating 
patterns to normal cells and distribution of cytotoxic drugs within this hypoxic region 
can also influence the response to chemotherapy. Following treatment, surviving 
hypoxic cells may be reoxygenated and cause the tumour to regrow. Therefore, these 
hypoxic cells represent a major obstacle to the success of cancer therapy.
2.1 What is Hypoxia?
In 1955, Thomlinson and Gray15 analysed the distribution of blood vessels, viable 
tumour tissue and necrosis in pathologic specimens from human bronchogenic 
carcinomas in terms of the distribution and utilisation of oxygen within the tissue. 
They concluded that the viable cells on the edge of necrotic regions in these tumours 
were severely hypoxic.
Hypoxic cells develop essentially as a result of rapid tumour growth outpacing the 
available vascular supply, leading to a tumour fraction of oxygen deprived cells, as 
well as increased acidity and nutrient deprivation16'19. As the neoplastic masses 
enlarge, the blood supply decreases further (Figure 1). This phenomenon is believed
5
to be due in part to a slower growth rate for endothelial cells of blood vessels than for 
malignant cells. Such a differential results in an inability to maintain an adequate 
vascular supply20.
It has also been reported that the tumour endothelium proliferates 20 to 2 000 times 
faster than any normal tissue endothelium19. The end-result of this oxygen deficiency 
is chronic and acute hypoxia in the neoplastic cell population. Protracted oxygen 
starvation, particularly within cells developing more than 90-140 pm 19 from the 
nearest blood supply, ultimately leads to cell death and the focal necrosis observed in 
most solid tumours. However, hypoxic cells in moderately adverse conditions can 
remain viable in this environment and, following treatment with radiation, the 








♦Sensitive to radiotherapy & 
chemotherapy
Hypoxic region 
♦Low oxygen concentration 
♦Not proliferating 
♦ Relatively insensitive to 
radiotherapy & chemotherapy
Necrotic region
•Dead cells and cell debris
Figure 1 Diagrammatic representation of a solid tumour.
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Evidence for the existence of hypoxic cells in solid tumours has been obtained using 
autochthonous (i.e. at the site of formation) and transplanted neoplasms21’22. Micro- 
electrodes23,24 have shown a range of median oxygen concentrations from 1.3 to 3.9% 
(oxygen partial pressure of 10 to 30 Torr) in human tumours compared to 3.1 to 8.7% 
(24 to 66 Torr) for normal tissue18. It appears that the vast majority of solid tumours 
contain hypoxic cells, which frequently constitute 10-20% and occasionally over half, 
of the total viable tumour cell population21,22. Moreover, significant numbers of 
hypoxic cells have been found in tumours as small as 1 mm in diameter21,22. 
Therefore, these hypoxic cells are of major importance in determining the outcome of 
treatment of tumours.
2.2 Methods for Determining the Proportion of Hypoxic Cells in Solid 
Tumours.
To exploit the physiological characteristics of hypoxic cells in the treatment of solid 
tumours effectively, methods for accurately predicting the proportion of these cells 
would be a distinct advantage. Thus hypoxia-selective drugs would produce more 
reliable results in clinical trials and would only be administered to patients with 
tumours containing a significant proportion of hypoxic cells.
Direct evidence of the existence of hypoxic regions has been achieved through 
measurements of the oxygen concentration in human tumours using needle 
microelectrodes25. Vaupel et al25 have used a computer-controlled electrode system 
to measure the oxygen partial pressure within individual neoplasms. However, these 
measurements are only convenient for accessible tumours and, owing to the technical
7
limitations of the methodology, these experiments only measure the mean oxygen 
concentration on a macroscopic scale and cannot distinguish between viable and 
necrotic regions within tumours2.
Numerous methods have been described for the detection of hypoxic cells using the 
addition of both stable and radioactive isotopes attached to labelled 2-nitro-
^  A i J  1 J  A M
imidazoles. Studies have been undertaken with various labels such as H, , C, , 
75Br, 76Br, 77Br,28 and 19F,29. These compounds, such as misonidazole, are known to 
be reduced under hypoxic conditions to metabolites which bind to intracellular 
molecules in hypoxic regions30. Thus an isotopic label incorporated in these 
compounds will become bound in hypoxic cells after bioreduction and act as a 
marker for hypoxic cells27,31’32. Clinical studies with radiolabelled misonidazole have 
been used to demonstrate the presence of hypoxia in small cell lung cancer and 
melanoma26. However, detection of hypoxia via this route requires the administration 
of substantial amounts of radioactivity to the whole body, followed by a biopsy and 
autoradiography.
Related compounds with clinical potential have been reported. Attachment of 
fluorophores to nitroimidazoles have been used as markers for hypoxic cells33 in a 
similar mechanism to that described previously. For example, linkage of the 
theophylline to 2-nitroimidazole, followed by detection through immunochemical 
procedures has been reported33 as a rapid, convenient assay for the measurement of 
the hypoxia fraction ex vivo.
8
Considerable interest remains in the use of non-invasive approaches of determining 
oxygen status. Recently nitroimidazoles radiolabelled with iodine-123 have been 
developed for the detection of tumour hypoxia using conventional nuclear medicine 
techniques. Iodoazomycin arabinoside (123I-IAZA) has been used in clinical studies 
for this purpose34,35 and is detected using single photon emission computed 
tomography (SPECT). The advantage of this non-invasive procedure is that it could 
be administered repeatedly to cancer patients to monitor treatment as a routine 
imaging procedure for outpatients.
2 3  Resistance of Tumour Cells to Radiation and Chemotherapy.
Experimental evidence that hypoxia may have a profound impact on malignant 
progression and on responsiveness to therapy is growing. It has been shown 
repeatedly that the hypoxic cells in solid tumours limit the responses of these 
neoplasms to treatment with ionizing radiation delivered as a single fraction8,36'38, 
and that hypoxic cells surviving large doses of radiation are capable of becoming 
reoxygenated and re-establishing the tumour in situ*’9.
To comprehend the role of hypoxic cells in this resistance, it is necessary to 
understand the processes taking place during irradiation of a tumour. When cells are 
irradiated with X-rays or y-rays, only a small fraction of the lethal damage results 
from direct interaction between the radiation photons and DNA. Most damage is 
produced indirectly. Absorption and scattering of the photons by atoms results in the 
ejection of high-energy electrons. As these fast-moving electrons traverse through the 





Figure 2 The role of oxygen in radiation induced DNA damage.
These short lived species can interact with each other resulting in undamaged DNA. 
However, interaction of these species with nearby molecules can produce 
superoxides or other free radicals which can undergo chemical reactions with DNA 
causing damage. When oxygen molecules are present at the time of irradiation, these 
extremely electron-affinic molecules participate in the chemical reactions, and 
therefore increase the DNA damage produced per quantum of radiation17. Thus, the 
effect of radiation in hypoxic cells is significantly reduced, and as a result the cell 
survival curve for hypoxic cells is three times that of cells irradiated under aerobic 
conditions (Figure 3).
Radiosensitisation occurs at relatively low concentrations of oxygen. A concentration 
of only 0.25% oxygen moves the dose-response curve half-way towards the fully 
aerated condition . Electron-affinic radiosensitisers have been developed to substitute 
for the required electron affinity of molecular oxygen and cause DNA damage by a
10
mechanism similar to that of oxygen3. The development of these compounds will be 
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Figure 3 A graph to show the survival of tumour cells irradiated in vitro under 
normal aeration and severe hypoxia (Reproduced from ref2).
Hypoxia may also limit the efficacy of chemotherapy. Many chemotherapeutic agents 
used in the 1980s were targeted towards those cells which were actively transversing 
the cell cycle. However, this approach is ineffective for hypoxic cells. This is due to 
the fact that the proliferation pattern of these cells differ from those of their well- 
oxygenated counterparts. Many hypoxic cells are non-cycling or cycle with prolonged 
or abnormal cell cycle times, but are capable of commencing proliferation at a later 
time and causing the tumour to regrow2,39,40.
Pharmacokinetic considerations may also be responsible for the resistance of hypoxic 
cells to chemotherapeutic agents. These cells are relatively inaccessible to cytotoxic
11
drugs, which are required to diffuse in the necessary concentrations to the hypoxic 
region through layers of growing, actively metabolising cells, which may inactivate 
the drug2-39’40.
Apoptosis is a genetically encoded programme of cell death and may be an important 
safeguard against tumour growth41. Recently, it has been reported42 that hypoxia 
induces apoptosis in oncogenically transformed cells modulated by p53, the tumour 
suppressor gene, and that a strong correlation exists between highly apoptotic regions 
and those hypoxic regions in transplanted tumours expressing p53. However it was 
also observed that hypoxia can select for cells with decreased apoptotic potential and 
in particular for cells acquiring mutations in p53. These results may also assist in 
explaining the resistance of hypoxic cells in solid tumours to cancer therapy.
Efficient cellular repair of damage induced by radiation has also been associated with 
the radioresistance of tumour cells10, and this factor will be discussed further in 
Chapter Four.
Thus a new approach is required to develop chemical agents which will exploit the 
metabolic characteristics unique to hypoxic cells, eventually enabling the selective 
destruction of these therapeutically resistant cells. Hypoxia directed drugs would 
have a limited use as single agents as they would not destroy normally oxygenated 
tumour cells. However regimens that incorporate use of such drugs in conjunction 




3. STRATEGIES FOR TARGETING HYPOXIC TISSUE IN SOLID
TUMOURS.
Over the last twenty years, the thinking towards hypoxia and the resistance of 
hypoxic tumour tissue to radiation and chemotherapy has changed. The oxygen 
deficiency of solid tumours is no longer regarded as a limiting factor in treatment but 
as a site of vulnerability that is amenable to therapeutic attack. Through this 
approach, various different strategies for targeting hypoxic tissue in solid tumours 
have been developed. The design, mechanism of action and limitations of these 
compounds will be discussed.
3.1 Radiosensitisers.
Radiosensitisers have been utilised as a method for overcoming the tumour 
radioresistance resulting from hypoxic cells. The principal approach is to substitute 
for the required electron-affinity of molecular oxygen by administering drugs 
containing electron-affinic nitroheterocycles that are able to penetrate into tumours 
and cause DNA damage by a mechanism similar to that of oxygen itself3. These 
radiosensitisers must be present in the cells at the time of irradiation for maximum 
sensitising efficiency.
Two independent groups43,44 reported the radiosensitising ability of
4-nitroacetophenone (1) in hypoxic mammalian cells in vitro with no radiobiological
13
effect on normal cells. Observations45,46 that a correlation existed between the more 
powerful oxidising agents and radiosensitising efficiency provided quantitative 
evidence that the one-electron reduction is the basis of radiosensitisation. 
Radiosensitisation occurs via a rapid process involving the activation of the parent 
compound by interaction with electrons or free radical centres to form nitro radical 
anions5,16. The one-electron reduction potential for oxygen is -155 mV47, thus these 
compounds do not affect aerobic cells which are already fully radiosensitive.
j o 1
(1)
A large number of compounds have since been found to act as radiosensitisers in 
hypoxic cells but attention has focused on the nitroimidazoles, as their biological 
effectiveness is less compromised by aerobic cytotoxicity. Metronidazole (2) has 
been shown to sensitise hypoxic cells selectively to damage by radiation48. However, 
the maximum tolerated dose was found to limit the concentration of drug achievable 
in the tumour and thus its potential as a radiosensitiser47.
Misonidazole (3) was found to be a superior radiosensitiser to Metronidazole both in 
vitro and in vivo49. This is in accord with the higher electron-affinity (ES -389 mV) 
of this compound compared to metronidazole (Table 1). Unfortunately, the results of 
the clinical trials of misonidazole were disappointing. The clinical use of this
N 02
Me
r = \  OH
'OH
OMe
Metronidazole (2) Misonidazole (3)
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compound was limited due to its neurological toxicity50 with cumulative neurotoxic 
properties limiting the total dose of drug that can be administered to approximately 
12 g m"2 over six weeks47. Studies have established that these neurotoxic properties 
of this compound and other nitroimidazole analogues are related to the lipophilicity 
of the compounds51.







Table 1 One-electron redox potentials at pH 7 (ES) for oxygen and 
nitroaromatics (from ref47).
Studies of analogues of misonidazole have led to the clinical development of 
etanidazole (4), a compound with a similar redox potential but with reduced 
lipophilicity. More polar compounds are less able to penetrate neural tissue owing to 
the lipid nature of the blood brain barrier. This compound exhibited comparable 
sensitising efficiency to misonidazole but was substantially less neurotoxic16,52. 
Another analogue, pimonidazole (5), was similarly found to be superior to 
misonidazole and displayed improved tumour penetration which has been attributed 
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Extensive studies have established that compounds should generally possess one-
3.2 Bioreductive Activation.
The concept of bioreductive activation was developed by Sartorelli in 197255. It was 
postulated that hypoxic cells, remote from the vascular supply, may exist in an 
environment that is more conducive to metabolic reduction than their oxygenated 
counterparts. Therefore, it was anticipated that this characteristic of hypoxic cells 
could be exploited by developing chemotherapeutic agents which were 
bioreductively activated to produce cytotoxins55. Two main classes of bioreductively 
activated agents have been developed - nitroheterocycles and quinones.
Nitroheterocycles. Radiobiologists first examined nitroheterocycles for their ability 
to sensitise hypoxic cells to the cytotoxic effects of radiation. Relatively early on in 
these studies, it was shown that these compounds were selectively toxic to hypoxic 
cells compared to aerobic cells. This was first observed with the 5-nitroimidazole,
electron redox potentials (E^) in the range -250 to -400 mV for radiosensitiSing 
efficiency without dose-limiting cytotoxicity towards normal or oxic tissues54.
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metronidazole39,56 (2) and has subsequently been demonstrated with misonidazole57* 
59 (3) and with other nitroimidazoles.
As for the radiosensitisers, the ability of these compounds to act as ‘hypoxic 
cytotoxins’ was shown to be dependent on their one-electron reduction potentials16,60. 
Compounds with higher (less negative) redox potential are more toxic under both 
hypoxic and aerobic conditions. However the mechanisms of these two processes are 
quite different. This can be illustrated by considering misonidazole (3), the first 
hypoxic cell sensitiser to be extensively investigated clinically. As described 
previously, radiosensitisation occurs via a very fast process to form nitro radical 
anions5,16. In contrast, hypoxic cell cytotoxicity only occurs after substantial contact 
time in which the nitro group is reduced to its corresponding amine by cellular 
enzymes, via nitro radical anion, nitroso and hydroxylamine intermediates16,58 
(Figure 4). This pathway was confirmed by the discovery of relatively large amounts 
of N-hydroxy and amine metabolites in hypoxic cells56,58,61.
In aerobic cells, cytotoxicity is reversed by molecular oxygen leading to the
ft)formation of the parent compound and a superoxide radical ’ . The toxicity 
observed in aerobic cells is dependent on the production of this radical species. 
However, the relatively low levels of aerobic toxicity would suggest that the active 
oxygen species is relatively non-toxic compared to the products from the reduction 
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Figure 4 The activation of misonidazole (3) (reproduced from ref2).
The dependence of both radiosensitisation and hypoxic cytotoxicity on the 
one-electron reduction potential of the nitro group generates fundamental problems in 
their design. Raising the reduction potential of the nitroimidazole can increase the 
radiosensitising potential but also decreases the selectivity as the compound is more 
toxic to both oxic and hypoxic cells. Thus one-electron potentials in the range 
-250 mV to -400 mV54 are generally required for effective radiosensitisation, 
bioreductive metabolism in hypoxic cells and efficient back-oxidation by molecular
18
oxygen of the transient intermediate, allowing selective cytotoxicity in hypoxic cells 
to be achieved.
The cytotoxic action of these nitroimidazoles has been based on the reduced species 
causing DNA damage60,64. However, there has been much debate concerning which 
metabolite is responsible for this damage. Some groups have reported evidence that 
the hydroxylamine metabolite is responsible63,65, while others have argued that it is 
the protonated nitro radical anion60 or the nitroso species30. Many groups seem to 
have disregarded the one-electron nitro radical anion on inconclusive grounds in 
favour of the other intermediates30,63, but due to the obvious difficulties in measuring 
its toxicity directly, no firm conclusions can be made.
Both the bioreductively activated cytotoxicity and radiosensitising efficiency of these 
nitroimidazoles can be greatly improved by incorporating monofiinctional alkylating 
groups into the molecule. The nitroimidazole, RSU 1069 (6) (ES -398 mV47) was the 
first compound of this type to be developed and bears an aziridine in its side 
chain66,67. Studies have shown that this compound can be up to ten-fold more 
efficient than misonidazole, both as a radiosensitiser and as a hypoxia-selective 
cytotoxin16. This potentiation has been attributed to a switch from a monofunctional 
alkylating agent under aerobic conditions, binding to DNA via the action of the 
aziridine group, to a bifimctional alkylating species following reduction of the nitro 
group68. However, preliminary clinical investigations showed that this compound 
caused dose-limiting gastrointestinal toxicity69. This prompted a search for equally
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potent, but less toxic analogues. However, it was found that substitution on the 
aziridine decreased the differential between hypoxic and aerobic cell toxicity70.
In order to overcome this aerobic toxicity, a less toxic pro-drug of RSU 1069, RB 
6145 (7) was prepared by hydrogen bromide ring opening of the aziridine, which has 
considerable promise as a radiosensitiser with enhanced therapeutic ratio71.
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Tirapazamine (SR 4233) (8) is the lead compound72, currently undergoing clinical 
trials, in a new class of bioreductive compounds - the benzotriazine di-N-oxides. It 
exhibited potent selective hypoxic cell cytotoxicity leading to extensive cell death in 
the presence of radiation73 and of some chemotherapeutic agents74. Since the 
compound was active when administered either prior to or after radiation, it was 
thought that direct killing of hypoxic cells rather than radiosensitisation was 





Tirapazamine (SR 4233) (8)
20
The metabolic activation of tirapazamine involves one-electron reduction to a free 
radical, which, under hypoxic conditions, can abstract a hydrogen atom from DNA 
and produce a DNA strand-break72. As with the other bioreductive agents described, 
back-oxidation can occur in aerobic cells to generate the parent compound and 
concomitant production of the superoxide, thus reducing the number of toxic 
reactions that can occur72. Preclinical studies have suggested that this compound has 
considerable potential in combination with fractionated radiation73. This strategy has 
been claimed to be superior to hypoxic radiosensitisers at clinically relevant doses75.
Quinones. Mitomycin C has been shown to act as a bifunctional alkylating agent2,76. 
Studies had shown that reduction of the quinone ring, possibly by an 
NADPH-dependent reductase system, was essential for activity77,78. A positive 
correlation has been observed between the reduction potential of a series of 
mitomycin analogues and their antineoplastic activity79.
Lin and Sartorelli proposed that this activity was due to the production of highly 
reactive quinone methides upon reduction of the quinone ring55. To investigate this 
hypothesis, they designed and synthesised a series of benzo- and naphtho-quinones 
with side-chains potentially capable of alkylation following reduction of the 
ring55,76,80-82. Evidence was obtained to prove formation of the methide intermediate, 
substantiating the proposed bioreductive activation mechanism of these 
compounds83. Thus enzymatic reduction of the quinone ring (9) occurs to form the 
corresponding dihydroquinone (10) which eliminates to form the o-quinone methide 







The structure-activity studies indicated that essentially all compounds possessing a 
quinone ring with potential alkylating ability exhibited neoplastic activity. Studies 
also revealed that compounds with a lower (more negative) redox potential possess 
more potent antitumour activity85. Mitomycin C (12) displayed the lowest redox 
potential and is the most efficacious of the quinone bioreductive alkylating agents 
known2.
Despite the selective activation of mitomycin C to an alkylating agent under hypoxic 
conditions, clinical use of this agent is limited by its severe toxicity to normal 
tissues2. Hypoxic toxicity occurs through the formation of a fully reduced 
bifunctional alkylating agent to cross-link DNA following one or two electron 
reduction. However, in the presence of oxygen, the semiquinone radical formed from 
one-electron reduction can be reoxidised to generate the parent compound (12) and 
superoxide86. This serves as a protective device to decrease exposure of the aerobic 











Figure 5 Potential pathways for the bioactivation of mitomycin C to an 
alkylating agent, (reproduced from ref86)
In search of agents with a greater differential toxicity to hypoxic cells, porfiromycin 
(13) an N-methylated analogue of mitomycin C, was synthesised. This compound has 
similar hypoxic cytotoxicity but was less toxic than mitomycin C to aerobic cells and 
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More recently, E09 (14), a bioreductive alkylating indoloquinone has been 
developed. This compound is metabolised more efficiently than mitomycin C by the 
two-electron reducing enzyme DT-diaphorase (sometimes termed NAD(P)H:quinone 
oxidoreductase)88, whilst also displaying a large differential in activity in oxic and 
hypoxic cells at low levels of the enzyme89. However, recent studies have shown that 
one-electron reducing enzymes such as cytochrome P450 reductase can also activate 
E0989. DNA crosslinking has been observed in intact cells and is believed to be the 
molecular mode of action of E09 after reduction88.
Synergistic effects of these bioreductive drugs and radiosensitisers in combination 
with radiation and chemotherapy have been widely reported52,72’87,90'92. Radiation will 
preferentially kill the aerobic cells in tumours, while administration of a 
bioreductively activated cytotoxin following radiation will eliminate the hypoxic 
cells and thus improve the tumour response to cancer therapy. Clinical trials will 
provide information regarding the structure-activity relationships of these compounds 
which will further assist in the design and development of new potent radiosensitisers 
and bioreductive drugs for cancer treatment.
3.3 Recent Approaches to the Development of Bioreductively Activated 
Cytotoxins.
The main limitation in the clinical application of the bioreductively activated 
cytotoxins described above has been the low differential between the toxicity of these 
agents to aerobic and hypoxic cells. Thus new methods must be designed which can
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overcome this aerobic toxicity and target these agents more effectively to hypoxic 
cells.
Recent strategies have extended the original concept of bioreductive activation to 
designing prodrugs which will release a diffusible cytotoxin upon reductive 
activation (‘the bystander effect’). The prodrug must have minimal toxicity, be stable 
to metabolism in aerobic conditions and be suitably activated to release a cytotoxin in 
hypoxic conditions93. Prodrugs can also be used to overcome pharmaceutical and 
solubility problems and therefore not compromise the activity of the cytotoxin. 
Various activation systems have been studied to this end.
A. Activation by endogenous enzymes. Endogenous reducing enzymes are used for 
activation of nitroaromatic94*97, transition metal complexes98,99 and some quinone
1 nosystems . Reduction of a prepositioned group can lead to activation by 
electron-release through an aromatic system. Generally a reduction potential in the 
range -450 mV to -300 mV is necessary for this metabolism to occur93.
Examples of this type of activation are the N-(4-nitroethyl) mustards94-97 (15). The 
reactivity and cytotoxicity of these compounds are controlled by the electron-density 
on the nitrogen atom. The nitrogen mustard is activated by reduction of the electron- 
withdrawing nitro group94. Although significant differential toxicity has been 
observed between the prodrug and reduced compound95, these compounds are limited 
due to their modest cytotoxicities and the inherently low reduction potential of the
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system . The use of multiple electron-withdrawing groups or heterocyclic systems 









Similarly, reduction of metal-centred complexes, such as Co(III), to the more labile 
Co(II) (16) releases free nitrogen mustard98,99 and reduction of quinones, such as 
DZQ (17), can activate attached aziridine groups through electron-release93.
B. Activation by tumour-specific enzymes. The potential use and selectivity of 
bioreductively activated cytotoxins will be enhanced by identifying the presence of 
suitable tumour specific enzymes for reductive bioactivation of these drugs. Thus, 
enzyme profiling can identify patients who are most likely to respond to particular 
treatments89. This approach is particularly applicable to DT-diaphorase for two 
reasons. First, the activities of DT-diaphorase have been reported to be generally 
higher in tumour cells when compared with normal cells of the same origin101 and 
secondly, this enzyme is important in the two-electron reductive activation of 
quinones, such as mitomycin C102 (12) and E09103 (14). Although little correlation 
has been observed between the activity of mitomycin C and DT-diaphorase activity, 
more success has been achieved with E09104. Under aerobic conditions, the response
to E09 was greatest in tumour cells expressing enzyme activities105, whereas with 
low levels of DT-diaphorase, a large differential in favour of activity in hypoxic cells 
was observed103. This suggests that one-electron reductases may predominate under 
hypoxic conditions89. Compounds such as E09 can be used to target aerobic tumour 
cells rich in DT-diaphorase, but also to overcome radio- and chemoresistant hypoxic 
cells in solid tumours with low DT-diaphorase levels.
C. Activation by introduced enzymes. Antibodies that recognise tumour selective 
antigens can be conjugated to an enzyme, which can convert prodrugs to active 
cytotoxins. This is referred to as ADEPT (antibody-directed enzyme- prodrug 
therapy)106. Work has been undertaken with various enzymes107*109, including 
bacterial nitroreductases, where activation was achieved either through reduction of a 
nitro group as in the case of the difunctional alkylating agent CB 1954110,111 (18), or 
through hydrolysis of a 4-nitrophenyl carbamate moiety such as in the nitrogen 
mustard (19)112. Differential cytotoxicity has been demonstrated between hypoxic 
and aerobic cells using this approach109,110,112. Since no endogenous enzymes are 
used for activation, selective drug targeting to tumourous cells can be achieved.
N
CB 1954 (18) (19)
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An analogous approach is gene-directed enzyme-prodrug therapy (GDEPT)113. 
Similar strategies to ADEPT can be used to exploit tumour hypoxia, such as the 
selective delivery of genes encoding prodrugs to kill hypoxic cells114 or more 
indirectly, the use of genes encoding a reductase to improve the therapeutic potential 
of bioreductive drugs113,115.
D. Activation by radiation. Use of ionising radiation to activate prodrugs through the 
reducing species from the radiolysis of water has also been reported116. Radiolytic 
activation is again a one-electron process and selectivity is achieved by restricting 
activation to the radiation field93. However, this approach has been limited by the 
need for very potent agents to be reduced by the low reducing capability of clinically 
feasible doses of radiation93,116.
Significant progress has been made in exploiting the physiological differences 
between hypoxic and normal tissue to target hypoxic cells more efficiently since the 
concept of bioreductive activation was first discovered in the 1970s. Furthermore, 
current research into methods for measuring tumour oxygenation and enzyme 
activities will enhance the role that bioreductively activated cytotoxins can play in 
modem multi-modality cancer therapy.
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CHAPTER FOUR
4. POLY(ADP-RIBOSE)POLYMERASE AND ITS INHIBITORS.
4.1 Introduction.
Poly(ADP-ribose)polymerase (PARP) is a chromatin-bound enzyme, abundant in all 
cell nuclei, that catalyses the transfer of an ADP-ribose moiety from its substrate, 
NAD+, to an acceptor protein on activation by DNA strand breaks117,118. Whilst the 
exact biological role of PARP is not fully understood, the activity of this enzyme has 
been shown to be elevated in the presence of DNA damage, suggesting that it may 
regulate or directly participate in the repair of DNA damage11'14. It is also known that 
rapidly proliferating cells in tumours and other sites have higher levels of the enzyme 
activity than normal or resting cells119.
Since the discovery of the synthesis of poly(ADP-ribose) in animal tissue in 1966120, 
a vast amount of research has been undertaken to investigate the structure, role and 
function of PARP, particularly in relation to DNA repair. Knowledge of its 
mechanism of action is an essential step towards our understanding of the role of 
PARP in response to DNA damage and would also assist in the design of potential 
inhibitors of this enzyme to potentiate the cytotoxic effects of radiation and 
chemotherapy in cancer treatment.
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4.1 Mono(ADP-ribosyl)ation.
ADP-ribosylation may occur with a single ADP-ribose moiety, termed mono(ADP- 
ribosyl)ation, or with a longer chain (linear or branched) of covalently linked ADP- 
ribose residues, termed poly(ADP-ribosyl)ation121,122. These two protein 
modifications do not solely differ on the length of the ribosyl chain but also in the 
chemical nature of the ADP-ribosyl protein bond. All mono(ADP-ribosyl)ations 
attach the ADP-ribose unit to a nitrogen atom producing N-glycosides, whereas, in 
poly(ADP-ribosyl)ation, the process begins with mono(ADP-ribosyl)ations on 
carboxyl groups to form O-glycosides. Other differences include the character of the 
enzyme (many microbial toxins vs eukaryotic enzymes), and the site of reaction 
(cytoplasm and cell membrane vs nucleus)121.
Arginine, diphthamide, cysteine, histidine and asparagine residues have been 
identified as acceptors for amino-acid specific mono ADP-ribosyltransferases. 
Enzymes such as diphtheria toxin and Pseudomonas aeruginosa exotoxin have been 
reported123,124 to catalyse mono(ADP-ribosyl)ation of elongation factor 2, which is a 
protein component required for polypeptide chain elongation on ribosomes in 
eukayrotic cells. ADP-ribosylation inhibits protein synthesis, ultimately causing cell 
death. These enzymes both use diphthamide as the acceptor amino-acid, while 
cholera toxin uses arginine and has been shown to be associated with NAD+ 
glycohydrolase activity125.
Comparative studies of the effects of inhibitors of PARP and mono(ADP-ribosyl) 
transferase revealed that the most potent PARP inhibitors are orders of magnitude
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less inhibitory towards mono(ADP-ribosyl)ation126. For example, the IC50 value for
5-aminoisoquinolinone was reported to be 0.24 |iM127 against PARP, but 
IC50 > 1000 JJ.M128 against diphtheria toxin. It therefore has been postulated that 
selectivity for the target enzyme PARP could be achieved.
4.2 Poly(ADP-ribosyI)ation.
At a site of DNA strand breakage, PARP catalyses the cleavage of the ribose- 
nicotinamide bond in NAD+ and transfers the ribose moiety to a nucleophilic centre 
on a protein acceptor, invariably a carboxylate residue117. This nucleophile can be on 
a target protein, such as a histone (heteromodification), or on the enzyme itself 
resulting in automodification118. Cleavage of the pyridinium-N-glycoside bond in 
NAD+ results in formation of an oxonium ion (20) in the ribose ring as illustrated in 
Figure 6. Inhibition of this process by the NAD+ analogue, carbanicotinamide 
adenine dinucleotide, where replacement of the ribose oxygen with a methylene 
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Figure 6 Proposed mechanism for poly(ADP-ribosyl)ation.
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Following this initiation, the process can be repeated through elongation, with 
branching interspersed every thirty to fifty residues130, to form long chains of 
branched ADP-ribose polymers118,121 as shown in Figure 7. Poly(ADP-ribosyl)ation 
results in a lack of affinity for DNA, possibly from electrostatic repulsions between 
the polymers and DNA, and results in the dissociation of PARP from the DNA strand 
break131,132. These polymers are rapidly degraded by poly(ADP- 
ribose)glycohydrolase to form ADP-ribose. ADP-Ribosyl protein lyase removes the 
final residue from the protein, returning PARP to its original form117,121. The rapid 
synthesis and degradation of the polymer has been reported to occur in some cells 
with a half-life of less than one minute133,134. This is paramount to the biological 
function of PARP and explains the rapid depletion of NAD+ in response to DNA 
damage through radiation or alkylating agents133,134.
PoIy(ADP-ribose)
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Biosynthesis and degradation of poly(ADP-ribose) (reproduced from 
ref121).
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4.3 Structure and Function of Poly(ADP-ribose)poIymerase.
Poly(ADP-ribose)polymerase is a multifunctional enzyme with molecular weight 
113 kDa. The polypeptide has a well conserved modular organisation, which can be 
separated into three functional domains by limited proteolytic cleavage: a 46 kDa 
amino-terminal DNA binding domain (DBD), a central 22 kDa automodification 
domain and a 54 kDa carboxy-terminal catalytic domain bearing the NAD+ binding 
site135 (Figure 8). This organisation has been also reflected by the identity profiles 
obtained from various PARP sequences, illustrating the highly conserved nature of 
the protein136'138. The two regions of lowest conservation coincide with the 
interdomains, as determined by limited proteolysis135. Very recently, the X-ray 
crystal structure of the catalytic fragment of chicken PARP has been claimed129, 
although the data are not yet in the public domain.
Automodification 
DNA binding domain domain NAD+ binding domain
42 KDa 22 KDa 52 KDa
Figure 8 Schematic representation of the three functional domains of PARP.
DNA-binding domain. Binding of PARP to DNA and its subsequent activation have 
been shown to be dependent on the presence of two putative zinc finger motifs in the 
region adjacent to the amino-terminal139'141. Site-directed mutagenesis studies have 
suggested that the second zinc finger (F2) plays an important role in the binding of 
DNA containing a single strand break, while mutations affecting FI result in a 
complete loss of enzymatic activity, irrespective of the nature of the DNA
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break142,143. Thus these results suggest differing roles for the two zinc fingers, with 
the F2 finger probably being involved in DNA binding and detection of strand 
breaks, while the FI finger may be responsible for PARP activation. This region also 
bears the essential nuclear location signal responsible for effective translocation of 
PARP into the nucleus144.
The question is asked - what does PARP recognise in DNA breaks? Visualisation of 
a single strand-break by electron microscopy revealed that a break induces flexibility 
in this region resulting in the DNA molecule adopting a characteristic 
V-conformation to which PARP binds to in a symmetrical and non-sequence-specific 
manner covering 7 ± 1 base pairs141,145.
Automodification domain. Once initiation of poly(ADP-ribosyl)ation has occurred, 
automodification occurs in a progressive manner with elongation and branching to 
form long polymer chains. The automodification domain can accept as many as 
fifteen ADP-ribose chains146 and it has been suggested that further sites for 
automodification exist in both the DNA binding and catalytic domains147.
Recently, a putative leucine zipper has been identified in the automodification 
domain, which may be involved in protein-protein interaction148. There is growing 
evidence149'151 to suggest that PARP actually functions as a dimer resulting in an 
intermolecular reaction for automodification, possibly with one PARP molecule 
binding to the DNA, while a second molecule acts as the acceptor for the polymer 
chains. A model is proposed by Uchida et alm  where the addition of a single PARP
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molecule will bind to DNA via its zinc fingers but will remain inactive until a second 
PARP molecule is attached through the leucine zipper, which will stimulate 




Figure 9 Schematic representation of the possible dimerisation of PARP via the
1 d Q
leucine zipper motif (reproduced from ref ).
This proposal was further substantiated through physical evidence for the existence 
of PARP dimers obtained by Bauer et al152. Also consistent is the symmetrical 
binding of PARP to a strand-break observed through electron microscopy145, as 
described previously. The enzyme could use the nick-induced flexibility of DNA to 
position two interacting PARP monomers precisely through the leucine zipper and 
start the automodification process117. However, dimerisation is not a universally 
accepted phenomenon and poor conservation of the leucine zipper motif in vertebrate 
sequences raises doubt about the role of this moiety in dimerisation117.
Catalytic binding domain. Synthesis of poly(ADP-ribose) following recognition and 
binding to a DNA strand break is controlled by the catalytic domain. This
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incorporates catalysing abortive NAD+ hydrolysis, initiation, elongation, branching 
and termination of poly(ADP-ribose) synthesised through heteromodification or 
automodification 144. Degradation studies demonstrated that this basal activity is 
independent of the presence of DNA strand breaks but the specific activity of this 
domain was five hundred times lower than that of the whole enzyme activated by 
DNA strand breaks153. Thus, the activity of PARP is totally dependent on binding to 
DNA strand breaks and hence on the integrity of the zinc finger domain142,154. 
Research144 has led to the speculation that the C-terminal region of this domain may 
be involved in binding the end of the ADP-ribose polymer undergoing auto­
modification, whilst the adjacent site contains the highly conserved NAD binding 
functionality.
4.4 Function of Poly(ADP-ribose)poIymerase in DNA Repair.
Use of PARP inhibitors as a tool for investigating the physiological role of this 
enzyme has provided strong evidence for a link between PARP and DNA repair. 
Known inhibitors of PARP, such as 3-aminobenzamide, have been shown to 
potentiate radiation-induced lethality in mammalian cells155,156, the cytotoxicity of 
certain chemotherapeutic agents12,157,158, and to inhibit repair of DNA strand 
breaks159. Ben-Hur et alm  have also reported a positive correlation between the 
potency of benzamide inhibitors of PARP and their ability to enhance the cytotoxic 
effects of radiation. Therefore, this enzyme provides an attractive target for 
enhancing the effects of both radiation and chemotherapy in cancer treatment but, 
before the design of inhibitors of PARP can be undertaken, it is important to 
understand the possible roles that PARP may play in DNA repair.
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PARP activity is completely dependent on the number and type of DNA 
strand-breaks and is independent of the sequence. However, not all types of DNA are 
capable of supporting polymer synthesis. Research11 has shown that, to activate the 
enzyme, the DNA must contain certain specific structural features:
1. It must be double stranded. Single stranded and covalently closed circular plasmid 
DNA are ineffective.
2. The duplex must have at least one strand broken. Greatest stimulation has been 
observed from DNA double strand breaks with blunt ends, followed by those with 
3' primes, then those with 5' primes and single strand breaks.
3. The effectiveness of the enzyme increases in proportion to the frequency of 
similar types of strand breakage.
Repair of a DNA strand break must involve at least four different stages - recognition 
of damage, excision of bases damaged by chemotherapeutic agents (for example 
alkylated purines and pyrimidines), unscheduled DNA synthesis and ligation159. 
Recent construction of PARP-deficient mice has established that PARP has no direct 
participatory role in DNA repair, but may adopt a more indirect function in DNA 
repair161. However, the physiological role of this enzyme and which of these stages 
PARP becomes involved in DNA repair still remain unsolved. Based on research 
with PARP inhibitors, Shall13 had suggested that PARP was involved at or near the 
ligation step. However, work by Molinete162 indicated that the DNA binding domain 
was interfering with steps earlier than ligation. The theories proposed for the role of 
PARP in DNA repair will now be discussed but the debate concerning the role of this 
enzyme in DNA repair continues.
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Althaus163,164 proposed a mechanism of transient chromatin relaxation. Enzyme 
probes have shown that sites of DNA damage are much less accessible when in the 
nucleosome than on naked DNA165,166. PARP may facilitate chromatin relaxation 
either through direct ADP-ribosylation on the histone in the nucleosome or through 
automodification, where the high affinity of histories for the polymers result in their 
temporary dissociation from DNA (histone shuttling). This results in electrostatic 
repulsion between DNA and the histone moiety, thus enabling access of the DNA 
repair enzymes. These effects are relieved through rapid degradation of the polymers 
by poly(ADP-ribose)glycohydrolase, allowing the histone complexes to reform163. 
Evidence for this proposal163,167,168 is consistent with the observations that NAD 
addition to the system results in an increase in the levels of repair due to enhanced 
polymer formation169, and also that inhibition of PARP prevents repair of DNA 
strand breaks159.
However, this theory was disputed by Satoh and Lindahl14,170 who reported 
poly(ADP-ribose) synthesis in the absence of histones. They proposed a model as 
illustrated in Figure 10, where PARP provides temporary block of the DNA strand 
break by preventing access, reducing the risk of recombination and replication before 
DNA repair occurs14,170. Poly(ADP-ribose) synthesis has a dual function - the 
formation of long chains causes negative charge repulsion, creating a nucleic 
acid-free zone in the vicinity of the strand interruption preventing potential 
recombination, whilst the reduction of the polymer chains to oligomer size by 
poly(ADP-ribose)glycohydrolase prevent immediate reattachment of PARP to the 
DNA strand break, allowing the rejoining of the DNA by the repair enzymes171.
38
^  DNA binding NAD* binding 4) Repaired
DNA




Figure 10 Model for the involvement of poly(ADP-ribosyl)ation in DNA
As illustrated above, the binding and repair process has four main steps:
1. After interruption of the DNA strand by y-irradiation, PARP initially competes 
with DNA repair enzymes for binding to the damaged site.
2. The binding of PARP to the damaged DNA inhibits repair and triggers rapid 
synthesis of long branched chains of poly(ADP-ribose).
3. As a consequence of automodification, PARP has a reduced affinity for DNA and 
is released, allowing access to the lesion by the DNA repair enzymes.
4. Digestion of polymers by poly(ADP-ribose) glycohydrolase (PGH) returns PARP 
to its original form, while the DNA repair enzymes seal the DNA strand break.
Thus poly(ADP-ribose) synthesis serves as a release mechanism which allows the 
strand-breaks to become available to the DNA repair enzymes after a short period of 
protection and inaccessibility. Inhibitors of PARP should ensure that the enzyme 
binds irreversibly to DNA and thus prevent access by the repair machinery.
repair
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This model is consistent with the research conducted by Simbulan172, suggesting that 
PARP may also interact with or even physically bind to the DNA synthesising 
enzyme, DNA polymerase a. At low concentrations of DNA, PARP was observed to 
inhibit the activity of the polymerase, possibly by a similar mechanism to that 
proposed by Satoh14, whilst at high concentrations, PARP greatly stimulated its 
activity173. In this case, a physical association of the two enzymes may result in 
localisation of the DNA polymerase a  to the DNA strand break, followed by release 
of PARP through automodification and subsequent repair. The detection of PARP- 
DNA polymerase a  complexes provides strong evidence for this proposal173.
A strong link between PARP and intrachromosomal recombinations has been 
observed. Inhibition of poly(ADP-ribose) synthesis with 3-aminobenzamide showed 
an increase in recombination which was visualised as an increase in sister-chromatid 
exchanges (SCE), an example of homologous recombination174. Furthermore, when 
inhibitors of PARP are used in conjunction with cytotoxic agents, the number of SCE 
increases further175,176.
To investigate these results further, Chatteijee and Berger177 found that the number of 
strand-breaks and the rate of repair were similar for PARP-deficient and for the 
parent cells, and also reported that cytotoxicity of radiation and chemotherapeutic 
agents was not potentiated in growth-arrested cells. In order to explain these results, 
they proposed that PARP protected the DNA strand end during replication and repair 
to control the availability of a strand break in order to favour ligation as opposed to 
recombination by a similar mechanism to that described by Satoh14. In the absence of
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PARP activity, the DNA strand ends will not be protected. This leads to an increase 
in SCE, which under these conditions will be mostly homologous and thus not 
cytotoxic. However, exposure to DNA-damaging agents under these conditions, will 
increase the number of recombinations, and it is likely that there will be a 
proportional increase in imperfect (nonhomologous) recombinations which can lead 
to mutations and/or cell death. Therefore, inhibition of PARP will ensure that cells 
undergo both homologous and nonhomologous recombinations at much lower doses 
of DNA damaging agents compared to cells with normal PARP activity, leading to 
enhanced cell death. This proposal also provides an explanation for the observation 
that PARP inhibitors potentiate the effects of radiation and chemotherapeutic agents 
in proliferating but not in quiescent cells.
PARP has also been linked to both apoptosis and toxicity initiated by nitric oxide 
(NO). An early consequence of proteases activated and required during apoptosis178 
is that PARP is cleaved from the 113 kDa active form to an 85-89 kDa carboxy- 
terminal fragment and a smaller fragment containing the zinc fingers, required for 
DNA binding179. Thus PARP cleavage provides an early marker for apoptosis and the 
generation of the small fragment may enhance cell death in conjunction with DNA 
fragmentation161. Elevated resistance to NO toxicity in pancreatic islet cells from 
PARP-deficient mice indicates that cellular NAD depletion by poly(ADP-ribose) 
synthesis contributes to the toxicity of that system180.
Other studies indicate that persistence of DNA damage may transmit signals to other 
cellular components, including p53, which may trigger apoptosis181. These
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observations suggest that DNA damage is processed not only by DNA repair 
enzymes but also by other nuclear factors involved in a variety of cellular 
functions170.
Therefore, it remains to be established exactly how this enzyme participates in DNA 
repair. Perhaps the answer will be elucidated through further physiological studies 
with the PARP deficient mice or using cell lines generated by targeted gene 
deletion161. However, irrespective of the exact role of PARP in DNA repair, the 
ability of the enzyme to bind to DNA strand breaks and interfere with poly(ADP- 
ribose) synthesis provides an attractive target for enhancing the cytotoxic effects of 
radiation and chemotherapeutic agents through its inhibition.
4.5 Development of Inhibitors of Poly(ADP-ribose)polymerase.
PARP inhibitors have been used as a tool for elucidating the physiological role of 
PARP in DNA repair. This role, together with the potential application of PARP 
inhibitors in cancer therapy as an adjunct to radiation and chemotherapy, has 
promoted much research since PARP was first discovered in 1966. Several criteria 
must be met by potential inhibitors including selectivity, potency, specific activity to 
the enzyme, lack of iatrogenicity and solubility. These factors will be discussed in 
relation to known inhibitors reported in the literature.
Early work was hampered by problems of selectivity for inhibition of PARP alone. 
Nicotinamide (22), one of the earliest compounds found to inhibit PARP182, was 
thought to act by competing with NAD+ (21). However, this compound showed only
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weak inhibition and also functioned as an antimetabolite of NAD+ synthesis182. 
Similar difficulties were encountered with purine- and pyrimidine-based inhibitors of 
PARP, such as thymidine, 5-bromouridine and theophylline, all of which affected 
other cellular processes. As a result, the apparent inhibitory activity of these 
compounds cannot be ascribed directly to inhibition of PARP183.
ADPO.
OH OH
NAD+ (21) Nicotinamide (22) 3-Aminobenzamide (23)
IC50 210 pM126 IC50 33 pM126
A close structural analogue of nicotinamide, benzamide, was first shown to be an 
effective inhibitor by Shall184 in 1975. Since it lacks the ring nitrogen of 
nicotinamide, it cannot be metabolised by NAD+-biosynthetic enzymes, although its 
use for physiological studies was hampered by its very low aqueous solubility and 
hydrophobic nature. However, this prompted the study of various benzamides and 
related compounds by Whish and Purnell185 with polar substituents at the 3-position 
to enhance solubility. 3-Aminobenzamide (23), 3-hydroxybenzamide and 3- 
methoxybenzamide emerged as potent competitive inhibitors of PARP with 
IC50 values of 33 pM, 9.1 pM and 17 pM respectively126. In competing with NAD+ 
(21), the natural substrate at the enzyme's binding site, these compounds exhibited K\ 
values of less than 2 pM185. These compounds combined favourable aqueous
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solubility with potent PARP inhibition and have become the benchmark PARP 
inhibitors against which all potential new inhibitors are compared.
These results185, together with those of other groups176’186 have assisted in elucidating 
the structure-activity relationships for PARP inhibitors. The presence of an 
unsubstituted carbamoyl group is an essential requirement for activity. Replacement 
of this group with an N-alkylamide, a sulphonamide or a thioamide resulted in a 
dramatic loss of activity186, while benzoic acids were devoid of activity185. 
Interestingly, alkylation at the amide nitrogen in 3-aminobenzamide was found to 
abolish activity, while acylation of this compound, to form 3-acetamidobenzamide or
3-propanamidobenzamide for example, was shown to slightly enhance activity, 
although solubility problems were encountered176,185.
The position of the carbamoyl group was found to be less critical with both pyridine-
2-carboxamide and pyridine-4-carboxamide exhibiting similar activity to 
nicotinamide. It was reported that an additional ring nitrogen was tolerated with 
pyrazinamide displaying similar inhibitory potency to nicotinamide, but activity was 
dramatically reduced on alkylation of the ring nitrogen. Reduction of the aromatic 
ring176 or substitution with a thiophene ring were also claimed to reduce inhibitory 
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Figure 11 Structure activity relationship for inhibitors of PARP.
A major step forward in the search for more potent and specific inhibitors of PARP 
was made by Suto et al127, through the synthesis of compounds designed to constrain 
the orientation of the required carbamoyl group in either the anti or 
syn-conformation, relative to the substituent R. Using the 3-substituted benzamides 
as a template, they approached this problem via two strategies as illustrated in Figure 
12. The first involved the preparation of ‘rigid* benzamides, where the amide 
nitrogen was closed via an ethane bridge to form 5- and 7-dihydroisoquinolinones. 
The second approach involved inserting substituents at the 2-position to form a series 
of 2,3-disubstituted benzamides.
R RR R
anti syn anti syn
Figure 12 Restriction of the carbamoyl group to ascertain the required 
conformation for PARP inhibitory activity.
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The 5-substituted dihydroisoquinolin-l-ones, where the carboxamide is in the anti- 
orientation, were found to be significantly more potent inhibitors of the enzyme than
3-aminobenzamide, with IC50 values of less than 0.5 p,M127. This represents a 50 -  75 
fold increase in potency by restricting the free rotation of the amide moiety in the anti 
conformation, compared to the 7-substituted syn analogues which were much less 
active and comparable to 3-aminobenzamide. The positioning of the substituent on 
the benzene ring was found to be critical for optimum activity - a decrease in activity 
was observed when the substituent was moved from the 5 to the 6, 7 or 8 position. 
The 2,3-disubstituted benzamide analogues were almost completely devoid of 
activity, and energy calculations revealed that the presence of a 2-substituent restricts 
the rotation of the amide nitrogen, which exists predominantly in the unfavourable
-conformation127.
In one of the most comprehensive surveys to date, Banasik et alne evaluated more 
than 170 compounds of diverse structure in an attempt to find specific inhibitors of
1 8 7PARP. In agreement with earlier reports , comparative studies of the effects of 
these inhibitors on poly(ADP-ribose)polymerase and arginine specific mono(ADP- 
ribosyl)transferase revealed a high specificity for the polymerase enzyme. These 
results reflected the findings of Suto et alu l with the most potent inhibitors 
exhibiting the carbamoyl function incorporated within a ring system. These include
4-amino-1,8-naphthalimide (24), 6(5H)-phenanthridinones (25a), 2-nitro-6(5H)- 
phenanthridinones (25b) and 5-hydroxyisoquinolin-l-one (26). Their IC50 values 
were approximately two orders of magnitude lower than that of 3-amino­
benzamide126.
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Through screening of natural products from micro-organisms, 2-methylquinazolin- 
4(3H)-one (from Bacillus cereus) was found to be a potent inhibitor of PARP with an 
IC50 value of 1.1 jiM188. This is comparable with the value (IC50 5.6 jiM) reported by 
Banasik126. Griffin et a/189 reported that 8-hydroxy-2-methylquinazolin-4(3H)-one
(27) was a more potent inhibitor in this quinazolinone series. A common structural 
feature is shared between these potent inhibitors - a carbonyl group is built into a 
second ring system conjugated with a six membered aromatic ring, again 
constraining the carbamoyl moiety in the active, a/zri-conformation, which is 
consistent with the preferred conformation of the carboxamide group in NAD+ found 












IC50 0.18 |lM126 a: R = H, IC50 0.30 nM126 IC50 0.39 |lM126




On the basis of these structural requirements for PARP inhibition, it is possible to 
propose a hypothesis for the interaction of these inhibitors with the enzyme active 
site. The benzamides are thought to occupy the nicotinamide-binding domain of 
PARP. Thus the importance of the carbamoyl group implies that this moiety may 
form hydrogen bonds with an amino acid donor to anchor the ring in the 
nicotinamide binding site. The carbonyl group may act as a hydrogen bond acceptor,
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which would be enhanced through an electron-rich aromatic ring. Accommodation of 
the 3-substituent for benzamides or analogous 5-substituent for dihydro- 
isoquinolinones is likely to be in the ribose binding domain, where they will act as 
competitive inhibitors due to the lack of a cleavable bond 189,191.
Griffin et alm  probed the ribose-nucleoside binding domain, using a series of
3-substituted benzamides with varied steric, electronic and hydrogen bonding 
properties. In another approach, involving a series of benzoxazole analogues (28), the 
the carbamoyl group was constrained in the active awri-conformation by 
hydrogen-bonding between the amide NH and the oxazole nitrogen. These 
compounds proved to be very potent inhibitors. Both the benzamide series and the 
introduction of substituents at the 2-position of oxazole showed that a bulky group is 
tolerated in that position. Alkylation of (28a) abolished activity completely and thus 
it was proposed 189 that two hydrogen bonds occur, namely between the carbonyl 
group and the enzyme, and the amide NH and the enzyme.
R
(28)
a: R = Me, IC50 9.5 pM 
b: R = Ph, ICsoO.44 pM189
The recently claimed1 crystal structure of the catalytic fragment of PARP with the 
known inhibitor 5-methyldihydroisoquinolinone (PD 128763) is consistent with the
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1 60above proposal . This inhibitor is bound through two hydrogen bonds: from its 
lactam group to the peptide backbone of Gly-863 and from its oxygen atom to the 
side chain of Ser-904 (Figure 13).
Me
Figure 13 The binding sites from 5-methyldihydroisoquinolinone to the enzyme 
obtained from the crystal structure of the catalytic fragment of PARP.
Early studies in vitro demonstrated that nicotinamide (22) and 3-aminobenzamide 
(23) can potentiate radiation-induced lethality in mammalian cells155,156 and the 
cytotoxicity of certain chemotherapeutic agents12,157,158. This role for PARP 
inhibitors was further substantiated by Ben-Hur et a/160, who demonstrated that a 
correlation existed between the ability of benzamide analogues to inhibit PARP and 
enhancement of the radiation response. Recently, comparison of the more potent 
bicyclic inhibitors, such as the 5-substituted dihydroisoquinolinones or 
quinazolinones, with 3-aminobenzamide, showed that this new generation of PARP 
inhibitors were at least 50- fold more effective as chemopotentiators192.
Due to these promising in vitro studies, investigations were extended to in vivo 
tumour models. Although, the ability of nicotinamide to potentiate the effects of 
radiation in sarcoma cells was first demonstrated in 1970193, results from early 
inhibitors were limited due to their lack of specificity, potency and solubility. In
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addition, there was no evidence to directly link PARP inhibition to the observed 
radio-potentiation.
Radio-potentiation studies for benzamides in vivo were first reported by Horsman 
etal.194, who demonstrated that benzamide, 3-hydroxybenzamide, and derivatives of
3-hydroxy- and 3-aminobenzamide could potentiate the activity of X-irradiation in 
the EMT-6 tumour system. The most promising results for radio-potentiation were 
obtained by Sebolt-Leopold et a/.195. It was demonstrated that the combination of 
irradiation and the 5-substituted dihydroisoquinolinone, PD 128763 against SCC7, 
RIF-1 and KHT murine tumours, resulted in tumour regression, whilst only a minor 
delay in growth was achieved with radiation alone.
Chemo-potentiation in vivo has been frequently reported for 3-aminobenzamide. For 
example, potentiation has been observed for this inhibitor in combination with 
bleomycin196 and cisplatin197 against the Ehrlich ascites tumour. However, most of
1 Qftthese investigations employ large doses of 3-aminobenzamide. It has been reported 
that doses greater than 100 mg/kg can cause marked reductions in the body 
temperature of mice, which may reduce the plasma clearance and thus lead to 
increased antitumour activity and normal tissue toxicity. These findings call into 
question results where the body temperature of the subject was not monitored. 
Therefore, in vivo data for radio- and chemopotentiation may be compromised by the 
haemodynamic and hypothermic effects of the PARP inhibitors used. Further in vivo 
studies should monitor these effects, and measurements of NAD+ and poly(ADP-
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ribose) levels in tumour would assist in clarifying whether radio- or chemo- 
potentiation was indeed occurring via PARP inhibition191.
The development of more potent and selective inhibitors of PARP for use in 
conjunction with new molecular biology techniques would greatly assist in defining 
the function of PARP in DNA repair, and establish the future role of PARP inhibitors 
in cancer treatment in conjunction with radiation and chemotherapy.
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CHAPTER FIVE
5. AIMS OF THE PROJECT.
The strategic aim is to develop inhibitors of repair of DNA damaged by radiation or 
by chemotherapy in order to increase the cytotoxic effects of these therapies in cancer 
cells. Pro-drugs will be designed and synthesised which would be reduced selectively 
in hypoxic cells to give potent inhibitors of PARP.
In order to achieve these objectives, several parameters must be met:
♦ good inhibitory activity of the predicted bioreduction metabolite.
♦ large differential between the inhibitory activity of the pro-drug and the active 
metabolite in order to give good selectivity for inhibition of DNA repair in 
hypoxic tumour tissue.
♦ appropriate redox potential (ES) for bioreductive metabolism of the pro-drug to 
the active inhibitor in hypoxic cells. This is usually in the region of -250 to 
-400 mV54.
♦ effective distribution to and within the hypoxic region of tumours.
From the inhibitors of PARP already developed126,127,185’189’191, an understanding can 
be formed of the structural requirements necessaiy for activity:
♦ constraining the amide group in the anrf-conformation through an ethane / ethene 
bridge potentiates the activity approximately 50 fold, compared to the free amide.
♦ one free N-H is required.
52
♦ the presence of an electron withdrawing group in both the benzamides and 
isoquinolinone series reduces activity considerably.
♦ steric bulk at the 2-position of benzamides abolishes inhibitory activity by 
changing the conformation of the carboxamide.
♦ for the benzamide series, a moderately large substituent is tolerated at the
3-position.





where R = electron donating group 
X = H or cyclised ring system
Figure 14 Basic template for potent inhibition of PARP.
In order to meet the outlined requirements, it is intended to design and synthesise 
nitroheterocyclic amides analogous to the template above, which would be 
selectively reduced in hypoxic cells to produce aminoheterocyclic inhibitors of 
PARP. From previous research carried out54’71,199, it is likely that the proposed 
nitroheterocycles will have redox potentials (ES) within the range -250 mV to 
-400 mV54 needed for bioreduction of the pro-drug. Selectivity will hopefully be 
achieved as it has been reported that the presence of a nitro group in the inhibitor 
reduces its activity against PARP ca. ten-fold compared to an amino group126,127’185. 
The additional advantage of this strategy is that the redox potentials of the parent 
nitroheterocycles are in the correct range to enable them to act as classical electron-
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affinic radiosensitisers. Thus, the nitroheterocyclic compounds developed through 
this project are potentially dual-mechanism radiosensititisers.
The synthesised compounds will be tested for their ability to inhibit PARP. Once 
active lead compounds have been identified, activity against the enzyme will be 
optimised by synthesising further analogues to establish structure-activity 
relationships. The presence of highly polar functional groups may enhance 
distribution both to and within the hypoxic region, and also reduce toxicity due to the 
lipid nature of the blood brain barrier. Refinement of the structural features for potent 
inhibition of PARP will provide an elegant strategy for the development of potent 
inhibitors of DNA repair acting selectively in hypoxic cells.
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CHAPTER SIX
6. NITROTHIOPHENECARBOXAMIDES AND AMINOTfflOPHENE- 
C ARB OXAMIDES.
Since thiophene was discovered in 1882 by Meyer200, its importance in the 
pharmaceutical field has increased rapidly. The fact that certain physical and 
chemical properties of thiophene and benzene are very similar aroused interest with 
respect to the biochemistry and pharmacology of these compounds. Thiophene and 
its nitro analogues have now been recognised as active elements in 
pharmacologically active substances, such as mutagens201, cytotoxic agents199 and 
radiosensitisers202. Cantoni et a/186 reported the weak inhibition of poly(ADP- 
ribose)polymerase186 by thiophene-3-carboxamide with 47% inhibition at 5 mM. 
However, Griffin et alm  dismissed this compound as inactive in a recent review of 
PARP inhibitors. Therefore, it still remains to be answered whether 
thiophenecarboxamides can indeed inhibit PARP.
^ X O N H 2
n h 2 R R R
a: R= N 02
(23) (29) (30) (31) b: R= NH2
The first synthetic targets were the three nitrothiophenecarboxamides (29a-31a) 
shown above, with the ‘meta’ relationship between the substituents as seen in the 
lead inhibitor 3-aminobenzamide (23). Subsequent reduction of these compounds
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would furnish the corresponding aminothiophenecarboxamides (29b-31b). Both sets 
of compounds were required for comparison of inhibitory activity, since the optimum 
bioreductively activated inhibitors need to have a large differential in activity 
between the nitro prodrug and the active amino metabolite.
6.1 Nitrothiophenecarboxamides.
5-Nitrothiophene-2-carboxamide. The first strategy was to oxidise 5-nitrothiophene-
2-carboxaldehyde (32) to the corresponding carboxylic acid (33), and then to 
synthesise the amide (29a) via the acid chloride. Campaigne and LeSuer203 have 
reported oxidation of thiophene-3-carboxaldehyde using silver(I) oxide; this method 
was investigated for the oxidation of 5-nitrothiophene-2-carboxaldehyde.
The acid (33) was formed in 40% yield by oxidation of (32) with silver(I) oxide 
prepared freshly from silver nitrate and aqueous sodium hydroxide. The relatively 
modest yield was due to difficulty in isolating the product from the mass of colloidal 
silver formed. Oxalyl chloride effected the quantitative conversion to the acid 
chloride, in a reaction catalysed by dimethylformamide. Treatment with ethereal 
ammonia then furnished 5-nitrothiophene-2-carboxamide (29a) in 60% yield. 
However, the overall yield from the conversion of 5-nitrothiophene-2- 
carboxaldehyde was only 24% (Scheme 1), thus other synthetic routes were 
investigated to improve the yield.
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/ ^ CH0 /^ ,/C02H / ^ / CONH2
Ag2Q / NaOH \ I  1. (COCl2), DMF, PCM ^  T
/  *" /  2.NH3,Et20  *" f
o 2n  o2n  o 2n
(32) (33) (29a)
Scheme 1
The classical work of Rinkes204,205 in the early 1930s showed, without doubt, that a 
typical ‘meta’ directing group did not solely control further substitution in the lmeta’ 
position, as had previously been believed. In contrast to nitration of acetophenone 
with concentrated nitric and sulphuric acids which produced 97% of
3-nitroacetophenone, nitration of 2-acetylthiophene produced a mixture of 5-nitro-2- 
acetylthiophene and 4-nitro-2-acetylthiophene. Formation of these isomers results 
from the competing effects of the a-directing sulphur atom and the meta directing 
acetyl group.
Electrophilic substitution at the a-position of five-membered heterocyclic rings such 
as thiophene, furan and pyrrole is strongly favoured over substitution at the 
P-position. Figure 15 shows that positive charge is more extensively delocalised in 
the intermediates derived from attack at the a-position (mesomers 34a,b, and c) than 
at the p-position (mesomers 35a and b). This results in a lower activation energy for 
the former pathway and therefore in selectivity for electrophilic attack at the 
a-position over the p-position206.
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( p < Es H
-H+
(34a) (34b) (34c)
Figure 15 Intermediates for electrophilic substitution of thiophene.
Therefore, based on this evidence, selective nitration of thiophene-2-carboxamide 
was investigated. Treatment of thiophene-2-carboxamide (36) with concentrated 
nitric acid and acetic anhydride at -10°C afforded only starting material. However, 
nitration under more vigorous conditions (acetyl nitrate prepared from fuming nitric 
acid and acetic anhydride) proved more successful, producing 5-nitrothiophene-2- 
carboxamide (29a) and 4-nitrothiophene-2-carboxamide (30a) in 18% and 7% yields 
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Proton NMR spectroscopy is a powerful tool for the structural elucidation of 
disubstituted thiophenes. Both the chemical shifts and coupling constants provide 
characteristic structural information. Generally, protons attached to a-carbon atoms 
will resonate at lower fields than those P to the sulphur atom. The range for a 
thiophene proton lies between 8 5.5, the upper limit for p-protons, and 8 10, the 
lower limit for a-protons, depending on the substituents present207. For 13C NMR, 
the situation is reversed with a-carbons resonating at higher field than p-carbons207. 
Investigations208 of coupling constants in the !H NMR spectra of thiophenes have 
shown that the magnitudes of coupling constants fall into four distinct ranges as 
illustrated in Figure 16. The dependence upon substituents is small and, although 
there is an overlap in the values of coupling constants for J2-5 and J3-4, this is rarely a 
problem, since pronounced differences in synthetic routes will have been used to 
afford 2,5- and 3,4-disubstituted thiophenes. Therefore these coupling constants are 
important diagnostic tools for the structure determination of isomers of these 
disubstituted thiophenes.
J2.5 = 3.20-3.65 Hz J2-4 = 1.25-1.70 Hz J3-4 = 3.45-4.35 Hz J2.3 = 4.90-5.80 Hz
Figure 16 Coupling constants in the *H NMR spectra of disubstituted 
thiophenes.
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Therefore coupling constant values of 4.4 Hz and 1.5 Hz give clear indication of the 
formation of 5-nitrothiophene-2-carboxamide (29a) and 4-nitrothiophene-2- 
carboxamide (30a) respectively.
4-Nitrothiopkene-2-carboxamide. Different reaction conditions also influence the 
composition of isomeric products formed. Founai and Chane209 observed that
5-nitrothiophene-2-carboxaldehyde was the major product when nitrating
thiophene-2-carboxaldehyde with fuming nitric acid and acetic anhydride, while
4-nitrothiophene-2-carboxaldehyde predominates with fuming nitric acid and
010concentrated sulphuric acid. Dell'Erba et al discovered that nitration of
2-thiophenecarboxamide (36) under the more forcing conditions of potassium nitrate 
and concentrated sulphuric acid at 10°C enabled nitration to occur at the less 
favourable p-position.
KNO




4-Nitrothiophene-2-carboxamide (30a) was synthesised by this procedure in 69% 
yield. The isomeric 5-nitrothiophene-2-carboxamide (29a) was also isolated in 22% 
yield (Scheme 3).
60
5-Nitrothiophene-3-carboxamide. Initial approaches to the synthesis of
5-nitrothiophene-3-carboxamide (31a) required the synthesis of thiophene-3- 
carboxamide. The method of Campaigne and LeSuer203 was again employed for the 
oxidation of thiophene-3-carboxaldehyde (37), using silver(I) oxide, to thiophene-3- 
carboxylic acid (38) in moderate yield (50%). Thionyl chloride was used for the 
subsequent conversion to the acid chloride, which was treated with aqueous ammonia 
to afford thiophene-3-carboxamide (39) in good yield (6 6 %). Nitration was attempted 
with acetyl nitrate, and with potassium nitrate and concentrated sulphuric acid. 
However, all attempts at regioselective nitration of this material were unsuccessful 
(Scheme 4) and an alternative route to this compound was sought.
KNO
CHO _ . C 0 2H ^  /C O N H 2
Ag2Q^ ^
H2°  2 .NH3 c.n2au4 q2N
(37) (38) (39) (31a)
Scheme 4
5.2 One-Step Conversion of Cyanothiophenes to Nitrothiophene-
carboxamides and Application to Related Compounds.
To improve the yields of these compounds, a two-step sequence with the amide 
moiety present as the cyano synthon was explored. This sequence involved nitration 
of the cyanothiophene followed by hydrolysis of the nitrile. Unexpectedly, treatment 
of 3-cyanothiophene (40) in concentrated sulphuric acid with one equivalent of 
potassium nitrate gave 5-nitrothiophene-3-carboxamide (31a) directly in 91% yield, 
rather than the corresponding nitrile (Scheme 5). Clearly, the vigorous acidic
CONH2
61
conditions were sufficient to hydrolyse the nitrile to the carboxamide since no 
cyanonitrothiophenes were isolated. The position of substitution is expected, since
sulphur atom; thus the two effects are additive.
This rapid one-pot synthesis was also applied to 2-cyanothiophene (41).
4-Nitrothiophene-2-carboxamide (30a) and 5-nitrothiophene-2-carboxamide (29a) 
were isolated in 41% and 32% respectively (Scheme 5). This predominant effect of 
the cyano group over the directing effect of the sulphur atom observed in this 
example has also been illustrated by Reynaud and Delaby211 .This procedure 
represents the most direct and high yielding approach to synthesise both 5-nitro- 
thiophene-3-carboxamide (29a) and 5-nitrothiophene-2-carboxamide (31a).
the 5-position is ‘meta' to the carboxamide substituent and is also activated by the
c o n h 2
o 2n
(40) (31a)




To investigate this direct conversion of cyanothiophenes to nitrothiophene- 
carboxamides, a series of control experiments to understand the requirements for the 
reaction and also to test the versatility of this reaction on other substrates.
3-Cyanothiophene (40) was treated with concentrated sulphuric acid alone to observe 
whether hydrolysis of the cyano group to the corresponding carboxamide was still 
executed. However, only a very small yield (4%) of thiophene-3-carboxamide (39) 
was isolated, suggesting that the thiophene ring is unstable on treatment with acid 
alone. From this evidence and the unsuccessful attempt at regioselective nitration of 
thiophene-3-carboxamide with potassium nitrate and concentrated sulphuric acid 
(Scheme 4), it is possible to speculate that nitration occurs first, followed by 
hydrolysis of the cyano group.
Application of this one-step conversion to the benzene series resulted in the high- 
yielding direct conversions of benzonitrile (42a) to 3-nitrobenzamide (43a) (73%) 
and 4-methylbenzonitrile (42b) to 4-methyl-3-nitrobenzamide (43b) (96%) (Scheme 
6).
K N O ,
c.H 2S04
R a: R = H
(43) b: R = Me
Scheme 6
The potential application of this procedure in the efficient synthesis of 
[15N]-nitrothiophenecarboxamides, using stoichiometric quantities of potassium 
[15N]-nitrate, was also explored. Other nitrating systems used for thiophenes, such as 
acetyl nitrate in acetic anhydride, or nitric acid in sulphuric acid, would be
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isotopically inefficient for 15N-labelling, since the nitric acid is used in excess in both
cases.
Potassium [15N]-nitrate was prepared by neutralisation of [15N]-nitric acid (95% 
isotopic enrichment) with one equivalent of potassium carbonate in water, followed 
by removal of the solvent by freeze-drying. Addition of this material to
3-cyanothiophene (40) in concentrated sulphuric acid gave 5-[15N]-nitrothiophene-3- 
carboxamide (44) in excellent chemical and isotopic yields (82%). Similar treatment 
of 2-cyanothiophene (41) gave satisfactory yields of 4-[15N]-nitrothiophene-2- 
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15N NMR and mass spectrometry demonstrated that each product contained only one 
15N as required. Although no coupling of 15N to other nuclei were seen in the 
15N spectra, probably owing to insufficient digital resolution, couplings to 15N were 
observed in the and 13C spectra. In 5-[15N]-nitrothiophene-3-carboxamide (44), 
15N coupled to the proton in position-2 and position-4 on the thiophene ring with a
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three-bond coupling constant 3J = 1.1 Hz and four bond coupling constant of 
V  = 1.1 Hz. In contrast, 15N-!H couplings were only evident to the proton in position- 
3 in (45) and to the proton in position-4 in (46), with 3J = 1.1 Hz in both cases. 
One bond 15N-13C coupling was clearly seen for all three compounds with 
lJ = ca.20 Hz, while the only three bond 15N-l3C coupling was observed in the 
spectrum of (44) with 3J -  3.7 Hz, between 15N in the nitro group at position 5 and 
the quaternary carbon 3-C bearing the carboxamide. This synthetic technique could 
be utilised for more general applications in the introduction of 15N in synthesis, using 
stoichiometric amounts of the readily available and inexpensive [15N]-nitric acid.
Thus the versatility of this reaction for the direct conversion of cyano(hetero)arenes 
to nitro(hetero)arenecarboxamides and its use for 15N labelled synthesis has been 
demonstrated.
6.3 Aminothiophenecarboxamides.
Having achieved the synthesis of the three nitrothiophenecarboxamides (29a-31a), 
reduction to the corresponding aminothiophenes (29b-31b), the heterocyclic 
analogues of the known PARP inhibitor 3-aminobenzamide (23), was undertaken.
^ - ^ C O N H 2 ^ . c o n h 2 s c o n h 2  . c o n h 2
y  ^  f
NH2 HBr.H2N HBr.H2N HBr.H2N
(23) (29b) (30b) (31b)
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The paucity of aminothiophenes reported in the literature gives an indication of the 
difficulty in isolating these compounds, which are generally known to be highly 
unstable212. More success has been achieved in isolating these compounds as the 
hydrochloride salts or as other stable derivatives213.
Initial work involved reduction of 5-nitrothiophene-3-carboxamide (31a) with tin(II) 
chloride and concentrated sulphuric acid, with the aim of isolating the corresponding 
amine as the hydrochloride salt. Hydrogen sulphide and nitrogen were passed through 
the final reaction mixture to precipitate tin(II) sulphide. Although tic analysis and 
development using ninhydrin spray provided evidence that the nitro group was being 
reduced, difficulties were encountered in isolating the hydrochloride salt due to two 
possible reasons. First, the instability of the aminothiophene may lead to 
disintegration of the ring system and secondly, the high solubility of the 
aminothiophene in water causes difficulty in isolating the product from the by­
products such as tin(II) sulphide. This latter problem could be counteracted by 
isolating the amines as f-butyl carbamates, thus increasing the solubility of the 
aminothiophene in organic solvents. However, there was little evidence of this 
reaction occurring, possibly due to the instability of the aminothiophene. Other 
reduction systems such as sodium borohydride / palladium and hydrogen / palladium 
were investigated but all attempts to isolate the free amine were unsuccessful.
More success was achieved by conversion of the aminothiophene in situ to the less 
polar benzyloxycarbonyl (Cbz) derivative (48). Finally, deprotection with hydrogen
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bromide yielded the required 5-aminothiophene-3-carboxamide (31b) as the 
hydrobromide salt in good yield (Scheme 8).












This procedure was applied to the reduction of the other nitrothiophenecarboxamide 
isomers. 5-Nitrothiophene-2-carboxamide (29a) and 4-nitrothiophene-2-carboxamide 
(30a) were also reduced and isolated as the benzyloxycarbonyl (Cbz) derivatives (49) 
and (50) respectively. Deprotection produced the corresponding aminothiophenes 
(29b) and (30b) in good yields as the hydrobromide salts. Interestingly, reduction and 
protection of 4-nitrothiophene-2-carboxamide (30a) yielded an additional protected 
side product with similar spectroscopic properties. Signals due to thiophene protons 
could not be identified in the NMR spectrum. This product could not be identified 
fully, but may be formed from ring-opening during the reaction.
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Biological evaluation of the three sets of nitro- and aminothiophenecarboxamides 
isomers (29-31,a and b) indicated that these compounds could indeed act as good 
inhibitors of PARP, in contrast to reports by Cantoni186 and by Griffin191. Inhibition 
was observed to be in the same order of magnitude as 3-aminobenzamide, thus 
showing that no significant penalty was incurred by replacing the benzene ring with a 
thiophene. The aminothiophenecarboxamides were found to be slightly more potent 
than the corresponding nitrothiophenes. However the differential between these 
compounds was not as large as was hoped, thus limiting the use of the 
nitrothiophenecarboxamides as potential as prodrugs of PARP inhibitors in hypoxic 
tissue. These results will be discussed in more detail in Chapter Ten. Figures showing 
PARP activity in the presence of these compounds can be found in the Appendix.
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CHAPTER SEVEN
7. TH3EN OP YRIDIN ONES.
The greater potency of the 5-substituted dihydroisoquinolinones (51), compared to 
the benzamides127, has prompted the elaboration of the nitro- and amino­
thiophenecarboxamides described in Chapter Six, to heterocyclic analogues of these 
compounds (52a and b). From previous research54,199, it seemed likely that these 
compounds would have redox potentials in the correct range for bioreduction of the 
nitrothienopyridinone prodrug in hypoxic tissue. The corresponding amino 







a: R = N 0 2 
b: R = NH2
(51) (52)
Retrosynthetic analysis of this compound (52) led to the conclusion that
4-bromothiophene-3-carboxylic acid would be a suitable template from which to 
build the pyridinone ring (Scheme 9). Condensation reactions could be used to attach 
the carbon units, followed by cyclisation to form the ring system. Finally, nitration of 
the thienopyridinone should occur at the required and favoured 5-position on the 




Challenges arise in the synthesis of these compounds since 3,4-disubstituted 
thiophenes are relatively inaccessible owing to the reactivity of the 2 -position as 
described in Chapter Six.
7.1 Synthesis of 4-Bromothiophene-3-carboxylic acid.
7.1.1 3,4-Dibromothiophene.
Initial approaches to the synthesis of the key intermediate, 4-bromothiophene-3- 
carboxylic acid (53) involved reduction of tetrabromothiophene (54). It is well 
documented in the literature214,215 that zinc can reduce a-bromine atoms selectively 
in thiophene derivatives. Synthesis of 3,4-dibromothiophene (55) was based on a 
method described by Gronowitz and Razniewicz215, by boiling tetrabromothiophene
(54) with zinc powder in acetic acid, as shown in Scheme 10. 3,4-Dibromothiophene 
was produced in 42% yield and further attempts at varying the reaction conditions did 







In 1934, Steinkopf et al,216 prepared 3,4-dibromothiophene (55) by hydrolysing the 









However this method was troublesome and time-consuming and still poorer yields 
were obtained when the reaction was carried out with tetrabromothiophene (54). 
Lawesson217 improved the yield for this reaction to 29% by using ethyl bromide as an 
‘entrainer’. At this time there was much rivalry between the widely used Grignard 
reagents and the highly reactive corresponding lithium intermediates which could be 
formed from a greater range of organic compounds. The difficulty in preparation of 
Grignard reagents and their lack of selectivity in thiophene chemistry gave greater 
importance to the use of lithium reagents in this series218.
0“\ nBased on a procedure reported by Lawesson , addition of n-butyllithium to 
tetrabromothiophene (54) in ether at 0°C, followed by an aqueous work-up, led to the 


















Regiospecificity is achieved in this reaction, as it is well documented in the 
literature217,219'221 that lithium-halogen interconversion will occur preferentially at a 
halogen atom ortho to a heteroatom having an unshared electron pair. This is 
rationalised by assuming that the reaction involves initial co-ordination of the lithium 
cation with an unshared electron pair on the sulphur atom as illustrated below.
8 ”
Bu-
8 + L i-
Bu-
8 ”
Figure 17 Initial co-ordination between butyllithium and tetrabromothiophene.
There are many differing schools of thought regarding the mechanism for the ensuing 
reaction of this co-ordination complex. Morton222 claims that it involves electrophilic 
attack by the lithium cation. However, proposals by Roberts and Curtin220, and 
Sunthankar and Gilman221 that lithium-halogen exchange occurs via nucleophilic 
attack by the carbanion seem more feasible.
7.1.2 4-Bromothiophene-3-carboxylic acid.
Lawesson217 synthesised 4-bromothiophene-3-carboxylic acid (53) in 38% yield from
3,4-dibromothiophene (55) via a Grignard reagent followed by carboxylation with 
carbon dioxide. Improved yields were obtained using the halogen-lithium 
interconversion. However problems arise between the competing effects of 
lithium-halogen exchange and hydrogen abstraction. On metalation of thiophene with
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organolithium compounds, the most acidic hydrogen i.e. in the a-position, will 
usually react most rapidly to give the thermodynamically most stable lithium 
compound219. Thus special care has to be taken in choosing the experimental 
conditions to control the regioselectivity between these two processes.
Thus, following the conditions set out by Lawesson217, w-butyllithium was added to
3,4-dibromothiophene (55) in dry ether at -78°C. After stirring the solution for 
2.5 minutes, the lithium intermediate (58) was treated with solid carbon dioxide as 
shown in Scheme 13.






However, several attempts at this preparation afforded 4-bromothiophene-3-
217carboxylic acid (53) in only 12% yield, in contrast to 73% reported by Lawesson . 
Formation of the lithium intermediate (58) was tested by quenching the lithium 
intermediate with benzaldehyde. Quenching the reaction with reagents such as 
deuterium oxide or iodomethane would produce a product that was too volatile to be 
isolated, therefore benzaldehyde was used to add organic bulk to the molecule. 
4-Bromo-a-phenylthiophene-3-methanol (59) was formed in 63% yield, confirming 
the formation of the lithium intermediate (Scheme 14). Therefore, the problem must 
lie in the poor electrophilicity of carbon dioxide and the use of alternative carbonyl 
electrophiles was explored.
Ph
Investigative reactions using the same conditions as described for Scheme 14 were 
carried out on several 'carboxy' electrophiles, including dimethyl carbonate, diethyl 
carbonate and di-f-butyl dicarbonate. However, all these reactions gave very complex 
mixtures of products. More success was achieved with the more electrophilic ethyl 
chloroformate and methyl chloroformate, forming ethyl 4-bromothiophene-3- 
carboxylate (60) and methyl 4-bromothiophene-3-carboxylate (61), respectively.
Initial reactions between 3,4-dibromothiophene and butyllithium at -78°C, followed 
by addition of ethyl chloroformate after 2.5 minutes, produced only 19% of 
ethyl 4-bromothiophene-3-carboxylate (60). The difficulty with the reaction seemed 
to lie in the stability and reactivity of the lithium intermediate. Although the lithium 
intermediate was only formed for 2.5 minutes before addition of the electrophilic 
reagent, the large number of side products suggest that side reactions are occurring 
due to its reactivity. To prevent these occurring and enable greater control of the 
intermediate, addition of ^-butyllithium was performed at -116°C. The existence of 
the thienyllithium intermediate (58) was also reduced to 1.5 minutes before treatment 

























Although a few side-products were still formed due to the high reactivity of the 
reagents, the desired ester (60) was isolated in 41% yield - a two-fold increase 
compared to performing the reaction at -70°C (see Experiments I and IV in Table 2). 
Analogous quenching with methyl chloroformate afforded methyl 4-bromothiophene-
3-carboxylate (61) in 36% yield. Thus the lower temperature gave greater control of 
the reaction.
The side products from the reaction with ethyl chloroformate were isolated in the 
hope that knowledge of the products and their mechanism would assist in optimising 
the reaction conditions. Ethyl 3,4-dibromothiophene-2-carboxylate (62) was formed 
through two possible mechanisms - direct lithiation or via a two stage mechanism as 
illustrated in Scheme 16.
From surveying the literature, the formation of this side product is not surprising. 
Lawesson217 isolated ethyl 3,4-dibromothiophene-2-carboxylate at -70°C. It is also 
reported217'219,223 that metalation rather than halide-metal interconversion will occur 
if the reaction between bromothiophene compounds and w-butyllithium is allowed to 
proceed for longer periods and at higher temperatures. The most plausible 
explanation for this reaction is that 4-bromo-3-thienyllithium (58) must be able to
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metalate 3,4-dibromothiophene (55) faster than the halogen-lithium interconversion 
can take place. Another argument for this case is that the inductive effect of the 

















Other side products resulted from reactions involving the required ester, 
ethyl 4-bromothiophene-3-carboxylate (60). For example, further halogen-metal 
exchange of this ester produced diethyl thiophene-3,4-dicarboxylate (63), whereas 
metalation resulted in the formation of diethyl 4-bromothiophene-2,3-dicarboxylate 
(64). Evidence for the formation of (64) as opposed to its isomer, diethyl
3-bromothiophene-2,4-carboxylate was provided through the presence of the mass 
spectral peak at m/z (El) 233, corresponding to the formation of the anhydride (65). 
This species could only form if both ester groups are in adjacent positions on the 
thiophene ring. It seems that these thienyllithium side products have undergone 





Finally, ethyl 4-(4-bromo-3-thienoyl)thiophene-3-carboxylate (6 6 ) was also isolated. 
This structure was supported by mass spectrometry and two carbonyl peaks at 1720 
and 1670 cm' 1 corresponding to the ester group and the ketone respectively. Two 




From these results, it was proposed to decrease the concentration of 4-bromo-3- 
thienyllithium, thus preventing these intermolecular side reactions. A series of 
experiments justified this approach by exhibiting an increase in yield with a decrease 
in concentration with both ethyl and methyl chloroformate (See Table 2, Experiments 
H-VI). The nature of the lithiating agent was also investigated. w-Butyllithium proved 
to be the most effective lithiating agent. f-Butyllithium and sec-butyllithium both
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gave low yields of the product possibly due to steric effects (Table 1, Experiments 
VnandVm ).













I Et02CCl 3% -70°C w-BuLi 2.5 19%
n Et02CCl 1 0 % -116°C /i-BuLi 1.5 27%
m Et02CCl 5% -116°C n-BuLi 1.5 34%
IV Et02CCl 3% -116°C /z-BuLi 1.5 41%
V Me02CCl 1 0 % -116°C n-BuLi 1 .0 31%
VI Me02CCl 5% -116°C w-BuLi 1 .0 36%
v n Me02CCl 3% -116°C f-BuLi 1 .0 14%
vm Me02CCl 5% -116°C jec-BuLi 1 .0 5%
a Concentration of the halide in ether before addition of the lithiating agent. 
b Reaction time after addition of butyllithium before treatment with the electrophile. 
c Yield of ethyl 4-bromothiophene-3-carboxylate (60) or methyl 4-bromothiophene-
3-carboxylate (61) respectively.
Thus, the optimum conditions for the synthesis of ethyl / methyl 4-bromothiophene-
3-carboxylate are as follows;
1. Low concentration of substrate in ether.
2. Addition of butyllithium at -116°C.
3. Addition of the electrophilic reagent after 1.5 minutes.
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Subsequent base-catalysed hydrolysis224 of the esters (60) and (61) yielded 
4-bromothiophene-3-carboxylic acid (53), the key intermediate for the synthetic 
sequence of the thienopyridinones, in virtually quantitative yield.
7.2 Condensation Reactions of 4-Bromothiophene-3-carboxylic Acid and 
Related Compounds with |3-Diketones.
In 1929, Hurtley225 showed that 2-bromobenzoic acid condensed with sodium 
enolates of various p-dicarbonyl compounds in ethanol, in the presence of either 
copper powder or copper (II) acetate as a catalyst (Scheme 18).




Cirigottis et al.226 varied Hurtley’s conditions in reactions of 2-bromobenzoic acid 
and other haloaromatic compounds with various (3-dicarbonyl compounds and 
reported the following conclusions:-
1. Apart from dimethylformamide, which gives a very low yield, the only effective 
solvents are alcohols or water.
2. The reaction succeeds best with aromatic obromocarboxylic acids, although 
oiodo acids give low yields.
3. Replacement of the carboxyl group by any other group prevents the reaction.
4. A copper species is an essential catalyst.
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Realising the potential value in the synthesis of heterocyclic compounds, Ames and 
Ribeiro227 applied the Hurtley reaction to condensation reactions with 
4-bromothiophene-3-carboxylic acid with good results. Therefore, this seemed the 
logical route for the introduction of the two-carbon unit shown below in bold, needed 




Consequently, ethyl 4-carboxythiophen-3-ylacetate (69) was synthesised by 
condensing the enolate of ethyl 3-oxobutanoate (70) with 4-bromothiophene-3- 
carboxylic acid (53) in the presence of copper powder as shown in Scheme 19.
,c o 2h  o  o  ^  x o 2h
|J |j NaOEt, EtOH, Cu
•Br Reflux, 16 h \ ^ K ^ C 0 2Bt
(53) (70) (69)
Scheme 19
This product is derived through loss of the acetyl group of the initially formed 
thiophene p-dicarbonyl intermediate (71) by a retro-Claisen reaction. Similar 
cleavage reactions have been reported occasionally for the thiophene and 
benzene228 series, and they are found to occur readily using the sodium ethoxide and 
ethanol system when excess base is present. The mechanism for this reaction is 
illustrated in Scheme 20. The possibility of intramolecular anchimeric assistance
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from the carboxylate group makes the thiophene p-dicarbonyl intermediate (71) 
remarkably sensitive to the base228.
2-Substituted quinazolin-4-ones are good inhibitors of PARP188,189, thus it was 
predicted that a methyl or aryl group at the corresponding 3-position in the 
thienopyridinone series may enhance activity. Therefore condensation reactions using 
pentane-2,4-dione and l-phenylbutane-l,3-dione were investigated to introduce
3-methyl- and 3-phenyl- to the thienopyridinone system (52).
Ames and Ribeiro227 had reported, that using the Hurtley conditions in the reaction 
between pentane-2,4-dione and 4-bromothiophene-3-carboxylic acid, partial 
deacetylation occurred to produce a mixture of mono- and di-oxo-acids. 
Deacetylation could however be avoided by performing the reaction with potassium 
r-butoxide in f-butyl alcohol i.e. in the absence of exogenous nucleophiles227. 
Consequently, pentane-2,4-dione enolate (formed using potassium f-butoxide) was 
condensed with 4-bromothiophene-3-carboxylic acid (53) in the presence of copper 
to afford 4-(l-acetyl-2-oxopropyl)thiophene-3-carboxylic acid (72) in 76% yield. 
This product (72) was efficiently deacetylated with aqueous ammonia to form the 




Analogous treatment of 4-bromothiophene-3-carboxylic acid (53) with
l-phenylbutane-l,3-dione and potassium r-butoxide yielded only starting material. 
However, 4-(2-oxo-2-phenylethyl)thiophene-3-carboxylic acid (74) was achieved 
using the Hurtley conditions, i.e. sodium ethoxide, ethanol and copper, albeit in low 



















4-Ethoxythiophene-3-carboxylic acid (75) was isolated as a side product to this 
reaction in 1 1 % yield and arises from competition between the anion of the
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(3-diketone and the conjugate base of the protic solvent. This phenomenon was also 
reported in the benzene series by Bruggink and McKillop228. Thus, owing to lower 
yields obtained as a result of this side-product, they investigated alternative solvent 
and base systems to avoid this undesired nucleophilic competition. They discovered 
that, as well as disfavouring the side-product, condensation of 2 -bromobenzoic acid 
with p-diketones in the presence of copper(I) bromide and sodium hydride occurred 
in excellent yield (see Table 3) and in shorter reaction times, and was widely 
applicable to a range of halo-benzoic acids and p-dicarbonyl compounds.
Table 3 Comparison of the yields for the condensation reaction of
2 -bromobenzoic acid under different reaction conditions.






R" for Yield Cc Yield C
NaH,
CuBr
c 6h 5 c h 3 CH2COPh 78% - CH(COMe)COPh 98%
c h 3 c h 3 CH(COMe) 2 34% 75% CH(COMe) 2 91%
c h 3 OC2H5 CH2C02Et 56% 95% CH(COMe)C02Et 91%
a Yields reported by Bruggink and McKillop228, reproducing reaction conditions 
described by Hurtley. 
b Yields reported by Hurtley225. 
c Yields reported by Bruggink and McKillop228.
Thus these new conditions were applied to the condensation reaction with
l-phenylbutane-l,3-dione to attempt to improve the yield of (74). However, 
treatment of 4-bromothiophene-3-carboxylic acid (53) with l-phenylbutane-l,3-dione
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in toluene with copper(I) bromide produced a modest 40% of 4-(2-oxo-2- 
phenylethyl)-thiophene-3-carboxylic acid (74). From the analogous condensation of 
4-bromothiophene-3-carboxylic acid (53) with pentane-2,4-dione, 64% of 
4-(l-acetyl-2-oxo-propyl)thiophene-3-carboxylic acid (72) was isolated.
Experimental evidence from Cirigottis et al226 shed light on the low yield of 
4-(2-oxophenylethyl)thiophene-3-carboxylic acid (74) using the Hurtley conditions 
(Scheme 21). They showed that, for condensation reactions using copper(II) acetate 
in the presence of oxygen, the yield of the reaction was significantly lower than a 
comparative reaction using copper, copper(I) oxide or chloride. Furthermore, 
Bruggink and McKillop also reported decreases in yield for similar reactions 
carried out under an atmosphere of nitrogen using copper powder. Therefore, from 
these observations one can speculate that Cu(I) must be the effective catalyst for the 
Hurtley reaction since there appears to be negligible catalysis occurring when Cu(II) 
or Cu(0) are present. In the synthesis of 4-(2-oxophenylethyl)thiophene-3-carboxylic 
acid (74), copper powder was used in the presence of nitrogen, thus preventing the 
formation of the effective copper(I) ions to catalyse the reaction and hence 
accounting for the low yield of the product.
Goldberg229 and Mayer and Fikentscher230 have postulated that the mechanism of the 
Hurtley reaction in the benzene series involves formation of a copper chelate of
2-bromobenzoic acid (6 8 ), as illustrated below (Scheme 22). The bromine is 
activated towards nucleophilic displacement by polarisation of the C-Br bond, which 








However, Bruggink and McKillop228 believe that the proximity of the bromo and 
carboxylate groups, as well as the ease of chelate formation, are more important 
factors than C-Br bond polarisation. They suggest that the mechanism proceeds 
through tetrahedral co-ordination of the copper(I) ion to 2-bromobenzoic acid and 
one of the oxygen atoms in the p-dicarbonyl carbanion, enabling the attacking 
nucleophile to be within easy reach of the electrophilic carbon centre. This possible 










Further condensation experiments were also carried out. Treatment of methyl
4-bromothiophene-3-carboxylate (61) with pentane-2,4-dione under the Hurtley 
conditions yielded only starting material. This is consistent with the literature
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reports225,226 that, under these conditions, substitution will only occur with 
compounds containing bromo- and carboxylic acid groups in close proximity.
Synthesis of 4-bromo-5-nitrothiophene-3-carboxylic acid (76) was achieved in 54% 
yield with acetyl nitrate formed in situ. It was planned that incorporation of the nitro 
group at this stage would avoid the need for regioselective nitration of the final 
thienopyridinone ring. One would predict that condensation reactions with 4-bromo-
5-nitrothiophene-3-carboxylic acid should be more facile than its unnitrated analogue 
due to the strong electron-withdrawing effect of the nitro group, making the bromo 
atom more susceptible to nucleophilic displacement. The mechanism for this reaction 
may be different and proceed through a Meisenheimer-type adduct (79) as 
illustrated in Scheme 24. However condensation of this analogous nitro compound 








Analogous treatment of 4-bromothiophene-3-carboxylic acid (53) with 3-methyl-2,4- 
pentane-2,4-dione produced none of the desired condensation product (77) 
(Scheme 21). The rigidly planar 3-methylpentane-2,4-dione enolate was probably
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prevented from adopting the necessary steric position for the displacement of the 
bromine atom.
7.3 Synthesis of 6-MethyltMeno[3,4-c]pyridin-4(5H)-one and 6 -Phenyl- 
thieno[3,4-c]pyridin-4(5H)-one.
Initially work was undertaken to cyclise ethyl 4-carboxythiophen-3-ylacetate (69) to 
6,7-dihydrothieno[3,4-c]pyridine-4(5H)-one (52), following the synthetic route 
outlined in Scheme 25. Selective reduction of the imide (81) should take place at the 
more electrophilic carbonyl group with sodium borohydride, followed by reduction 














Preparation of 4-carboxythiophen-3-ylacetamide (80) was achieved in 92% yield by 
treatment of the ester (69) with ammonia. However, all attempts at cyclisation of this 
acid-amide (80) failed. An alternative route to this thienopyridone (52) involved
conversion of the acetate (69) to 4-thiophenecarboxamide-3-acetate, via an acid 
chloride. Subsequent cyclisation of this compound would lead to the dione (81). 
However, only a small amount of the amide could be isolated. Other possible routes 
could be investigated. However, at this stage it was important to determine whether 
this series of thienopyridinones do in fact inhibit PARP. Suto had reported127 little 
deviation in inhibitory activity between dihydroisoquinolinones and isoquinolinones. 
Thus, the more straightforward cyclisation of 6 -methyl- (83a) and 6 -phenyl- 
thienopyridinones (83b) were undertaken.
4-(2-Oxopropyl)thiophene-3-carboxylic acid (73) and 4-(2-oxo-2-phenylethyl)- 
thiophene-3-carboxylic acid (74) were cyclised to (83a) and (83b) respectively using 
ammonium acetate in hot acetic acid, in 6 8 % and 43% yields, respectively 
(Scheme 26). All attempts to reduce the double bond in the pyridinone ring of 
6-methylthieno[3,4-c]pyridin-4(5H)one (83a) with sodium cyanoborohydride under 
acidic conditions were unsuccessful.
reflux, 2 0  h
a: R = Me (73) 
b: R = Ph (74)
Scheme 26
These synthesised thienopyridinones were tested immediately. The 6 -methyl- (83a) 
and 6 -phenylthienopyridinones (83b) were found to inhibit 90% and 93% of PARP
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activity, respectively, at 10 jiM . These results are discussed in more detail in Chapter 
Ten. In the light of these results, further work was undertaken on analogues of 
6 -phenylthienopyridinone to define the structural requirements necessary for potent 
inhibition of PARP.
7.4 Synthesis of 6 -Arylthienopyridinones.
It is reported189,191 that the presence of bulky groups in a PARP inhibitor are not only 
tolerated but enhance activity when placed in appropriate regions in space. This 
evidence, together with the promising PARP activity exhibited by the
6 -phenylthienopyridinone (83b), prompted extension of this series to 6 -aryl- 
thienopyridinones (84).
(83)
a: R = Me 
b: R = Ph
(84)
X: a = N 0 2  
x  b = Br
c = I 
d = OMe
It was intended to undertake a similar synthetic route as described for the preparation 
of (83). Thus condensation of 4-bromothiophene-3-carboxylic acid (53) with
4-substituted phenyl p-diketones (85) and subsequent cyclisation should lead to the 
required 6 -(substituted phenyl)thienopyridinones (84). These electronegative and 
electron-donating groups were selected to observe their effects on inhibitory activity. 
They also provide opportunities for further elaboration on the phenyl ring, for
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example, through reduction then diazotisation of the nitro analogue (84a) or through 
Stille couplings with the iodo analogue (84c).
6.4.1 Synthesis of 4-Substituted Phenyl p-Diketones.
Synthesis of the required 4-substituted phenyl P-diketones (85a-85d) was undertaken 
through the reaction of bis(pentane-2,4-dionato)copper(II) (8 6 ) with the 
corresponding 4-substituted-benzoyl chloride to produce the trione (87). 
Deacetylation with ammonia produced the corresponding 4-bromo-, 4-iodo- and







X: a = N 0 2 
b = Br 
c = I 
d = OMe
Scheme 27




The high yields of 4-substituted benzamides (90) form either through the reaction of 
the unreacted substrate with ammonia or from inappropriate acyl cleavage of the
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trione (87) by ammonia. The other side-products result from a second deacetylation 
of the p-diketone formed to produce 4-substituted acetylbenzenes (8 8 ) and hydrolysis 
of the acid chloride to yield the corresponding carboxylic acid (89).
Table 4 Yields of the products from various 4-substituted benzoyl chlorides in 









X = N 0 2 (a) 7% 5% - 2 %
X = Br (b) 45% 3% 2 % 26%
X = I (c) 17% 2 % - 77%
X = OMe (d) 3% - - 59%
Despite performing the reaction under more vigorous conditions, the yield was not 
improved. Thus a different method was adopted for the preparation of the 
l-(4-methoxyphenyl)butane-l,3-dione (85d). Claisen condensation of 4-methoxy-l- 
acetylbenzene (8 8 d) with ethyl acetate produced l-(4-methoxyphenyl)butane-l,3- 
dione (85d) in 91% yield. (Scheme 28). The ratio of keto : enol tautomers was found 
to be 5 : 1 from the NMR spectrum.








7.4.2 Condensation Reactions of 4-Bromothiophene-3-carboxylic Acid with
4-Substituted Phenyl-p-diketones.
Condensation of 4-bromothiophene-3-carboxylic acid (53) with these synthesised 
p-diketones was undertaken using the Hurtley conditions as described in Section 7.3. 
Thus, the sodium enolate of the 4-substituted phenyl P-diketones (85a-85d) was 
condensed with 4-bromothiophene-3-carboxylic acid (53) using copper as a catalyst, 
as illustrated in Scheme 29. Again, deacetylation occurs by a retro-Claisen reaction of 
the initially formed thiophene p-dicarbonyl product.
C 02H X: a = N 0 2 
b = Br 
c = I






However, only the 4-nitrophenylbutane-l,3-dione (85a) condensed with the 
thiophene (53) to form 4-[2-(4-nitrophenyl)-2-oxoethyl]thiophene-3-carboxylic acid 
(92a) in 14 % yield (See Table 5). The nature of the side products and the large 
percentage of recovery of the thiophene substrate indicate that the P-diketone is more 
susceptible to attack by the ethoxide nucleophile than the thiophene ring.
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Table 5 The products obtained from the condensation reaction using the
Hurtley conditions between 4-bromothiophene-3-carboxylic acid and 









.J O * - .J O * - . X T ”
HOjC OEt HO2C Br
Compd. No (92) (91) (8 8 ) (89) (75) (53)
4-N02 (a) 14% - - 40% - -
4-Br (b) - 1 1 % 25% 29% 1 0 % 41%
4-1 (c) - 16% 28% 5% - -
4-OMe (d) a 23% 57% 17% 16% 76%
a 23 % of the analogous 4-(l,2-dioxo-2-(4-methoxyphenyl)ethyl)thiophene-3- 
carboxylic acid (93) was produced (see Scheme 31).
There is evidence in the literature that this cleavage of the p-diketones occurs in the 
keto form rather than the enol form233'235. The p-diketones side products result from 
nucleophilic attack at the two different carbonyl groups in a reverse Claisen reaction 
as shown in Scheme 30. There is a decrease in the products arising from route A, i.e. 
the 4-substituted acetylbenzene, as one moves down the table due to the electronic 
effects of the substituents. The electron withdrawing groups make the carbonyl a  to 
the benzene ring more electrophilic and nucleophilic attack occurs mainly through 
route B. The presence of the nitro group also promotes hydrolysis to the 











An interesting result was obtained in the reaction with the 4-methoxyphenyl 
p-diketone (85d). NMR and mass spectrometry confirmed the formation of
4-[l,2-dioxo-2-(4-methoxyphenyl)ethyl]thiophene-3-carboxylic acid (93) shown 
below, as a product of the condensation reaction in Scheme 29. This compound must 
have formed from oxidation of the methylene group in the desired condensation 
product (92d). One may speculate that copper(II) bromide, formed through a reaction 
of 4-bromothiophene-3-carboxylic acid and the copper catalyst, may lead to 
bromination at the methylene group adjacent to the thiophene ring (94). Hydrolysis of 




7.5 Attempted Synthesis of 6-(4-Nitrophenyl)thieno[3,4-c]pyridin- 
4(5H)-one.
Cyclisation of 4-[2-(4-nitrophenyl)-2-oxoethyl]thiophene-3-carboxylic acid (92a) 
was attempted by the method of Ames227, which was successfully employed in the 
synthesis of the 6 -methyl (83a) and 6 -phenylthienopyridinones (83b). However, only 
starting material was obtained following treatment of (92a) with ammonium acetate 




7.6 Nitration of 6-Methylthieno[3,4-c]pyridin-4(5H)-one and 6 -Phenyl-
thieno[3,4-c]pyridin-4(5H)-one.
Selective nitration of the thienopyridinones (83) was required at the 1-position, 




n h 2 a: R = Me 
b: R = Ph
(23) (95) (96)
Strong nitrating systems, such as a mixture of nitric and sulphuric acid, may cause 
the ring to disintegrate, thus acetyl nitrate, formed from fuming nitric acid and acetic 
anhydride, was utilised initially.
90% HN03, Ac20  
-10 °C, 5 min . Me
Me
(83a)











A mixture of products was isolated from the nitration of 6 -methylthieno- 
[3,4c]pyridin-4(5H)-one (83a), with 22% of the required product (96a), nitrated at 
the 1-position (Scheme 33). A longer reaction time led to dinitration (98) of the 
substrate. Observations of the ratios of yields obtained for these compounds (see 
Table 6 ) suggests that the second nitration occurs on (96a) between 5-10 minutes as 
shown by the dotted arrow in Scheme 33.













r Y S t
02N N02
(98)
R = Me (a) 90% HN03 / Ac20, 
5 min, -10°C
2 2 % 38%
R = Me (a) 90% HNO3 / Ac20 , 
10 min, -10°C
1 0 % 25%
R = Me (a) KNO3 /CF 3CO2H, 
5 min, -10°C
36%
R = Ph (b) 90% HNO3 / Ac20 , 
5 min, -10°C
16% 25%
R = Ph (b) KNO3 /CF 3CO2H, 
5 min, -10°C
36%
The structures were elucidated by NMR spectroscopy. Nitration is unlikely at the
3-position of the ring system adjacent to the electron-withdrawing carbonyl group. 
Two singlets at 6  6.89 and 8.87 ppm were assigned as the signals from the 7-position
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of the pyridinone and 3-position on the thiophene ring, confirming that selective 
nitration had occurred at the latter position to yield the required structure (96a). The 
presence of a well resolved AB pattern for the two thiophene ring protons, together 
with a W-coupling constant of 3.3 Hz (illustrated below (97a)) in the region observed 
for 3,4-disubstituted thiophenes208, substantiated structure (97a). More difficulty was 
found in assigning the structure of (98a). The singlet at 8  8.99 ppm could, in 
principle, belong to three possible dinitrated structures (98a), (99), or (100), 
illustrated below.
(97a) (98a) (99) (100)
Again, since it is unlikely that a second nitration would occur at the 3-position of the 
ring system, structures (99) and (100) can be discounted. From previous results, the 
chemical shift for the pyridinone proton in structure (1 0 0 ) is expected to be further 
upfield.Thus, this circumstantial evidence suggests that the most plausible structure 
is l,7-dinitro-6-methyl-thieno[3,4-c]pyridin-4(5H)-one (98a).
Nitration of 6 -phenylthienopyridinone (83b) with acetyl nitrate produced a similar 
result to the 6 -methyl analogue when the reaction was quenched after 5 minutes, as 
shown in Scheme 34. The required compound, l-nitro-6-phenylthieno[3,4-c]pyridin- 
4(5H)-one (96b) was synthesised in 16% yield.
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H 90% HN03, Ac20







Owing to the low yields obtained for the required nitro compound in both the 
6 -methyl and 6 -phenylthienopyridinone series, further nitrating systems were 
investigated to attempt to improve the synthesis. Kawazoe and Yoshioka reported 
that nitration of isoquinolin-l-one with potassium nitrate and sulphuric acid produced 
5-nitro- and 7-nitroisoquinolinone. It was proposed that nitration took place in the 
phenyl ring owing to deactivation of the pyridone ring by protonation. This selective 
nitration had also been achieved in the furan ring of 2 -(furan-2 -ylmethyl)isoquinolin-
1-one by Berry et al231. Therefore, it was hoped that nitration in a strongly acidic 
medium would promote selective nitration in the thiophene ring also. Thus, nitration 
was performed using potassium nitrate and trifluroacetic acid on both the 6 -methyl 
and 6 -phenylthienopyridinone (83a and 83b) substrates, as illustrated in Scheme 35. 




a: R = Me 
b: R = Ph
Scheme 35
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Analysis of the inhibitory activity of these nitrated thienopyridinones showed that the 
differential between nitrated and unnitrated analogues was not as large as was hoped. 
In comparison to the inhibitory activity of the parent compounds, nitration at the
1-position significantly reduced inhibition of PARP in 6 -methylthienopyridinone 
(96a), whereas the analogous 6 -phenyl compound (96b) exhibited only a very slight 
decrease in inhibitory activity. This effect was reversed when nitration of these 
thienopyridinones occured in the 7-position, with 7-nitro-6-methylthienopyridinone 
(97a) exhibiting comparative activity to (83a), whereas the 7-nitro-6-phenyl analogue 




Quinazolinones (27, 101) have been reported in the literature188’189 to be potent 
inhibitors of PARP and of the same order of potency as the isoquinolinones reported 
by Suto127. As a result of the promising activity obtained in the thienopyridinone 
series, the investigation of a series of thienopyrimidinones (1 0 2 ) was undertaken in 










a: R = Me 
b: R= Ph
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It was intended to build the pyrimidinone ring from ethyl 4-aminothiophene-3- 
carboxylate hydrochloride (103), a key intermediate in the synthesis of these 
compounds. Due to the difficulty in forming aminothiophenes through reduction of 
the corresponding nitro compound as described in Chapter Six, it was decided that 
this intermediate should be synthesised through rearrangement of the corresponding 
oxime (104).
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8.1 Synthesis of Ethyl 4-amino-thiophene-3-carboxylate hydrochloride.
Initial steps to the synthesis of ethyl 4-aminothiophene-3-carboxylate hydrochloride 
(103) involved the formation of methyl 3-(methoxycarbonylmethylthio)propanoate 
(105), which was prepared in high yield through the nucleophilic addition of methyl 
mercaptoacetate (106) to methyl propenoate (107) in the presence of catalytic 










Dieckmann cyclisation of the diester (105) can take place in two directions to form 
the cyclic P-keto esters methyl (±)-3-oxotetrahydrothiophene-2-carboxylate (108), or 










Woodward and Eastman238, and Duus239 reported that the direction of cyclisation 
may be controlled by the choice of reaction conditions. When the cyclisation is 
undertaken at 0°C using sodium methoxide or ethoxide as a base, the p-keto ester 
(108) is the major product, whereas if the reaction is performed under the same 
conditions but in boiling toluene, (109) is the sole product. This dual potentiality of 
the sulphide diester has been interpreted by Woodward and Eastman238 to be a result 
of anion stabilisation by the sulphur atom. Anion (105a) is formed more rapidly 
through kinetic control and forms (108), whereas, at higher temperatures, 
thermodynamic control results in the formation of (109).
238However, all attempts to cyclise to (109) with sodium methoxide in toluene 
resulted in the isolation of starting material (105). Stronger bases such as sodium 
hydride, lithium hexamethyldisilazide and potassium r-butoxide in higher boiling 
solvents, such as xylene did not produce the p-keto ester (109). Success was achieved 
by refluxing the diester (105) in dry ethanol with sodium ethoxide, producing 14% of 
the required product, ethyl (±)-4-oxotetrahydrothiophene-3-carboxylate (110) through 
transesterification, and 10% of the isomeric p-keto ester, (111) (Scheme 38).
The presence of double sets of ester group protons and an distinct enol proton signal 
at 11.0 ppm in the NMR spectrum of ethyl (±)-4-oxotetrahydrothiophene-3- 
carboxylate (1 1 0 ) indicate that both tautomers (1 1 0 a) and (1 1 0 b) are present. 
However, both NMR and IR spectra confirmed that the predominant tautomer in this 
compound is the enolic form (110b). In contrast, the isomeric ethyl 
(±)-3 -oxotetrahydrothiophene-2 -carboxylate (1 1 1 ) exists mainly in the keto form
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(111a) under the same conditions. This is a surprising result as one would have 
expected the stability of the 2 -thiolene system (1 1 1 b) to be greater than that of the
3-thiolene isomer (110b) due to the potential for conjugative interaction between the 
C=C double bond and the sulphur atom239. However, this observation is consistent 
with experimental evidence reported by Biichi et al240 that 4-acetylthiophen-3-one is 
completely enolic in tetrachloromethane, whereas 2 -acetylthiophen-2 -one is only 






O reflux, 16 h
(105)
(1 1 0 b)
EtO
(1 1 1 b)
Scheme 38
Problems were encountered on scale up of this reaction and the yield of the required 
p-keto ester (110) dropped to 10%. This may be due to a reverse Michael reaction to 
reform the original substrates (106 and 107). The yields reported in the literature for 
Dieckmann condensation to form this p-keto ester are very low, generally 
30-35%238,239.
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Ethyl (±)-4-oxotetrahydrothiophene-3-carboxylate (110) was subsequently converted 
to the corresponding oxime (104) in 95% yield, by treatment with hydroxylamine 
hydrochloride and barium carbonate241. NMR spectroscopy indicates a 4 : 1 mixture 
of geometrical isomers and it is likely that the predominant isomer is the trans isomer 
due to steric effects.
C° 2Et BaC03> ' C° 2Et - ' C° 2Et
H2NOH. HC1 s. | HCl,Et20  S.




Subsequent treatment of the oxime (104) with hydrogen chloride241 produced ethyl 
4-aminothiophene-3-carboxylate hydrochloride (103), the key intermediate for this 
series in 95% yield (Scheme 39).
8.2 Synthesis of 2-Methylthieno[3,4-d]pyrimidin-4(3H)-one and 2-Phenyl- 
thieno[3,4-d]pyrimidin-4(3H)-one.
Acylation of ethyl 4-aminothiophene-3-carboxylate hydrochloride (103), with acetyl 
chloride and benzoyl chloride produced the corresponding 4-acetamido- (112a) and 
4-benzamido compounds (112b) as shown in Scheme 40. Cyclisation to the 
corresponding thienopyrimidinones was initially attempted with ammonium acetate 
in hot acetic acid227. This method was used effectively for cyclisation in the 
thienopyridinone series, however, only starting material was recovered in the 
attempted cyclisation of starting material (1 1 2 ) using this method.
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o
C02a  a: AcCl, 
„ / ^ f  b: PhCOCl
S\ A   - s
n h2.hci Et3N
C02Et NH4OAC, AcOH 
 X  ► s
NHCOR reflux, 20 h \ X a
(103) (112a) R = CH3 




However, cyclisation of this compound (112b) to the required thienopyrimidinone 
(103b) was achieved using an alternative route as illustrated in Scheme 41. 
Base-catalysed hydrolysis produced the corresponding carboxylic acid (113b) in 
virtually quantitative yield. The carbonyl group was subsequently activated through 
cyclisation with acetic anhydride to the thienooxazinone (114b) in 94% yield, and 
treated with ammonia to furnish the corresponding amide (115b). Mehta and Patel242 
reported base-catalysed cyclisation of 3-acetamino-2-naphthamide to yield the 
corresponding benzoquinazolinone. This method was adopted for the analogous 









a: R = Me 











A similar sequence of high yielding reactions produced the required
2-methylthienopyrimidinone (102a). A proposed mechanism for this base-catalysed 
cyclisation is illustrated in Scheme 42.
Biological evaluation of the these thienopyrimidinones was undertaken in this series.
2-Mehylthienopyrimidinone (103a) exhibited good inhibitory activity of PARP with 
81% inhibition at 10.8 jjM. This result again confirms that heterocyclic analogues of 
PARP inhibitors can also act as good inhibitors of PARP. 2-Phenylthieno- 
pyrinidinone (103b) however, was not a good inhibitor exhibiting only 42% 











To investigate the effect of other heterocyclic rings on PARP inhibition, the synthesis 
of a series of imidazopyrimidinones (116) and imidazopyrazinones (117) were 
undertaken. These compounds are analogues of the potent 5-substituted
177dihydroisoquinolinone (51) PARP inhibitors .
The radiosensitising ability of nitroimidazoles is well known3,16,71, but, to date, there 
are no reports of imidazoles acting as PARP inhibitors. Furthermore, it is known that 
nitroimidazoles are selectively reduced in hypoxic tumour cells to the corresponding 
aminoimidazoles30. Thus this evidence makes fused imidazoles ideal candidates for 
potential selective PARP inhibitors.
9.1 Imidazopyrimidinones.
Initial approaches to the synthesis of the target imidazopyrimidinone (116b) involved 
synthesis of 7,8-dihydroimidazo[ 1,5-c]pyrimidin-5(6H)-one (116a) based on the 
method of Jairam and Potvin243. Treatment of imidazole-4-ethanamine (118) with
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bis(4-nitrophenyl) carbonate, a phosgene equivalent, gave the parent 
imidazopyrimidine (116a) in 78% yield (Scheme 43).
Imidazoles are not as susceptible to electrophilic attack as thiophene, furan or 
pyrrole, and can only be nitrated under forcing conditions. The presence of the 
nitrogen atom deactivates the ring towards electrophilic attack by withdrawing 
electron density from the ring. A further feature of imidazoles is the ease with which 
the nitrogen at N-3 is protonated. Thus nitration carried out in strongly acidic 
conditions occurs on the imidazolium cation (119) yielding nitroimidazole (120) after 
loss of two protons206 (Scheme 44). Nitration occurs at position 4 or 5 on the 
imidazole, and nitration at C-2 is very unusual244.
O
NH2 (4-02NC6H40)2C0
i, reflux, 24 h











Various nitrating systems were employed to nitrate the imidazopyrimidinone 
substrate (116a) as shown in Scheme 45 (See Table 7).
(116a) (116b)
Scheme 45
Table 7 The yields of l-nitro-7,8-dihydroimidazo[l,5-c]pyrimidin-5(6H)-one 
(116b) using various nitrating reagents (Scheme 45).
Experiment
No.
Reagents Yield of 
(116b)
a 90% HN03, Ac20 multiple
products
b k n o 3, h 2s o 4 1 0 %
c c. HN03, c. H2S04,40°C 38%
Success was achieved using the 'mixed acids' nitrating system of concentrated nitric 
and sulphuric acids, and also with potassium nitrate. However, these yields were low 
and further work was undertaken to synthesise this target compound through other 
routes.
It was proposed that imidazole-4-ethanamine (118) should be nitrated initially 
followed by ring closure to furnish the imidazopyrimidinone (116b). As amines can 
be N-nitrated and are also vulnerable to oxidation by nitric acid245, the side chain was
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protected as an amide prior to nitration with acetic anhydride. Tautz et al246 reported 
the successful nitration of histamine derivatives using concentrated nitric and 
sulphuric acids at 40°C. This system was applied to 4-(2-acetamidoethyl)imidazole 
(121). Concurrent nitration and deacetylation occurred to produce 5-nitroimidazole-
4-ethanamine (122) in 8 6 % yield (Scheme 46).
/ i^ N H  NH2  ... . _ / ^ N A c  NHAc NHAc
N I pyridine, Ac20  N I I MeOH N I I
reflux,24h *  *■
(118) (121)




A VariousN - H rea®entS , / ^ N H  NH2
N I I —  N,
0 2N 0 2N
(116b) (122)
Scheme 46
However, all attempts to cyclise this compound with phosgene and its equivalents 
failed. Interestingly, in all attempted cyclisations a small amount (15-20%) of the 
ethenylnitroimidazole (123) was observed in the NMR spectrum of the crude 
mixtures. One may postulate that this side product arises via the carbamoyl chloride 
(124) (Scheme 47). No elimination product was obtained when the same reactions 
were performed in the absence of base. This confirms that this elimination must 
occur on the initial substrate or an intermediate rather than through elimination of
111
any product formed, since the dihydroimidazopyrimidinone (116b) is stable to non- 
nucleophilic base.
THF




A further route to (116b) involved nitration of imidazole-4-propanoic acid and 
cyclisation of an isocyanate formed by a Curtius rearrangement. Hydrogenation of 
imidazole-4-propenoic acid (125) by the method of Altman et a / 247 furnished 
imidazole-4-propanoic acid (126) in moderate yield. Nitration of this product with 
concentrated nitric and sulphuric acids 246 gave 5-nitroimidazole-4-propanoic acid 
(127) in 27% yield (Scheme 48).
H2 /Pd,AcOH ^  c.HNOi /  C.H2 SO4  _
N^ N H  n^ n h  - 40O^ -  > n^ nh
Scheme 48
'C 02H nc o 2h  /  v  x o 2h
o 2n
(125) (126) (127)
The Curtius rearrangement via the corresponding acid chloride (128) was monitored 
by infra-red spectroscopy. The appearance of a azide (129) peak at Vma* 2130 cm' 1 
was observed on addition of sodium azide to the acid chloride. This peak was
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replaced by an isocyanate (130) peak at Vmax 2270 cm' 1 when the isolated azide was 
heated to 70°C in an inert solvent. Further heating caused cyclisation on to the 
required nitroimidazopyrimidinone (116b) (Scheme 49) in 15% yield. Migration of 
the alkyl group to form the isocyanate is thought to be a concerted process in the 
Curtius reaction248,249.
SOCl2/DM F NaN3 /H 20 , 0 °C
/^N H  --------------- ► /T'NH  ► /T'NH
N 16h N I Acetone N
‘C 0 2H f  COC1 /  c o n 3









The nitroimidazopyrimidinone (116b) was obtained via this synthetic route in only 
2.2% overall yield. Thus the direct approach, nitrating the imidazopyrimidinone 
(116a) with concentrated nitric and sulphuric acids, is the most efficient route to this 
target compound.
Imidazopyrimidinone (116a) and the corresponding 1-nitrated imidazopyrimidinone 
(116b) were found to inhibit 50% and 5% of PARP activity respectively at 10 |liM. 
This low inhibition may result from hydrolysis of the N-acyl group at the pH of the
113
assay conditions and thus may not be due to the presence of the imidazole ring. 
However, the difference between these results is interesting. Assuming that the 
aminoimidazopyrimidinone would have no lower activity than (116a), the large 
differential between the nitro and amino compounds needed for selectivity in hypoxic 
tissue could be achieved in this series. Thus, more work must be undertaken in order 
to obtain analogues displaying more potent inhibition of PARP, whilst still retaining 
the desirable large differential.
9.2 Imidazopyrazinones.
Retrosynthetic analysis of the target imidazopyrazinone (117c) showed an alternative 
and challenging synthetic route to this compound. It was proposed to construct the 
piperazinone ring initially and then build the imidazole onto this template as 






9.2.1 Synthesis of Piperazinone.
Aspinall250 synthesised piperazinone (131) in 45% yield, through the addition of 
ethyl chloroacetate to an excess of ethane-1 ,2 -diamine with subsequent cyclisation at 
200°C under high vacuum (Scheme 51). However, use of this procedure resulted in 
the formation of a black tar from which only 3% of the required product could be 
isolated. Thus alternative routes to this key intermediate were sought.
The first stepwise approach to piperazinone confirmed initial formation of the amide 
bond, with proposed ring closure of the 4,5-bond. Boc-glycine pentafluorophenyl 
active ester281 (132) was converted to the 2-chloroethylamide (133). Acidic 
deprotection gave the salt (134). However, this could not be cyclised under a variety 
of basic conditions and treatment of the crude reaction mixture with benzyl 




































This inability to cyclise is probably due to the unfavourable conformation of the 
amide. The most favourable geometrical isomer for amides both on electronic and 
steric grounds is the trans (Z) isomer. However, for cyclisation to occur it is 





The feasibility of constructing an N-4-protected piperazinone by final formation of 
the 1,6-bond was investigated. The acetal (139) is a key intermediate, containing a 
masked aldehyde for subsequent reductive animation. The anion of N-trifluoromethyl 
glycinamide (137) (prepared from glycinamide and ethyl trifluoroacetate) did not 
react with bromoacetaldehyde dimethyl acetal. The alternative sequence to (139), 
trifluoroacetylation of aminoacetaldehyde dimethyl acetal and introduction of the 
acetamide to give N-(2,2-dimethoxyethyl)-trifluoroacetamide (138), also failed at the 
alkylation step, again owing to insolubility of the anion.
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DiMaio and Belleau251 prepared ethyl (2,2-dimethoxyethylamino)acetate (141) in 
60% from the addition of ethyl iodoacetate to a mixture of 2 ,2 -dimethoxyethylamine 
(140) and sodium carbonate at 0°C, as shown in Scheme 54.
MeCX 1. K2CO3, EtOH, 0°C MeO>^
N H 2 -----------------------------------► Y  rr  X 0 2Et
I ^  OEt I HOMe 2. OMe
(140) O (141)
Scheme 54
The utility of this reaction in constructing the framework of the piperazinone ring 
through the formation of the 1,2-bond, was instantly recognised. This reaction was 
repeated and also the procedure applied to the synthesis of analogous compounds 
with good success, as shown in Table 8 .
Table 8  A summary of the yields obtained for the monalkylation of 
2 , 2 -dimethoxyethylamine with various compounds.
Me° 'V ^ v NH 1' K2C° 3’EtOH’OPC
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(141) r^ c c ^ E t 1 1.03 1.51 0.5 63%
(143) 1 1.03 1.51 0.5 18%
(143) r"^CN
2 1 3 2 . 0 99%
(145) i/ ^conh 2
1 1.03 1.51 0.5 52%
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Initial preparation of N-(cyanomethyl)-2,2-dimethoxyethlamine (143) using the 
conditions reported by DiMaio and Belleau251 led to 51% of the dialkylated product 
(144), with only 18% of the required monoalkylation product. However, addition of 
bromoacetonitrile at ambient temperature to an excess of substrate over a longer 
period of time improved the yield of (143) fi ve fold.
Protection of the secondary amine group in these monalkylation products prevents 
oxidation and the presence of a bulky group will control the direction of cyclisation. 
Efficient protection of N-(cyanomethyl)-2,2-dimethoxyethylamine (143) was 
achieved with benzoyl chloroformate to produce (146). Subsequent hydrolysis of the 
carbonitrile gave the required product N-(2,2-dimethoxyethyl)-N-(phenylmethoxy- 
carbonyl)glycinamide (147) in good yield (83%), thus achieving a 41% overall yield 
from (140).
The more direct approach to this compound (147), involving protection of the 
monoalkylation product N-(2,2-dimethoxyethyl)glycinamide (145) proved less 
efficient, giving only 37% overall yield from (140) (Scheme 55). However, yields for 
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The NMR spectrum at 22°C in (CD3)2SO for compound (147) clearly shows the 
presence of rotamers. This is because 7i-bonding between the nitrogen and the 
carbonyl atom in the protecting group slows the rotation about this bond. A similar 
phenomenon is observed in the !H NMR spectra for phenylmethyl N-(cyanomethyl)- 
N-(2,2-dimethoxyethyl)carbamate (146).
The acetal (147) was hydrolysed to the corresponding aldehyde (148)252, which was 
then subjected to reductive animation via an acyliminium species (149) with sodium 
cyanoborohydride in trifluoroacetic acid, to produce 4-(phenylmethoxy- 
carbonyl)piperazinone (150) in 18% yield (Scheme 56). The use of a labelled 




Figure 18 lH NMR spectra for N-(2 ,2 -dimethoxyethyl)-N-(phenylmethoxy- 




(148) H+ (149) H“ BH2CN
©
O O
H N ^ I






However, the yield of the piperazinone (150) was improved two fold by performing 
the reaction with triethylsilane in place of sodium cyanoborohydride. Deprotection 
was achieved through hydrogenolysis of this compound to furnish the required key 
intermediate, piperazinone (131) (Scheme 56).
9.2.2 Attempted Synthesis of 5,6-Dihydroimidazo[l,5-a]pyrazin-8-one.
Having synthesised the piperazinone ring, it was now necessary to build the 
imidazole ring onto this template. Therefore, piperazinone (131) was treated with 
cyanamide in acidic conditions253 to form the guanidine (151) as illustrated in 
Scheme 57. Although difficulty was found in assigning the complex *H NMR 
spectrum, proof of the structure was attained through mass spectrometry with a major 







In order to introduce the remaining one-carbon unit, the guanidine (151) was treated 
with various reagents such as triethylorthoformate, formic acid, ethyl formate, 
dimethyl fomamide dimethyl acetal and ethyl formate with potassium carbonate. 
However, none of these routes were successful.
It was proposed that addition of the cyanamide moiety with the carbon unit already 
attached may prove more effective. Subsequent heating would effect the cyclisation 
to the imidazole. Therefore, formylation of cyanamide with ethyl formate in ethanol 
was undertaken. However, only one peak in the 13C NMR spectrum was observed 
due to cyanamide, proving that the reaction had not occurred. Therefore, alternative 
routes to form formylcyanamide were explored.
Krimen254 reported the preparation of acetic formic anhydride (152) in good yield 
through the addition of acetyl chloride to sodium formate. Anhydrous conditions are 
essential in this procedure, since hydrolysis leads to formic and acetic acids, which 
can be difficult to separate from the required product. Acetic formic anhydride was 
prepared and immediately added to both 4-(aminoiminomethyl)piperazinone (151)
123
and to cyanamide as shown in Scheme 58. However, only starting material was 
recovered for both these reactions.
O
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As acetic formic anhydride is known to be unstable, its formation was proven 
through both infra-red spectroscopy and also in a test reaction with phenylamine. 
Addition of acetic formic anhydride prepared to phenylamine gave a 1 : 1 ratio of 
N-phenylfomamide to N-phenylacetamide, proving the formation of acetic formic 
anhydride. N-Phenylacetamide was produced from the reaction of phenylamine with 
excess acetyl chloride. However, following several attempts to prepare N-formyl- 
cyanamide via this route, this line of investigation was terminated.
In order to prove that it was feasible to construct the imidazole ring in this manner, it 
was decided to prepare the methyl imidazopyrazinone analogue. Although, this 
compound would not meet the structural requirements necessary for inhibition of 
PARP, its preparation would prove that this was a feasible synthetic pathway.
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Acetylcyanamide was prepared through the addition of acetyl chloride to a 
suspension of sodium cyanamide255 in tetrahydrofuran, as described by Kwon 
et al256. However, addition of this compound to the guanidine (151) did not yield the 
intended product. Thus, further investigative work must be undertaken in order to 





Preliminary investigations of the inhibitory effect of these compounds on PARP 
activity was examined using an assay system in vitro by measuring the incorporation
«5 t
of [adenine- H]NAD into acid-insoluble material. Most of the assays were kindly 
performed by Mrs Joan Whish of the School of Biology and Biochemistry, 
University of Bath.
Nuclei were isolated257 from EAhy 926 cells (human hybrid cells from huvecs and 
human lung carcinoma A929). The assay mixture contained of magnesium chloride 
(10 mM), dithiothreitol (1 mM), triethanolamine (100 mM) and DNA (10 pg) in 
incubation assay buffer (75 pi) at pH 8.0. Following incubation of the mixture with 
the nuclei at 27°C for 5 min, the reaction was initiated by addition of [3H]NAD+ 
(6 pi, containing 16 pCi pmol*1). The final concentration of [3H]NAD+ is 2.0 pM). 
Samples (25 pi) were taken from the mixture at 30 sec, 1 min, 2 min, 3 min and 
4 min after initiation and were added to aqueous trichloroacetic acid (TCA) (1 ml 
20% w/v) and kept overnight on ice. The insoluble material was collected on a glass 
fibre filter (Whatman, GC/C) and was washed three times with aqueous 
trichloroacetic acid (5 ml, cold 5%) and with cold ethanol (6 ml). Incorporation of the
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radioactive label into TCA-precipitated material was measured by liquid scintillation 
counting of the dried disc (Figure 19).
The short assay was selected in view of the short time that poly(ADP-ribose) 
polymers are reported133,134 to exist in vivo - rapid synthesis and degradation of the 
polymer by poly(ADP-ribose) glycohydrolase occurs in some cells with a half-life of 
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Figure 19 Measurement of PARP activity in salt extract from nuclei of cultured 
cells.
Different assay systems have been used for PARP inhibitory activity by different 
research teams. These vary from studies using partially purified enzyme to whole 
cells or models in vitro. Suto127 and Banasik126 used PARP isolated from calf 
thymus. While Suto measured incorporation from [3H]NAD+, as in our assay system, 
Banasik followed incorporation from [14C]NAD+. The widely differing 
concentrations of NAD+ used further hamper comparison of results. These factors
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must be taken into account when comparing the activity of compounds. Published 
values may only be used for studying general trends in inhibitory activity.
Graphs showing PARP activity in the presence of ca. 10 jxM concentrations of 
compounds over the full time-course of 4 min are shown in the Appendix. The data 
for the PARP activity taken at 1 min from these results are given in Tables 9 to 12. 
The time of 1 min was selected due to the short half-life of the poly(ADP-ribose) 
polymers (see above).
The general shape of many graphs shows a sigmoidal increase. However, some 
graphs show a unexpected decrease in activity after the 3 min time interval. One may 
speculate that this may be the result of either decomposition of the compound, or 
inhibition of poly(ADP-ribose) glycohydrolase. Decomposition of the test 
compounds is clearly not the case since the assay mixtures were incubated for 5 min 
before the reaction was initiated.
10.2 Nitrothiophenecarboxamides and Aminothiophenecarboxamides.
In the benzamide series, a differential {ca. 5 times) was observed 185 between the 
PARP inhibitory activity of 3-nitrobenzamide (IC50 160 (iM126) and
3-aminobenzamide (IC50 33 pM126). It was hoped to exploit this differential by 
designing pairs of compounds where the nitro analogue would act as a relatively 
inactive prodrug which would become bioreductively activated to an inhibitor of 
PARP in hypoxic tissue. There is further evidence that selectivity can be achieved
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through similar differentials in PARP activity in other series of compounds126,127. 
Heterocyclic analogues of these compounds have been tested for their ability to 
inhibit PARP. Cantoni et alm  reported that thiophene-3-carboxamide exhibited very 
weak inhibition of PARP with 47% inhibition at 5 mM. However, Griffin et alm  
dismissed this compound as inactive. Thus the question remains as to whether a 
heteroarene-carboxamide can indeed inhibit PARP. The initial results show that the 
isomeric thiophene-2-carboxamide (36) displays good inhibition of PARP with 
similar potency to benzamide (IC50 22pM126). This suggests that a thiophene may 
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Table 9 PARP activity after 1 min in the presence of ca. 10 jiM concentration 
of nitrothiophenecarboxamides and aminothiophenecarboxamides.
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Similar inhibitory activity was observed for the three isomeric pairs of nitro- and 
aminothiophene-carboxamides with the 'meta' relationship. In each pair, the amino 
analogue appears to be slightly more potent an inhibitor than the corresponding 
nitrothiophene. However, the differential between these compounds was small, 
limiting the potential use of nitrothiophenecarboxamides as prodrugs of PARP 
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Figure 20 PARP activity after 1 min in the presence of ca. 10 jliM concentration 
of nitrothiophene carboxamides and aminothiophenecarboxamides .
10.3 Thienopyridinones.
Isoquinolin-l-ones are more potent inhibitors than the benzamides with IC50 values 
ca. 50 times lower127. Again, a differential (ca. 8 times) was observed between 
5-nitroisoquinolinone (IC50 3.2 |iM) and 5-aminoisoquinolinone (IC50 0.41 |iM).
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When a substituent is absent from the 5-position, there is a large decrease in activity





1 77In contrast to the isoquinolinone series , two analogous thienopyridinones with a 
methyl (83a) or phenyl substituents (83b) at the 6-position (equivalent to the
3-position of isoquinolinone), yet unsubstituted at the 1-position (equivalent to the
5-position of isoquinolinone), were potent inhibitors of PARP with 90% and 93% 
inhibition at 10 pM respectively. This is consistent with the earlier observation for 
thiophenecarboxamides, that no major penalty is incurred by replacing the benzene 
ring with a thiophene (Figure 21).
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Figure 21 PARP activity in the presence of 6-phenylthieno[3,4-c]pyridin- 
4(5H)-one (83b) [9.9 pM].
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Analysis of the inhibitory activity of nitro analogues of these thienopyridinones did 
not show a large differential between the nitro and unsubstituted pairs. Nitration at 
the 1-position (equivalent to the 5-position of isoquinolinone) significantly reduced 
the inhibition of PARP in 6-methylthienopyridinone (96a), as observed with
1975-nitroisoquinolinone . However, the analogous 6-phenyl compound (96b) 
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Table 10 PARP activity after 1 min in the presence of ca. 10 |iM concentration 
of thienopyridinones.
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The effect was reversed when nitration of these thienopyridinones occurred in the 
7-position (equivalent to the 4-position of isoquinolinone). No change in inhibitory 
activity was observed for the 7-nitro-6-methylthienopyridinone (97a) in comparison 
with (83a), whereas 7-nitro-6-phenyl analogue (97b) was inactive. These results 
cannot be compared with the isoquinolinones as the activity of the
4-nitroisoquinolinones have not been reported. One may speculate that these apparent 
anomalous activities may result from conformational changes. Severe steric 
interaction may cause the phenyl ring and nitro group in the 7-position to be twisted 
orthogonally out of plane with the thienopyridinone, diminishing binding to the 
active site of PARP (Figure 22).




Quinazolinones are very potent inhibitors of PARP. 2-Methylquinazolin-4(3H)-one 
and 8-hydroxy-2-methylquinazolin-4(3H)-one have been reported to have IC50 values 






In the thienopyrimidinone series, 2-methylthienopyrimidinone (103a) (equivalent to
2-methylquinazolin-4-one) exhibited good inhibitory activity of PARP.
2-Phenylthienopyrimidinone (103b) was not a good inhibitor. The analogous 
7-nitro-6-phenylthienopyridinone (97b) was inactive (see above). However, in drug 
design, similar electronic properties of nitrobenzenes and pyridine rings are often 
utilised in defining structure-activity relationships. This may suggest that 














No previous results have been published on PARP inhibition of compounds 
containing an imidazole. However, our results show that these compounds only 
exhibit weak inhibition of PARP. This may not be indicative of the nature of the 

















Table 12 PARP activity after 1 min in the presence of ca. 10 |iM concentration 
of imidazopyrimidinones.
HBr.H2N HBr.H2N
Figure 23 A comparison of the PARP activity exhibited after 1 min of ca. 
10 |iM concentration of different compounds.
135
Therefore, it has been consistently shown through these results, contrary to the 
findings of Cantoni186 and Griffin191, that the presence of a thiophene ring can 
produce good inhibition of PARP. As for the benzamides and isoquinolinones, 
constraining the carbamoyl group produced a significant increase in potency on 
elaboration of the thiophenecarboxamides to the thienopyridinones. On comparison 
of the inhibitory properties of all the compounds tested, the 6-methyl- (83a) and
6-phenylthienopyridinone (83b) were by far the most potent inhibitors (Figure 23). 
Selectivity was not achieved between nitro and amino compounds. Refinement of the 
structural features of these thienopyridinones for inhibition of PARP may provide 
inhibitors with sufficient potency to merit their use in increasing the cytotoxic effects 
of radiation and chemotherapy.
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CONCLUSION.
Three isomeric nitrothiophenecarboxamides with the ‘meta ’ relationship between the 
substituents as seen in the lead inhibitor 3-aminobenzamide, have been synthesised. 
Investigations into the subsequent reduction of these compounds led to a suitable 
reduction method using tin(D) chloride. Conversion of the aminothiophenes in situ to 
the less polar benzyloxycarbonyl (Cbz) derivatives and deprotection with hydrogen 
bromide produced the required aminothiophenecarboxamides as the hydrobromide 
salts in good yields. These compounds were shown to be good inhibitors of PARP 
and illustrated that a thiophene may replace a benzene ring without an adverse effect 
on inhibition, in contrast to previous reports in the literature.
A method for direct conversion of cyanothiophenes to nitrothiophene-carboxamides 
using stoichiometric quantities of potassium nitrate in concentrated sulphuric acid 
has been developed. Application of this method to the benzene series and to use in 
isotopically efficient 15N-labelled synthesis of [15N]-nitrothiophene-carboxamides 
has been demonstrated.
Elaboration of these nitrothiophenecarboxamides to bicyclic analogues of the more 
potent 5-substituted isoquinolinones led to the synthesis of 6-methylthieno[3,4-c]- 
pyridin-4(5H)one and 6-phenylthieno[3,4-c]pyridin-4(5H)one. Both compounds were 
shown to cause >90% inhibition of PARP activity at 10 |iM. Much work was 
invested to develop a viable synthetic route to the key intermediate,
4-bromothiophene-3-carboxylic acid, needed for the synthesis of these compounds.
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A lower temperature of -116°C provided greater control of the crucial lithiation 
reaction to form the corresponding 4-bromothiophene ester.
6-Methyl- and 6-phenylthienopyrimidinones were also synthesised from this key 
intermediate. However, only the 6-methyl analogue exhibited good inhibitory activity 
of PARP. Substitution of these heterocyclic analogues of the potent 5-substituted 
isoquinolinone inhibitors with an imidazole to form imidazopyrimidinones led to a 
reduction in inhibitory activity.
It was hoped that a large differential in activity would exist between the 
corresponding nitro- and amino compounds to enable bioreductive activation to 
inhibitors of PARP to occur selectively in hypoxic tissue. However, comparison of 
biological results for corresponding nitro- and aminothiophenes led to the conclusion 
that the differential in activity would not be sufficient for this selectivity to be 
achieved. This approach could, nevertheless, be implemented using other prodrug 
release systems such as those described in Chapter Three, to allow this selectivity to 
be achieved.
Thus further work to define the structure relationships in these heterocyclic 
compounds for potent inhibition of PARP may provide inhibitors with increased 
potency. The lower oxygen concentration in hypoxic tissue could then be exploited to 
activate these inhibitors selectively, and thus increase the cytotoxic effects of 




All chemicals were purchased from Aldrich Chemical Company, with the exception 
of thiophene-3-carbonitrile which was purchased from Lancaster Chemical 
Company. [15N]-Nitric acid (95 atom %, ca. 5 M) was purchased from MSD 
Isotopes. Where experiments were repeated, only one description is provided. Ether 
refers to diethyl ether. When required, solvents were dried by distillation from the 
indicated drying agents according to standard procedures258: ether, toluene (sodium / 
benzophenone), ethanol, methanol (magnesium), hexane (phosphorus (V) oxide). 
Brine refers to saturated aqueous sodium chloride and all references to water imply 
distilled water. All solutions were aqueous unless otherwise stated. A solution of 
ethereal ammonia was formed through the addition of ether (50 ml) to aqueous NH3 
(d 0.88 gm'1, 10 ml). The solution was dried with potassium carbonate and filtered. 
Procedures were conducted at ambient temperature, unless otherwise stated. 
Solutions in organic solvents were dried with magnesium sulphate and filtered unless 
indicated otherwise. Solvents were evaporated under reduced pressure.
Analytical thin layer chromatography was carried out using Merck Kieselgel 60F 
plates. Visualisation was accomplished by UV light, phosphomolybdic acid, iodine, 
ninhydrin or iron (IH) chloride. Flash chromatography was performed using Merck 
Silica gel 60 (0.040-0.063 mm) flash silica, with eluents as indicated. Melting points 
and boiling points are uncorrected. Melting points were recorded on a Reichert-Jung
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Thermo Galen Kofler hot-stage apparatus. Kugelrohr distillations were carried out in 
a Buchi GKR-51 apparatus and the boiling points given correspond to the Kugelrohr 
oven temperature.
Nuclear magnetic resonance data were recorded on a Jeol GX270 spectrometer 
(270.05 MHz *H, 67.8 MHz, 13C) or a Jeol EX400 spectrometer (399.65 MHz, lH, 
100.4 MHz, 13C). Tetramethylsilane was used as an internal standard for samples in 
CDCI3 or (CD 3)2SO. Multiplicities are indicated by s (singlet), d (doublet), t (triplet), 
q (quartet), m (multiplet) and br (broad). The 15N chemical shifts are referenced 
externally to [15N]-ammonium nitrate (2.9 M in 1.0 M aqueous hydrochloric acid : 8n 
+24.90)259.
Infrared spectra were recorded on a Perkin-Elmer 782IR spectrometer or on a Perkin 
Elmer 1600 Series FTIR, either as liquid film (film) or KBr disc (KBr). Mass spectra 
were obtained by electron-impact (El), chemical ionisation (Cl) or fast atom 
bombardment (FAB) with m-nitrobenzyl alcohol as the matrix) using a VG7070 or 
ZAB-E spectrometers. Data are reported in the form m/z (intensity relative to 




5-Nitrothiophene-2-carboxylic acid (33), Silver(I) oxide was prepared by addition 
of silver nitrate (5.92 g, 3.5 mmol) in water (15 ml) to sodium hydroxide (2.79 g,
7.0 mmol) in water (15 ml). Continuous stirring during the addition ensured complete 
reaction and resulted in the formation of a brown semisolid. 5-Nitrothiophene-2- 
carboxaldehyde (32) (2.73 g, 17.4 mmol) was added in small portions at 0°C. After 
5 min, the silver suspension was removed by filtration and washed with hot water 
(5 x 50 ml). The combined filtrate and washings were acidified with concentrated 
hydrochloric acid and extracted with ethyl acetate. The extract was dried and the 
solvent was evaporated. Recrystallisation of the residue from ethyl acetate furnished 
5-nitrothiophene-2-carboxylic acid (33) (1.2 g, 40%) as a light brown solid. Rf 0.1 
(ethyl acetate); mp 149-152°C (lit-199 mp 155-157°C); 'H NMR (270 MHz, 
(CD3)2SO) 87.74 (1 H, d, 7 = 4 .4Hz, thiophene3-H), 8.13 (1 H, d, 7 = 4.4 Hz, 




5-Nitrothiophene-2-carboxamide (29a). Method A: Oxalyl chloride in 
dichloromethane (2.0 M, 6.9 ml, 14 mmol) and dry DMF (50 pi) were added to
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5-nitrothiophene-2-carboxylic acid (33) (1.2 g, 6.9 mmol) in dichloromethane 
(10 ml) and the mixture was stirred for 2 h. The solvent and excess reagent were 
evaporated. Hexane was added and evaporated and this procedure was repeated three 
times. A solution of ethereal ammonia was produced by addition of ether (200 ml) to 
concentrated aqueous ammonia (20 ml), drying (K2CO3) and filtration. The ethereal 
ammonia solution was added to the prepared acid chloride in ethyl acetate ( 1 0  ml). 
The solution was washed with dilute hydrochloric acid and water and was dried. The 
solvent was evaporated to produce 5-nitrothiophene-2-carboxamide (29a) as a yellow 
solid (0.72 g, 60%). Rf 0.17 (hexane : ethyl acetate 1:1); mp 188-190°C (compound 
reported by Occhipinti et al.260 and by Johnson et al,261 but no mp given); 
1HNMR(270MHz, (CD3)2SO) 8  7.79 (1 H, d, /  = 4.0 Hz, thiophene 3-H), 8.00 
(1 H, s, N-H), 8.15 (1 H, d, /  = 4.4 Hz, thiophene 4-H), 8.45 (1 H, s, N-H).
(30a) (29a)
4-Nitrothiophene-2-carboxamide (30a) and 5-Nitrothiophene-2-carboxamide 
(29a). Method B: Fuming nitric acid (90%, 1.6 ml, 39 mmol) was added slowly to 
stirred acetic anhydride (4.01 g, 39 mmol) at -10°C. To this mixture, 2-thiophene- 
carboxamide (36) (1.00 g, 7.9 mmol) was added slowly, followed by acetic acid 
(15 ml) and the mixture was stirred for 20 min at -10°C. Water was added and the 
solution was extracted with ethyl acetate. The extract was washed three times with 
5% sodium carbonate and dried. The solvent was evaporated to produce a light
brown solid. Column chromatography [hexane : ethyl acetate 1:1] yielded
4-nitrothiophene-2-carboxamide (30a) (0.10 g, 7%) as a pale buff solid. Rf 0.33 
(hexane : ethyl acetate 1:1); mp 146-149°C (lit.210 mp 152-153°C); !H NMR 
(270 MHz, (CD3)2SO) 87.99 (1 H, s, N-H), 8.33 (1 H, s, N-H), 8.41 (1 H, d, 
7=  1.5 Hz, thiophene 3-H), 8.94 (1 H, d, 7 = 1.5 Hz, thiophene 5-H).
Further elution yielded 5-nitrothiophene-2-carboxamide (29a) (0.24 g, 18%) as a pale 
buff solid. Rf0.2 (hexane : ethyl acetate 1:1); mp 189-191°C (compound reported by 
Occhipinti et al.260) and by Johnson et al.261 but no mp given); !H NMR (270 MHz, 
(CD3)2SO) 8 7.79 (1 H, d, 7= 4.4 Hz, thiophene 3-H), 7.99 (1 H, s, N-H), 8.14 (1 H, 
d, 7 = 4.0 Hz, thiophene 4-H), 8.45 (1 H, s, N-H).
o 2n  o 2n
(30a) (29a)
4-Nitrothiophene-2-carboxamide (30a) and 5-nitrothiophene-2-carboxamide 
(29a). Potassium nitrate (2.07 g, 20 mmol) was added slowly to a stirred solution of 
thiophene-2-carboxamide (36) (2.6 g, 20 mmol) in concentrated sulphuric acid 
(20 ml) at 10°C. The mixture was stirred for 30 min, then poured onto crushed ice 
and extracted with ethyl acetate. The extract was washed with water and dried. 
Evaporation and column chromatography [hexane : ethyl acetate 1:1] afforded
4-nitrothiophene-2-carboxamide (30a) (2.42 g, 69%) as a white solid. Rf 0.21 
(hexane : ethyl acetate 3:2); mp 152-153°C (lit.210 mp 152-153°C); !H NMR 
(270 MHz, (CD3)2SO) 8 7.81 (1 H, s, N-H), 8.33 (1 H, s, N-H), 8.41 (1 H, d,
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7 = 1.7 Hz, thiophene 3-H), 8.94 (1 H, d, 7 = 1.7 Hz, thiophene 5-H); m/z (El) 172 
(M, 100); Vmax (KBr, cm'1) 3360, 3180 (NH2), 1680 (amide I), 1605 (amide II), 1520, 
1380 (N02).
Further elution yielded 5-nitrothiophene-2-carboxamide (29a) (0.74 g, 22%) as a pale 
yellow solid. Rf 0.1 (hexane : ethyl acetate 3:2); mp 188-190°C (compound reported 
by Occhipinti et al.260) and by Johnson et al.261 but no mp given); ]H NMR 
(270 MHz, (CD3)2SO) 8 7.79 (1 H, d, J=  4.4 Hz, thiophene 3-H), 7.99 (1 H, s, N-H),
8.14 (1 H, d, J  = 4.4 Hz, thiophene 4-H), 8.44 (1 H, s, N-H); m/z (Cl) 173 
(M + H, 30); Vmax (KBr, cm'1) 3440, 3160 (NH2), 1660 (amide I), 1615 (amide II),
1515,1340 (N02).
Thiophene-3-carboxylic acid (38). To sodium hydroxide (1.4 g, 35 mmol) in water 
(6 ml), silver nitrate (3.00 g, 18 mmol) in water (6 ml) was added to form silver 
oxide as a brown semi-solid. Thiophene-3-carboxaldehyde (37) (0.95 g, 8.5 mmol) 
was added to this mixture in small portions. After 5 min, the black suspension was 
filtered and the solid was washed with hot water (5 x 30 ml). The extracts were 
acidified with concentrated hydrochloric acid. The precipitate was collected, washed 
with water and dried to give thiophene-3-carboxylic acid (38) (0.54 g, 50%) as white 
needles. Rf 0.13 (ethyl acetate); mp 137-138°C (lit.203 mp 137-138°C); 1H NMR 
(270 MHz, (CD3)2SO) 8 7.42 (1 H, dd, 7 = 5.1, 1.5 Hz, thiophene 5-H), 7.61 (1 H,
(38)
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dd, J  = 4.8, 3.3 Hz, thiophene 4-H), 8.26 (1 H, dd, J  = 3.0, 1.5 Hz, 2-H), 12.93 (1 H, 




Thiophene-3-carboxamide (39). Thionyl chloride (1 ml) was added to thiophene-3- 
carboxylic acid (38) (0.41 g, 3.2 mmol) and the mixture was heated under reflux for 
1 h. Excess thionyl chloride was removed by evaporation to yield a white solid. This 
solid was suspended in 1,4-dioxane (4 ml) and treated with aqueous ammonia 
(d 0.88 gm'1, 1 ml). The white precipitate formed was extracted with ethyl acetate 
and washed with water. The combined organic layers were dried. The solvent was 
evaporated to produce thiophene-3-carboxamide (39) (0.27 g, 66%) as a white 
crystalline solid. Rf0.48 (ethyl acetate); mp 178-180°C (lit.262 178-179°C); 'HNMR 
(400 MHz, (CD3)2SO) 8 7.22 (1 H, s, N-H), 7.47 (1 H, dd, 7=4.9, 1.2 Hz, thiophene 
5-H), 7.55 (1 H, dd, 7=4.9, 3.1 Hz, thiophene 4-H), 7.77 (1 H, s, N-H), 8.12 (1 H, 
dd, 7 = 1.2, 3.1 Hz, 2-H); vmax (KBr, cm'1) 3360, 3170 (NH2), 1655 (amide I), 1610
0 2N
(40)
5-Nitrothiophene-3-carboxamide (31a). Potassium nitrate (1.85 g, 18.3 mmol) was 





acid (20 ml). The mixture was stirred for 16 h, poured onto crushed ice and extracted 
with ethyl acetate. The extract was washed with water, 10% aqueous sodium 
carbonate and was dried. The solvent was evaporated to produce a brown solid which 
was recrystallised from ethanol to yield 5-nitrothiophene-3-carboxamide (31a) 
(2.86 g, 91%) as a pale buff solid. Rf0.12 (hexane : ethyl acetate 1:1); mp 161-162°C 
(lit.263 mp 161-162°C); ’H NMR (270 MHz, (CD3)2SO) 8 7.63 (1 H, s, N-H), 8.11 
(1 H, s, N-H), 8.46 (1 H, d, J  = 2.2 Hz, thiophene 4-H), 8.51 (1 H, d, J  = 1.8 Hz, 
thiophene 2-H); 13C NMR (100 MHz, (CD3)2SO) 8 128.11 (C-4), 136.66 (C-3), 
136.90 (C-2), 151.19 (C-5), 161.85 (C=0); m/z (El) 172 (M, 100); V™* (KBr disc, 
cm'1) 3450,3300 (NH2), 1700 (amide I), 1670 (amide II), 1500,1345 (N02).
(30a) (29a)
4-Nitrothiophene-2-carboxamide (30a) and 5-nitrothiophene-2-carboxamide 
(29a). Method C: Potassium nitrate (0.93 g, 9.2 mmol) was added slowly
2-cyanothiophene (41) (1.00 g, 9.2 mmol) in concentrated sulphuric acid (10 ml). 
The mixture was stirred at ambient temperature for 16 h before being poured onto 
crushed ice and extracted with ethyl acetate. The combined organic extracts were 
washed with water and 10% sodium carbonate and dried. The solvent was evaporated 
to produce an off-white solid. The product was purified by column chromatography 
[hexane : ethyl acetate 3:2] to yield 4-nitrothiophene-2-carboxamide (30a) (0.64 g, 
41%) as a white solid. Rf 0.2 (hexane : ethyl acetate 3:2); mp 151-152°C (lit.210 mp
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152-153°C); 'H NMR (270 MHz, (CD3)2SO) 8 7.82 (1 H, s, N-H), 8.33 (1 H, s, 
N-H), 8.42 (1 H, d, /  = 1.5 Hz, thiophene 3-H), 8.94 (1 H, d, 7=  1.5 Hz, thiophene
5-H); m/z (El) 172 (M, 40); (KBr, cm 1) 3480,3270 (NH2), 1715 (amide I), 1620 
(amide II), 1510,1310 (N02).
Further elution furnished 5-nitrothiophene-2-carboxamide (29a) (0.51 g, 32%) as a 
white solid. Rf 0.1 (hexane : ethyl acetate 3:2); mp 191-193°C (compound reported 
by Occhipinti et al.260) and by Johnson et al.261 but no mp given); *H NMR 
(270 MHz, (CD3)2SO) 8 7.79 (1 H, d, J  = 4.4 Hz, thiophene 3-H), 7.99 (1 H, s, N-H),
8.14 (1 H, d, J  = 4.4 Hz, thiophene 4-H), 8.45 (1H, s, N-H); m/z (El) 172 (M, 2); 
Vmax(KBr, cm'1) 3460, 3170 (NH2), 1660 (amide I), 1620 (amide II), 1515, 1340 
(N02).
3-Thiophenecarboxamide (39) (control experiment). 3-Cyanothiophene (40) 
(0.20 g, 1.83 mmol) was treated with concentrated sulphuric acid (4 ml) for 16 h at 
ambient temperature. The mixture was then poured onto ice and extracted with ethyl 
acetate. The extract was washed with aqueous sodium hydrogen carbonate and water, 
and was dried. The solvent was evaporated to furnish 3-thiophenecarboxamide (39) 
(0.01 g, 4%) as a white solid. Rf 0.48 (ethyl acetate); !H NMR (270 MHz, (CD3)2SO)
CONH2
(39)
8 7.26 (1 H, s, N-H), 7.48 (1 H, dd, J  = 5.1, 1.5 Hz, 5-H), 7.56 (1 H, dd, J=  5.1,




3-Nitrobenzamide (43a). Potassium nitrate (0.49 g, 4.9 mmol) was added slowly to 
benzonitrile (42a) (0.50 g, 4.9 mmol) in concentrated sulphuric acid (5 ml). The 
mixture was stirred for 16 h before being poured onto crushed ice and extracted with 
ethyl acetate. The combined organic extracts were washed with water and with 10% 
aqueous sodium carbonate and were dried. The solvent was evaporated to furnish
3-nitrobenzamide (43a) (0.59 g, 73%) as a pale orange solid. Rf 0.21 (hexane : ethyl 
acetate 1:1); mp 136-138°C (lit.264 mp 142-143°C); ‘H NMR (270 MHz, (CD3)2SO) 
5 7.75 (1 H, s, N-H), 7.78 (1 H, t, /  = ca. 8 Hz, 5-H), 8.32 (1 H, dd, J  = 8.8, 1.1 Hz,
6-H), 8.37 (1 H, s, N-H), 8.39 (1 H, ddd, J  = 8.6, 1.5, 1.1 Hz, 4-H), 8.70 (1 H, ca. t, 
ca. J=  1.5 Hz, 2-H); m/z (El) 166 (M, 15); (KBr disc, cm'1) 3460, 3350 (NH2), 
1695 (amide I), 1625 (amide II), 1530,1355 (C-N02).
Me
(43b)
4-Methyl-3-nitrobenzamide (43b). Potassium nitrate (0.43 g, 4.3 mmol) was added 
to 4-methylbenzonitrile (42b) (0.50 g, 4.3 mmol) in concentrated sulphuric acid 
(5 ml). The mixture was stirred for 16 h before being poured onto crushed ice and
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extracted with ethyl acetate. The combined organic extracts were washed with water 
and with 10% aqueous sodium carbonate and were dried. The solvent was evaporated 
to furnish 4-methyl-3-nitrobenzamide (43b) (0.74 g, 96%) as a white solid. Rf 0.16 
(hexane : ethyl acetate 1:1); mp 161-163°C (lit.265 mp 168-169°C; *H NMR 
(270 MHz, (CD3)2SO) 6 2.57 (3 H, s, Me), 7.61 (1 H, d, /  = 8.1 Hz, 5-H), 7.65 (1 H, 
s, N-H), 8.13 (1 H, dd, J  = 7.7, 1.8 Hz, 6-H), 8.24 (1 H, s, N-H), 8.47 (1 H, d, 
J  = 1.8 Hz, 2-H); m/z (Cl) 181 (M + H, 100); (KBr disc, cm'1) 3450, 3170 
(NH2), 1685 (amide I), 1615 (amide II), 1530, 1345 (N02).
(44)
5-[15N]-Nitrothiophene-3-carboxamide (44). Potassium [15N]-nitrate (0.079 g, 
0.77 mmol, 95 atom %) was added to 3-cyanothiophene (40) (0.84 g, 0.77 mmol) in 
concentrated sulphuric acid (1 ml). The mixture was stirred for 16 h before being 
poured onto crushed ice and extracted with ethyl acetate. The combined organic 
extracts were washed with water and with 10% aqueous sodium carbonate and were 
dried. Evaporation furnished 5-[15N]-nitrothiophene-3-carboxamide (44) (0.10 g, 
75%) as a pale buff solid. Rf 0.43 (hexane : ethyl acetate 1:1); mp 158-160°C (lit263 
mp 162-163°C for 31a); *H NMR (270 MHz, (CD3)2SO) 8 7.62 (1 H, s, NH), 8.10 
(1 H, s, NH), 8.46 (1 H, dd, 7 H-h = 1.8 Hz, 37 H-n = 1.1 Hz, thiophene 4-H), 8.51 (1 H, 
dd, 7 r -h  = 1.8 Hz, 4/h - n  =1.1 Hz, thiophene 2-H); 13C NMR (100 MHz, (CD3)2SO) 
5 128.05 (C-4), 136.59 (d, 3/ C-n = 3.7 Hz, C-3), 136.85 (C-2), 151.10 (d, ^ c - n  =
149
20.3 Hz, C-5), 161.79 (CONH2); 15N NMR (40.5 MHz, (CD3)2SO) 8 +365.07; 
m/z (El) 173 (M, 3); \ moi (KBr, cm'1) 3350, 3180 (NH2), 1685 (amide I), 1620 
(amide II), 1530,1320 (NO2).
4-[15N]-Nitrothiophene-2-carboxamide (45) and 5-[lsN]-Nitrothiophene-2- 
carboxamide (46). Potassium [15N]-nitrate (0.28 g, 2.8 mmol, 95 atom %) was 
added to 2-cyanothiophene (41) (0.30 g, 2.8 mmol) in concentrated sulphuric acid 
(1 ml). The mixture was stirred for 16 h, before being poured onto crushed ice and 
extracted with ethyl acetate. The combined organic extracts were washed with water, 
10% aqueous sodium carbonate and were dried. Evaporation and column 
chromatography (hexane : ethyl acetate 1:1) gave 4- [15N] -nitrothiophene-2- 
carboxamide (45) (0.18 g, 38%) as a pale buff solid. Rf 0.43 (hexane : ethyl acetate 
1:1); mp 151-152°C (lit.210 mp 152-153°C for 30a); ‘H NMR (270 MHz, (CD3)2SO) 
8 7.80 (1 H, s, N-H), 8.32 (1H, s, N-H), 8.40 (1 H, d, J  = 1.5 Hz, thiophene 3-H), 
8.93 (1 H, dd, JH-a = 1.5 Hz, JH-n = 1.1 Hz, thiophene 5-H); 13C NMR (67 MHz, 
(CD3)2SO) 8 122.49 (C-5), 133.16 (C-3), 141.48 (C-2), 147.07 (d, VC-n = 18.4 Hz,
4-C), 161.32 (CONH2); 15N NMR (40.5 MHz, (CD3)2SO) 8 +367.48; m/z (El) 173 
(M, 100); VmjH (KBr, cm'1) 3370,3290 (NH2), 1670 (amide I), 1615 (amide IT), 1500, 
1320 (N02).
c o n h 2c o n h 2
(45) (46)
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Further elution produced 5-[15N]-nitrothiophene-2-carboxamide (46) (0.069 g, 14%) 
as an off-white solid. Rf 0.43 (hexane : ethyl acetate 1:1); mp 188-190°C (lit.260,261 
mp 188-190°C for 29a); ‘H NMR (270 MHz, (CD3)2SO) 8 7.78 (1 H, d, J = 4.4 Hz, 
thiophene 3-H), 7.98 (1 H, s, N-H), 8.14 (1H, dd, JH-h = 4.4 Hz, * . N= 1.1 Hz, 
thiophene 4-H), 8.44 (1 H, s, N-H); 13C NMR (67 MHz, (CD3)2SO) 5127.87 (d, VC-n 
= 3.7 Hz, C-2), 130.27 (C-4), 146.93 (C-3), 152.93 (d, 17 C-n = ca. 20 Hz, C-5), 
161.30 (CONH2); 15N NMR (40.5 MHz, (CD3)2SO) 5 +367.52; m/z (El) 173 (M, 7); 
Vmax (KBr, cm'1) 3450, 3160 (NH2), 1660 (amide I), 1615 (amide II), 1540, 1320 
(N02).





5-Nitrothiophene-3-carboxamide (31a) (1.00 g, 5.8 mmol) was wanned with 
concentrated hydrochloric acid (17 ml) to 40-45°C. Tin(IT) chloride (5.24 g, 
23 mmol) was added during 10-15 min, maintaining the temperature at 40-45°C with 
external cooling. The solution was heated for 1 h at this temperature produced a pale 
orange precipitate, which was filtered and dried to yield crude 5-aminothiophene-3- 
carboxamide hexachlorostannate (47) (1.07 g). Phenylmethyl chloroformate (0.89 g,
5.2 mmol) was added to this material (1.07 g, 3.5 mmol) in water (10 ml). To this 
stirred solution, 2 M sodium hydroxide was added until a pH of 11 was achieved and
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the mixture was stirred for 48 h. The mixture was extracted with ethyl acetate and the 
extract was washed with water and dried. Evaporation and column chromatography 
(hexane : ethyl acetate 4:1) furnished 5-(phenylmethoxycarbonylamino)thiophene-3- 
carboxamide (48) (0.34 g, 36%) as a white solid. Rf 0.24 (10% methanol : 
chloroform); mp 168-170°C; lU NMR (270 MHz, (CD3)2SO) 8 5.18 (2H, s, CH2), 
6.87 (1 H, d, /  = 1.5 Hz, thiophene 4-H), 7.12 (1 H, br, NH), 7.38 (5H, m, Ph-H5), 
7.55 (1 H, d, J  = 0.9 Hz, thiophene 2-H), 7.71 (1 H, br, NH), 10.89 (1 H, br, 




5-Aminothiophene-3-carboxamide hydrobromide (31b). Hydrogen bromide (30% 
w/v in acetic acid, 0.5 ml) was added to 5-(phenylmethoxycarbonylamino)- 
thiophene-3-carboxamide (48) (0.05 g, 0.18 mmol), followed by acetic acid (1 ml) 
and stirred for 2 h. The mixture was triturated with dry ether ( 1 1 x 2  ml) to yield
5-aminothiophene-3-carboxamide hydrobromide (31b) 0.040 g, 98%) as a white 
solid. Rf 0.18 (10% methanol : chloroform); mp 181-183°C; *H NMR (270 MHz, 
(CD3)2SO) 8 6.02 (3 H, br, NHs*), 7.24 (1 H, d, thiophene 2-H), 7.91 (1 H, d, 






5-Nitrothiophene-2-carboxamide (29a) (0.85 g, 4.9 mmol) was warmed with 
concentrated hydrochloric acid (15 ml) to 40-45°C. Tin(13) chloride (4.46 g, 
20 mmol) was added during 10-15 min, maintaining the temperature at 40-45°C with 
external cooling. The solution was heated under reflux for 48 h. The solvent was 
evaporated to produce crude 5-aminothiophene-2-carboxamide hexachlorostannate 
(1.83 g) as a yellow solid. This material was suspended in water (20 ml) and 
phenylmethyl chloroformate (1.52 g, 8.9 mmol) was added. To this solution, 2M  
sodium hydroxide was added until a pH of 11 was achieved. The mixture was stirred 
for a further 48 h and then extracted with ethyl acetate. The extract were washed with 
water and dried. Concentration and column chromatography (hexane : ethyl acetate 
1:1) yielded 5-(phenylmethoxycarbonylamino)thiophene-2-carboxamide (49) (0.42 g, 
31%) as an off-white solid. Rf 0.22 (10% methanol : chloroform); mp 121-123°C; 
!HNMR (270 MHz, (CD3)2SO) 8  5.20 (2 H, s, CH2), 6.51 (1 H, d, /  = 4.4 Hz, 
thiophene 4-H), 7.14 (1 H, br, NH), 7.39 (5 H, m, Ph-H5), 7.48 (1 H, d, J  = 4 Hz, 
thiophene 3-H), 7.75 (1 H, br, NH), 11.08 (1 H, br, carbamate NH); m/z (FAB+) 
277.0668 (M + H, 100) (Ci3Hi3N20 3S requires 277.0647).
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c o n h 2
(29b)
5-Aminothiophene-2-carboxamide hydrobromide (29b). Hydrogen bromide (30% 
w/v in acetic acid, 0.4 ml) was stirred with 5-(phenylmethoxycarbonylamino)- 
thiophene-2-carboxamide (49) (0.05 g, 0.18 mmol) for 2 h. The mixture was 
triturated with dry ether (11 x 2 ml) to yield 5-aminothiophene-2-carboxamide 
hydrobromide (29b) (0.04 g, 100%) as an off-white solid. Rf 0.18 (10% methanol : 
chloroform); mp 160-162°C; *H NMR (270 MHz, (CD3)2SO) 8  6.22 (1 H, d, 
7=3.7 Hz, thiophene 4-H), 6.85 (3 H, br, NH3+), 7.41 (1 H, d, J  = 3.7 Hz, 
thiophene 3-H); m/z (El) 142.0206 (M - Br, 64) (C5H6N2OS requires 142.0201), 82, 





To 4-nitrothiophene-2-carboxamide (30a) (1.00 g, 5.8 mmol) in concentrated 
hydrochloric acid (17 ml) at 40-45°C, tin(II) chloride (5.24 g, 23 mmol) was added 
over 10-15 min, maintaining the temperature at 40-45°C with external cooling. The 
mixture was stirred for 1 h at this temperature. The solvent was evaporated to furnish 
crude 4-aminothiophene-2-carboxamide hexachlorostannate as a white solid (2.15 g).
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Phenylmethyl chloroformate (1.78 g, 10.5 mmol) was added to a solution of this 
material (2.15 g, 7.0 mmol) in water (20 ml). To this stirred mixture, 2 M sodium 
hydroxide solution was added until a pH of 11 was achieved. The mixture was stirred 
for 48 h and was extracted with ethyl acetate. The extracts were washed with water 
and were dried. Evaporation of the solvent and column chromatography (hexane : 
ethyl acetate 1:1) yielded 4-(phenylmethoxycarbonylamino)thiophene-2-carboxamide
(50) (0.55 g, 34%) as a white solid. Rf 0.58 (10% methanol : chloroform); 
mp 184-186°C; ‘H NMR (400 MHz, (CD3)2SO) 8  5.15 (2 H, s, CH2), 7.39 (7 H, m, 
Ph-H5, thiophene 5-H, NH), 7.65 (1 H, d, J  = 1.1 Hz, thiophene 3-H), 8.03 (1 H, s, 
NH), 10.2 (1 H, br, carbamate NH); m/z (FAS'1)  277.0650 (M - Br, 62) 
(CnHi3N20 3S requires 277.0647); 1W  (KBr, cm'1) 3400, 3200 (NH), 1710 (C=0, 
Cbz), 1650 (amide I), 1620 (amide II).
An unidentified by-product (0.77 g) was also isolated as a yellow solid. Rf 0.24 (10% 
methanol: chloroform); mp 185-187°C; [H NMR (270 MHz, (CD3)2SO) 8  5.15 (2 H, 
s, CH2), 7.38 ( 6  H, m), 7.58 (1 H, br, NH), 7.90 (1 H, s), 8.14 (1 H, br, NH), 9.63 
(1 H, br, NH); m/z (El) 311 (M, 39); t w  (KBr, cm'1) 3440, 3400, 3340, 3300 (NH), 
1720 (C=0, Cbz), 1650 (amide I), 1600 (amide II).
(30b)
4-Aminothiophene-2-carboxamide hydrobromide (30b). Hydrogen bromide (30% 
w/v in acetic acid, 0.4 ml) was stirred with 4-(phenylmethoxycarbonylamino)- 
thiophene-2-carboxamide (50) (0.05 g, 0.18 mmol) for 2 h. Trituration with dry ether
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(1 1 x 2  ml) yielded 4-aminothiophene-2-carboxamide hydrobromide (30b) (0.039 g, 
97%) as a cream solid. Rf 0.26 (10% methanol : chloroform); mp 210-213°C; 
'HNMR (270 MHz, (CDslzSO) 8 4.49 (3 H, br, NHj*), 7.61 (1 H, br, NH), 7.73 
(1 H, s, thiophene 5-H), 7.76 (1 H, s, thiophene 3-H), 8.22 (1 H, br, NH); m/z (FAB+) 




3,4-Dibromothiophene (55). Method A: Zinc dust (4.91 g, 75 mmol) was boiled 
under reflux with a solution of tetrabromothiophene (54) (10.0 g, 25 mmol) in acetic 
acid (70 ml) and heated under reflux for 16 h. The acetic acid was distilled off and 
the remaining viscous residue was partitioned between ether and water. The organic 
fraction was washed with saturated sodium hydrogen carbonate solution (5 x 50 ml) 
and brine and was dried. Distillation (Kugelrohr) furnished 3,4-dibromothiophene 
(55) (2.54 g, 42%) as a pale yellow oil. Rf 0.71 (hexane : ether 7:1); bp76o 230°C 
(lit.217 bpi093-95°C); *H NMR (400 MHz, CDCI3) 7.31 (s, thiophene 2,5-H2); 
13C NMR (100 MHz, CDC13) 8  113.95 (C-3, C-4), 123.77 (C-2, C-5).
3,4-Dibromothiophene (55). Method B: To tetrabromothiophene (54) (11.8 g, 
29 mmol) in dry ether (150 ml) at 0°C under nitrogen, n-butyl-lithium (2.5 M in 
hexane, 25 ml, 62 mmol) was added in 5 ml aliquots during 1 h. After 15 min, the 
solution was poured into cold water (300 ml), and was extracted with ether. The
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extract was washed with water and with brine and was dried. Evaporation and 
distillation (Kugelrohr) yielded 3.4-dibromothiophene (55) (5.42 g, 76%) as a pale 
yellow oil. Rf0.71 (hexane : ether 7:1); bp76o 230°C (lit.217 bpio 93-95°C); !HNMR 
(400 MHz, CDCI3) 8  7.31 (s, thiophene 2,5-H2); 13C NMR (100 MHz, CDCI3) 




4-Bromothiophene-3-carboxylic acid (53). To 3,4-dibromothiophene (55) (0.3 g,
1.2 mmol) in dry ether (10 ml) at -78°C under nitrogen, /i-butyllithium (2.5 M in 
hexanes, 0.52 ml, 1.3 mmol) was added during 30 sec. The mixture was stirred for
2.5 min before being added to an excess of powdered solid carbon dioxide. Water 
(20 ml) was added and the mixture was extracted with ether. The combined organic 
layers were extracted with 2 M sodium hydroxide solution. The aqueous solution was 
acidified with 2M sulphuric acid and was extracted with ether. The extract was dried. 
The solvent was evaporated to yield 4-bromothiophene-3-carboxylic acid (53) 
(0.030 g, 12%) a yellow solid. Rf 0.49 (ethyl acetate); mp 152-155°C (lit.224 mp
156-158°C); lU NMR (270 MHz, (CD3)2SO) 8  7.77 (1 H, d, /  = 3.3 Hz, thiophene
5-H), 8.37 (1 H, d, J  = 3.7 Hz, thiophene 2-H), 10.16 (1 H, br, C0 2H); o w  (KBr, 







4-Bromo-a-phenyIthiophene-3-methanol (59). To 3,4-dibromothiophene (55) 
(0.30 g, 1.2 mmol) in dry ether (10 ml) at -78°C under N2, n-butyllithium (2.5 M in 
hexanes, 0.52 ml, 1.30 mmol) was added during 30 sec. The mixture was stirred for
2.5 min and treated with benzaldehyde (0.15 g, 1.4 mmol) in dry ether (10 ml). The 
mixture was stirred for 30 min at ambient temperature. The solution was washed with 
water (30 ml) and was dried. Concentration and column chromatography (hexane : 
ethyl acetate 5:1) yielded 4-bromo-a-phenylthiophene-3-methanol (59) (0.21 g, 63%) 
as a yellow oil. (lit.266 bpo.i 100°C); Rf0.27 (hexane : ethyl acetate 5:1); !H NMR 
(270 MHz, CDCI3) 6  5.91 (1 H, s, CH(OH)-Ph), 7.22 (1 H, d, / =  3.4 Hz, thiophene
5-H), 7.57 (7 H, m, Ph-H5 + thiophene 2-H + OH); m/z (El) 268, 270 (M, 21).
Ethyl 4-bromothiophene-3-carboxylate (60), ethyl 3,4-dibromothiophene-2- 
carboxylate (62), diethyl 4-bromothiophene-2,3-dicarboxylate (64), diethyl 
thiophene-3,4-dicarboxylate (63), and ethyl 4-(4-bromo-3-thienoyl)thiophene-3-
(63) (66)
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carboxylate (66). 3,4-Dibromothiophene (55) (0.30 g, 1.2 mmol) in dry ether (10 ml) 
was held at -116°C under N2, using liquid nitrogen to freeze a bath of ether. 
rc-Butyllithium (2.5 M in hexanes, 0.52 ml, 1.3 mmol) was added rapidly and the 
mixture was stirred for 1.5 min before being treated with ethyl chloroformate (0.27 g,
2.5 mmol) and being stirred for 5 min at ambient temperature. The reaction mixture 
was partitioned between ether and water. The organic layer was separated, washed 
with water and brine, and was dried. Evaporation of the solvent and chromatography 
(hexane : ethyl acetate 5:1) yielded ethyl 4-bromothiophene-3-carboxylate (60) 
(0.12 g, 43%) as a yellow oil. Rf 0.5 (hexane : ethyl acetate 10:1); !H NMR 
(400 MHz, CDCI3) 5 1.39 (3 H, t, 7 = 7.0 Hz, CH3), 4.35 (2 H, q, 7=  7.0 Hz, CH2), 
7.32 (1 H, d, 7 = 3.7 Hz, thiophene 5-H), 8.12 (1 H, d, 7 = 3.7 Hz, thiophene 2-H); 
I3C NMR (100 MHz, CDCI3) 6  110.82 (C-4), 125.21 (C-5), 131.37 (C-2), 134.13 
(C-3), 161.32 (C02Et); m/z (Cl) 191, 189 (M - Q U A  40); r w  (film, cm'1) 1735 
(C=0).
All the side products to this reaction were isolated and characterised by NMR and 
mass spectroscopy:
Ethyl 3,4-dibromothiophene-2-carboxylate (62) (23 mg, 6 %); yellow oil; Rf 0.63 
(hexane : ethyl acetate 10:1); (lit267 mp 62-63°C); 1H NMR (400 MHz, CDC13) 
5 1.30 (3 H, t, J  = 7.0 Hz, CH3), 4.17 (2 H, q, J  = 7.0 Hz, CH2), 7.31 (1 H, s, 
thiophene 5-H); m/z (El) 312,314 (M, 20).
Diethyl 4-bromothiophene-2,3-dicarboxylate (64) (20 mg, 5%); yellow oil; Rf 0.39 
(hexane : ethyl acetate 10:1); *H NMR (400 MHz, CDC13) 5 1.35 (3 H, t, 7= 7 .0  Hz, 
CH3), 1.41 (3 H, t, 7 = 7.0 Hz, CH3), 4.35 (2 H, q, 7 = 7.3 Hz, CH2), 4.45 (2 H, q,
159
7 = 7 . 0  Hz, CH2), 7.45 (1 H, s, thiophene 5-H); m/z (FAB*) 306.9643 (M + H, 30) 
(CioHi279Br0 4S requires 306.9640), 308.9624 (M* + H, 28) (CioH1281Br04S requires 
308.9619).
Diethyl thiophene-3,4-dicarboxylate (63) (30 mg, 11%); yellow oil; Rf 0.33 (hexane : 
ethyl acetate 10:1); (lit 268 bp760 136-142°C); 'H NMR (400 MHz, CDCI3) 6  1.36 
( 6  H, t, 7 = 7.0 Hz, 2  x CH3), 4.34 (4 H, q, 7 = 7.0 Hz, 2  x CH2), 7.84 (2 H, s, 
thiophene 2,5-H2), m/z (El) 228 (M, 19).
Ethyl 4-(4-bromo-3-thienoyl)thiophene-3-carboxylate (6 6 ) (40 mg, 10%); pale brown 
oil; Rf 0.22 (hexane : ethyl acetate 10:1); !H NMR (270 MHz, CDC13) 5 1.16 (3 H, t, 
7=  7.2 Hz, CH3), 4.14 (2 H, q, 7 = 1.2 Hz, CH2), 7.35 (1 H, d, 7 = 3.5 Hz, thiophene
5-H), 7.62 (1 H, d, 7 = 3.3 Hz) and 7.67 (1 H, 2d, 7 = 3.3 Hz) (thiophene 2-H, 
thiophene 5-H), 8.11 (1 H, d, 7=3.1 Hz, thiophene 2-H); m/z (FAB*) 344.9252 
(M + H, 40) (Ci2Hio79Br03S2 requires 344.9255), 346.9239 (M + H, 44) 





Methyl 4-bromothiophene-3-carboxylate (61) and methyl 3,4-dibromo- 
thiophene-2 -carboxylate (67). w-Butyllithium (1.6 M in hexanes, 14.2 ml, 
22.7 mmol) was added to 3,4-dibromothiophene (55) (5.00 g, 20.7 mmol) in dry 
ether (100 ml) at -116°C under N2, using nitrogen to freeze a bath of ether. The
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mixture was stirred for 5 min at this temperature. Methyl chloroformate (3.91 g, 
41 mmol) was added and the mixture was stirred for 2 0  min at ambient temperature 
before being partitioned between ether and water. The combined organic fractions 
were washed with brine and were dried. Evaporation and column chromatography 
(hexane : ethyl acetate 20:1) yielded methyl 4-bromothiophene-3-carboxylate (61) 
(1.65 g, 36%) as a yellow solid. Rf0.38 (hexane : ethyl acetate 4:1); mp 47-49°C 
(lit.224 mp 49-51°C); ‘H NMR (270 MHz, CDC13) 8  3.88, (3 H, s, C 0 2Me), 7.31 
(1 H, d, J  = 3.4 Hz, thiophene 5-H) 8.11 (1 H, d, J  = 3.4 Hz, thiophene 2-H)); 
m/z (El) 220,222 (M, 42); t w  (KBr, cm'1) 1720 (C=0).
Methyl 3,4-dibromothiophene-2-carboxylate (67) (0.21 g, 4%) was also isolated as a 
white solid. Rf 0.48 (hexane : ethyl acetate 4:1); (compound reported by Hakansson 
et a l269); [H NMR (270 MHz, CDCI3) 8  3.92, (3 H, s, C02Me), 7.56 (1 H, s, 
thiophene 5-H).
4-Bromothiophene-3-carboxylic acid (53). Method A: Ethyl 4-bromothiophene-3- 
carboxylate (60) (1.69 g, 7.2 mmol) in ethanol (50 ml) and sodium hydroxide (0.5 M. 
29 ml, 14.5 mmol) were heated under reflux for 30 min. The solvent was evaporated. 
The residue was dissolved in water (50 ml) and was acidified with 2 M hydrochloric 
acid. The precipitate was collected, washed with water and dried to yield 
4-bromothiophene-3-carboxylic acid (53) (1.4 g, 94%) as an off-white solid. Rf 0.49 
(ethyl acetate); mp 152-155°C (lit.224 mp 156-158°C); 1H NMR (270 MHz,
(53)
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(CD3)2SO) 8  7.77 (1 H, d, 7 = 3.7 Hz, thiophene 5-H), 8.37 (1 H, d, 7=3.7  Hz, 
thiophene 2-H), 12.98 (1 H, br, CO2H); m/z (El) 206, 208 (M, 90), 189, 191 (100); 
t W  (KB r, cm'1) 3100-2500 (O-H str), 1700 (C=0).
4-Bromothiophene-3-carboxylic acid (53). Method B: Methyl 4-bromothiophene-3- 
carboxylate (61) (1.18 g, 5.3 mmol) in methanol (12 ml) was heated under reflux for 
30 min with sodium hydroxide solution (1 M. 12 ml, 12 mmol). The solvent was 
evaporated. The residue was dissolved in water (20 ml) and was acidified with 2 M 
hydrochloric acid. The precipitate was collected, washed with water and dried to 
yield 4-bromothiophene-3-carboxylic acid (53) (0.99 g, 90%) as an off-white solid. 
R, 0.49 (ethyl acetate); mp 151-154°C (lit.224 mp 156-158°C); 1H NMR (270 MHz, 
CDCI3) 8  7.35 (1 H, d, 7= 3.3 Hz, thiophene 5-H), 8.29 (1 H, d, 7=  3.7 Hz, thiophene
2-H); (KBr, cm'1) 3100-2500 (O-H str), 1700 (C=0).
Ethyl 4-carboxythiophen-3-ylacetate (69). Ethyl 3-oxobutanoate (0.47 g,
(0.13 g, 5.7 mmol) in ethanol ( 8  ml). 4-Bromothiophene-3-carboxylic acid (53) (0.5 
g, 2.4 mmol) and copper powder (100 mg) were added and the mixture was boiled 
under reflux for 16 h. The reaction mixture was poured onto water, and acidified with 
2 M aqueous hydrochloric acid and extracted with ether. The extracts were washed 
with water and dried. Evaporation of the solvent and recrystallisation (ethyl acetate)
(69)
3.6 mmol) was added to a cooled solution of sodium ethoxide, formed from sodium
162
gave ethyl 4-carboxythiophen-3-ylacetate (69) (0.45 g, 87%) as an off-white crystals. 
Rf0.30 (10% methanol : chloroform); mp 160-162°C (lit.227 mp 159.5-161 °C); 
'HNMR (270 MHz, (CD3)2SO) 8  1.16 (3 H, t, J  = 7.3 Hz, CH3), 3.85 (2 H, s, 
CHj-COjEt), 4.05 (2 H, q, J  = 7 Hz, CH2-CH3), 7.44 (1 H, A,J=ca. 3 Hz, thiophene
2-H), 8.23 ( 1  H, d ,J  = ca. 3 Hz, thiophene 5-H), 12.61 (1 H, br, COjH); m/z (El) 214 





Method A: Pentane-2,4-dione (2.42 g, 24.1 mmol) was added to potassium f-butoxide 
(1.08 g, 9.7 mmol) in 2-methylpropanol (25 ml), followed by 4-bromothiophene-3- 
carboxylic acid (53) (1.0 g, 4.8 mmol) and copper powder (31 mg). The mixture was 
heated under reflux for 16 h, poured into water (40 ml) and acidified with 2 M 
hydrochloric acid. The precipitate was collected and dried to furnish 4-(l-acetyl-2- 
oxopropyl)thiophene-3-carboxylic acid (72) (0.83 g, 76%) as an off-white solid. Rf 
0.33 (hexane : ethyl acetate 2:1 and formic acid (trace)); mp 193-195°C (lit.227 mp 
198-199°C); 1H NMR (270 MHz, (CD3)2SO) 8  1.79 ( 6  H, s, 2  x Me), 7.51 ( 1  H, d, 
J = 3.3 Hz, thiophene 5-H), 8.40 (1 H, d, J  = 3.3 Hz, thiophene 2-H), 12.66 (1 H, br, 
C02H), 16.57 (1 H, s, OH enol); m/z (El) 226 (M, 32), 43 (100); i w  (KBr, cm'1) 
3200-2800 (O-H), 1690 (C=0).
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4-(l-Acetyl-2-oxopropyI)thiophene-3-carboxylic acid (72). Method B: Sodium 
hydride (60% w/w in oil, 0.65 g, 6 . 8  mmol) was added during 5 min to 
4-bromothiophene-3-carboxylic acid (53) (1.4 g, 6 . 8  mmol) and copper(I) bromide 
(60 mg) in pentane-2,4-dione (10.2 g, 10.2 mmol) under nitrogen. The mixture was 
stirred at 80°C for 16 h. The mixture was poured onto water (50 ml) and washed with 
ether four times. The aqueous layer was acidified with concentrated hydrochloric acid 
and was extracted with ethyl acetate. The extract was dried and the solvent was 
evaporated to afford 4-(l-acetyl-2-oxopropyl)thiophene-3-carboxylic acid (72) 
(1.25 g, 64%) as an off-white crystals. RfO.33 (2:1 hexane : ethyl acetate and formic
acid (trace)); lH NMR (270 MHz, CDCI3) 8  1.88 ( 6  H, s, 2 x Me), 7.16 (1 H, d, J  =
3.3 Hz, thiophene 5-H), 8.38 (1 H, d, J  = 3.3 Hz, thiophene 2-H), 9.66 (1 H, br, 
C 0 2H), 16.56 (1 H, s, OH).
4-(2-Oxopropyl)thiophene-3-carboxylic acid (73).
4-(l-Acetyl-2-oxopropyl)thiophene-3-carboxylic acid (72) (0.81 g, 3.6 mmol) was 
stirred with aqueous ammonia (54 ml, 35%) for 24 h. The solvent and excess reagent 
were evaporated and the residue was acidified with 10% hydrochloric acid. The 
mixture was extracted with ethyl acetate. The extract was washed with water and 
dried. Evaporation and chromatography (ethyl acetate : hexane 2:1) yielded 4-(2-oxo- 
propyl)thiophene-3-carboxylic acid (73) (0.48 g, 73%) as white crystals. Rf 0.26
(73)
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(hexane : ethyl acetate 3:2); mp 150-152°C (lit.227 mp 153-154°C); 'H NMR 
(270 MHz, (CD3)2SO) 8  2.12 (3 H, s, Me), 3.95 (2 H, s, CHz-COMe), 7.32 (1 H, d, 
J  = 3.5 Hz, thiophene 5-H), 8.24 (1 H, d, /  = 3.3 Hz, thiophene 2-H), 12.5 (1 H, br, 
C 0 2H); m/z (El) 184 (M, 6 ), 124 (100); t w  (KBr, cm 1) 3200-2700 (O-H), 1720 
(C=0, ketone), 1690 (C=0, acid).




4-(2-Oxo-2-phenylethyl)thiophene-3-carboxylic acid (74) and 4-ethoxy- 
thiophene-3-carboxylic acid (75). Method A: Sodium ethoxide was formed by 
dissolving sodium (0.26 g, 11 mmol) in ethanol (15 ml). To this solution, 
l-phenylbutane-l,3-dione (1.18 g, 7.2 mmol) was added, followed by 
4-bromothiophene-3-carboxylic acid (53) (1.00 g, 4.8 mmol) and copper powder 
( 1 0 0  mg), and the reaction was heated under reflux under an atmosphere of nitrogen 
for 24 h. The mixture was poured into water (50 ml) and filtered. The filtrate was 
acidified with 2 M hydrochloric acid, and extracted with ether. The extract was 
washed with brine and dried. Evaporation and chromatography (10% methanol : 
chloroform) yielded 4-(2-oxo-2-phenylethyl)-thiophene-3-carboxylic acid (74) 
(0.26 g, 22%) as a white solid Rf 0.32; mp 200-202°C (lit.227 mp 212-214°C); 
!H NMR (270 MHz, (CD3)2SO) 8  4.62 (2 H, s, PhCOCH^), 7.38 (1 H, d, J  = 3.3 Hz, 
thiophene 5-H), 7.56 (3 H, m, Ph 3,4,5-H3), 8.02 (2 H, dd, J  = 7.8, 1.5 Hz,
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Ph 2,6-Hfe), 8.27 (1 H, d,J=  3.3 Hz, thiophene 2-H), 12.58 (1 H, br, C 0 2H); m/z (Cl) 
247 (M + H, 95); 1W  (KBr, cm'1) 3200-2600 (O-H), 1690 (C=0). 
4-Ethoxythiophene-3-carboxylic acid (75) ( 8 8  mg, 11%) was also isolated as a 
yellow solid. Rf 0.07 (hexane : acetone 6:1); mp 161-164°C (lit. 270 170.6-171.5°C); 
*H NMR (270 MHz, (CD3)2SO) 6  DMSO) 1.33 (3 H, t; 7 = 7 Hz, CH3), 4.0 (2 H, q, 
7 = 7 Hz, CHb), 6 . 6 6  (1 H, d, 7 = 3.3 Hz, thiophene-5-H), 8.13 (1 H, d, 7 = 3.7 Hz, 
thiophene-2-H), 12.65 (1 H, br, C0 2H).
4-(2-Oxo-2-phenyIethyl)thiophene-3-carboxylic acid (74). Method B: Sodium 
hydride (60% w/w in oil, 0.5 g, 21 mmol) was added to a rapidly stirred suspension 
of 4-bromothiophene-3-carboxylic acid (53) (1.8 g, 8.7 mmol), l-phenylbutane-1,3- 
dione (7.05 g, 44 mmol) and copper(I) bromide (75 mg) in toluene (20 ml), during 
5 min under nitrogen. The mixture was stirred at 130°C for 48 h, cooled, poured onto 
water (50 ml) and washed with ether four times. The aqueous solution was acidified 
with concentrated aqueous hydrochloric acid and extracted with ethyl acetate. The 
extract was dried and the solvent was evaporated to produce 4-(2-oxo-2- 
phenylethyl)thiophene-3-carboxylic acid (74) (0.86 g, 40%) as an off-white solid. 
Rf0.22 (2:1 hexane ethyl acetate and formic acid (trace); mp 198-201°C (lit.227 mp 
212-214°C); *H NMR (270 MHz, (CD3)2SO) 8  4.62 (2 H, s, PhCOCH^ 7.38 (1 H, d, 
7 = 3.3 Hz, thiophene 5-H), 7.57 (3 H, m, Ph 3,4,5-H3), 7.99 (2 H, dd, 7 = 8.42 Hz, 
Ph 2,6-H2), 8.27 (1 H, d, 7=  3.3 Hz, thiophene 2-H), 12.75 (1 H, br, C 0 2H); m/z (Cl) 







4-Bromo-5-nitrothiophene-3-carboxylic acid (76). Fuming nitric acid (90%,
1.01 ml, 24 mmol) was added slowly to acetic anhydride (2.46 g, 24.1 mmol) at 
-10°C, followed by 4-bromothiophene-3-carboxylic acid (53) (1.00 g, 4.83 mmol) 
and acetic acid (5.0 ml). The mixture was stirred for 20 min. Water (30 ml) was 
added and the mixture was extracted with ethyl acetate. The extract was washed 
thrice with saturated sodium hydrogen carbonate solution, and once with water and 
dried. Evaporation and chromatography (hexane : ethyl acetate 1:1 and acetic acid 
(trace)) yielded 4-bromo-5-nitrothiophene-3-carboxylic acid (76) (0.66 g, 54%) as a 
pale yellow solid. Rf 0.23 (hexane : ethyl acetate 1:12); mp 231-233°C (lit.217 mp 
236-238°C); !H NMR (270 MHz, (CD3)2SO) 8 8.69 (1 H, s, thiophene 2-H), 13.62 
(1 H, br, CQ2H); m/z (Cl) 252,254 (M + H, 100).
4-Carboxythiophene-3-acetamide (80). Ethyl 4-carboxythiophene-3-acetate (69) 
(0.24 g, 1.1 mmol) was stirred with aqueous ammonia (25 ml, 35%) for 24 h. The 
excess reagent was evaporated to furnish 4-carboxythiophene-3-acetamide (80) 
(0.19 g, 92%) as a pale brown crystalline solid. Rf 0.04 (15% methanol: chloroform); 






s, CH2-CONH2), 6.67 (1 H, br, NH), 7.23 (1 H, d, 7= 3.3 Hz, thiophene 2-H), 7.81 





6-Methylthieno[3,4-c]pyridin-4(5H)-one (83a). 4-(2-Oxopropyl)thiophene-3- 
carboxylic acid (73) (0.41 g, 2.2 mmol) was boiled with ammonium acetate (5.5 g, 
71 mmol) in acetic acid (6.2 ml) under reflux for 20 h. The mixture was poured into 
water (30 ml) and was extracted with ethyl acetate. The extract was washed with 
saturated sodium hydrogen carbonate and water, and was dried. Evaporation of the 
solvent furnished 6-methylthieno[3,4-c]pyridin-4(5H)-one (83a) (0.25 g, 6 8 %) as an 
orange solid. Rf 0.43 (10% methanol : chloroform); mp 184-187°C (lit.227 mp 
184-186°C); lH NMR (270 MHz, (CD3)2SO) 8  2.10 (3 H, s, Me), 6.16 (1 H, s, 7-H), 
7.48 (1 H, d, 7 = 2.9 Hz, 1-H), 8.35 (1 H, d, 7 = 3.4 Hz, 3-H), 10.56 (1 H, br, N-H); 
m/z (El) 165 (M, 100); Dmax (KBr, cm'1) 3450, 3180 (NH), 1675 (amide I), 1650
6-Phenylthieno[3,4-c]pyridin-4(5H)-one (83b). A mixture of 4-(2-oxo-2- 





acetate (1.8 g, 23 mmol) in acetic acid (3.0 ml) was boiled under reflux for 16 h. The 
mixture was poured into water (14 ml) and extracted with ethyl acetate. The extract 
was dried. Evaporation and chromatography (dichloromethane : methanol 40:1) 
produced 6-phenylthieno[3,4-c]-pyridin-4(5H)-one (83b) (72 mg, 43%) as a yellow 
solid. Rf 0.37 (dichloromethane : methanol 20:1); mp 150-153°C (lit.227 mp
157-158°C); *H NMR (270 MHz, (CD3)2SO) 8  6 . 6 8  (1 H, s, 7-H), 7.42 (1 H, d, 
J  = 2.9 Hz, 1-H), 7.48 (3 H, m, Ph 3,4,5-H3), 7.61 (2 H, dd, J  = 8.1, 1.7 Hz, 
Ph 2,6-H2), 8.40 (1 H, d, J = 2.9 Hz, 3-H), 8.95 (1 H, br, N-H); m/z (El) 227 (M, 10), 
149 (100).
(85a) (8 8 a) (90a)
l-(4-Nitrophenyl)butane-l,3-dione (85a). Bis(pentane-2,4-dionato)copper(IT) (8 6 ) 
(7.00 g, 27 mmol) was shaken with 4-nitrobenzoyl chloride (4.96 g, 27 mmol) in 
chloroform (120 ml) for 72 h. The mixture was washed with 2 M aqueous sulphuric 
acid four times and was dried. The evaporation residue was heated under reflux with 
aqueous ammonia (3 M, 100 ml) for 15 min and acidified with concentrated aqueous 
hydrochloric acid. The solution was concentrated and the crystals were collected and 
purified by chromatography (hexane : ethyl acetate 5:1) to produce
1 -(4-nitrophenyl)butane-1,3-dione (85a) (0.36 g, 7%) as a yellow crystalline solid. 
Rf 0.42 (hexane : ethyl acetate 2:1); mp 112-113°C (lit.232 mp 112-114°C); *H NMR 
(270 MHz, (CD3)2SO) 5 2.26 (3 H, s, Me), 4.40 (0.2 H, s, Clfc keto), 6.72 (0.9 H, s,
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C=CH enol), 8.19 (2 H, d, /  = 8 . 8  Hz, Ph 2,6-H2), 8.35 (2H, d, J  = 8 . 8  Hz, 
Ph 3,5-H2), 16.0 (0.9 H, br, OH enol); m/z (El) 207 (M, 40), 192 (100); Calcd. for 
C10H9NO4 : C, 57.96; H, 4.39; N, 6.76; Found: C, 57.80; H, 4.20; N, 6.83.
Further elution furnished l-acetyl-4-nitrobenzene (8 8 a) (0.22 g, 5%) as a yellow 
solid. Rf 0.36 (hexane : ethyl acetate 2:1); *H NMR (270 MHz, (CD3)2SO) 8  2.26 
(3 H, s, Me), 8.19 (2 H, d, J  = 8.4 Hz, Ph 2,6-H2), 8.35 (2 H, d, J  = 8 . 8  Hz, 
Ph 3,5-H2).
4-Nitrobenzamide (90a) (80 mg, 2%) was also isolated as an orange solid. Rf 0.031 
(hexane : ethyl acetate 2:1); !H NMR (270 MHz, (CD3)2SO) 8  7.74 (1 H, br, NH), 
8.17 (2 H, d, J  = 8.4 Hz, Ph 2,6-H2), 8.32 (3 H, m, Ph 3,5-H2 and NH).
OH
(90b)(89b)(8 8 b)(85b)
1 -(4-Bromophenyl)butane-l,3-dione (85b). Bis(pentane-2,4-dionato)copper(II) (8 6 ) 
(6.00 g, 23 mmol) was shaken with 4-bromobenzoyl chloride (5.03 g, 23 mmol) in 
chloroform (130 ml) for 72 h. The mixture was washed with 2 M aqueous sulphuric 
acid four times and dried. The evaporation residue was heated under reflux with 
aqueous ammonia (3 M, 100 ml) for 15 min and acidified with concentrated 
hydrochloric acid. The solution was concentrated and the precipitate was collected. 
Chromatography (hexane : ethyl acetate 10:1) produced l-(4-bromo-phenyl)butane- 
1,3-dione (85b) (2.49 g, 45%) as white crystals. Rf 0.43 (hexane : ethyl acetate 2:1); 
mp 89-91°C Oit.271 mp 94-96°C); 'H NMR (270 MHz, (CDskSO) 8  2.20 (2.4 H, s,
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Me keto), 2.26 (0.6H, s, Me enol), 4.29 (0.4 H, s, CH2 keto), 6.60 (0.8 H, s, C=CH 
enol), 7.74 (2 H, d, J  = 8.4 Hz, Ph 3,5-H2), 7.90 (2 H, d, /  = 8.4 Hz, Ph 2,6-H2), 16.0 
(0.8 H, br, OH enol); m/z (El) 240, 242 (M, 29), 183, 185 (100); Calcd. for 
CioH9Br02: C, 49.82; H, 3.77; Found: C, 50.0; H, 3.77.
Further elution furnished l-acetyl-4-bromobenzene (8 8 b) (0.12 g, 3%) as a yellow 
solid. Rf 0.35 (hexane : ethyl acetate 2:1); *H NMR (270 MHz, (CD3)2SO) 8  2.58 
(3 H, s, Me), 7.74 (2 H, d, /  = 8.4 Hz, Ph 3,5-H2), 7.90 (2 H, d, /  = 8.4 Hz, 
Ph 2,6-H2).
4-Bromobenzoic acid (89b) (0.11 g, 2%) was also isolated as a white solid. Rf 0.04 
(hexane : ethyl acetate 2:1); *H NMR (270 MHz, (CD3)2SO) 8  7.72 (2 H, d, 
J  = 8.4 Hz, Ph 3,5-H2), 7.87 (2 H, d, J  = 8.4 Hz, Ph 2,6-H2).
Further elution a furnished 4-bromobenzamide (90b) (1.17 g, 26%). Rf 0.03 (hexane : 
ethyl acetate 2:1 ); mp 186-189°C (lit.272 mp 192°C); *H NMR (270 MHz, 
(CD3)2SO) 8  7.49 (1 H, br, NH), 7.67 (2 H, d, /  = 8.8 Hz, Ph 3,5-H2), 7.83 (2 H, d, 
J = 8.8 Hz, Ph 2,6-H2), 8.06 (1 H, br, NH).
(85c) (8 8 c) (90c)
l-(4-Iodophenyl)butane-l,3-dione (85c). Bis(pentane-2,4-dionato)copper(II) (8 6 ) 
(5.00 g, 19 mmol) was shaken with 4-iodobenzoyl chloride (5.09 g, 19 mmol) in 
chloroform (100 ml) for 72 h. The mixture was washed with 2 M sulphuric acid four 
times and dried. The evaporation residue was heated under reflux with aqueous
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ammonia (3 M, 100 ml) for 15 min and acidified with concentrated hydrochloric 
acid. The solution was concentrated and the precipitate was collected. 
Chromatography (hexane : ethyl acetate 20:1) produced l-(4-iodophenyl)butane-l,3- 
dione (85c) (0.93 g, 17%) as a white crystalline solid. Rf 0.19 (hexane : ethyl acetate 
10:1); mp 115-117°C (compound reported by Daniel et al?73 and by Kopecky et 
al.274 but no mp given); *H NMR (270 MHz, (CD3)2SO) 8  2.19 (2.4 H, s, Me enol),
2.26 (0.6 H, s, Me keto), 4.27 (0.4 H, s, CH2 keto), 6.58 (0.8 H, s, C=CH enol), 7.72 
(2 H, d, / =  8.4 Hz, Ph 3,5-H2), 7.92 (2 H, d, / =  8 . 8  Hz, Ph 2,6-H2), 16.21 (0.8 H, br, 
OH enol); m/z (El) 288 (M, 100); Calcd. for Ci0H9IO2: C,41.69; H, 3.16; Found: 
C, 41.9; H, 3.00.
Further elution furnished l-acetyl-4-iodobenzene (8 8 c) (0.53 g, 2%) as a white solid. 
Rf 0.15 (hexane : ethyl acetate 10:1); *H NMR (270 MHz, (CD3)2SO) 8  2.56 (3 H, s, 
Me), 7.71 (2 H, d, J  = 8.1 Hz, Ph 3,5-H2), 7.92 (2 H, d, J  = 8.1 Hz, 
Ph 2,6-H2).
4-Iodobenzamide (90c) (3.61 g, 77%) was also isolated as a buff solid. Rf 0.01 
(hexane : ethyl acetate 10:1); lR NMR (270 MHz, (CD3)2SO) 8 7.44 (1 H, br, NH), 





l-(4-Methoxyphenyl)butane-l,3-dione (85d). Sodium ethoxide (4.53 g, 67 mmol) 
was added to a solution of l-acetyl-4-methoxybenzene (8 8 d) (5.0 g, 33 mmol) in
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ethyl acetate (50 ml) and the mixture was heated under reflux for 7 h. The mixture 
was acidified with concentrated hydrochloric acid and extracted with ethyl acetate. 
The extract was dried. Evaporation of the solvent and chromatography (hexane : 
ethyl acetate 5:1) yielded 1 -(4-methoxyphenyl)butane- 1 ,3 -d io n e  (85d) (5.79 g, 91%) 
as white crystals. Rf 0.29 (hexane : ethyl acetate 5:1); mp 54-55°C (lit.275 mp 
53-54°C); *H NMR (270 MHz, CDC13) 5 2.17 (2.4 H, s, CMe enol), 2.29 (0.6 H, s, 
CMe keto), 3.87 (3 H, s, OMe), 4.05 (0.4 H, s, CH2 keto), 6.12 (0.8 H, s, C=CH 
enol), 6.94 (0.4 H, d, J  = 9.2 Hz, Ph 3,5-H2 keto), 6.94 (1.6 H, d, /  = 8 . 8  Hz, 
Ph 3,5-H2 enol), 7.87 (1.6 H, d, J  = 8 . 8  Hz, Ph 2,6-H2 enol) and (0.4 H, Ph 2,6-H2 
keto), 16.0 (0.8 H, br, OH enol); m/z (El) 192 (M, 52), 135 (100).
Ethyl 4-methoxybenzoate (91d) (0.45 g, 8 %) was also isolated as a yellow oil. 
Rf 0.40 (hexane : ethyl acetate 5:1); (lit.276 bp? 151-151.8°C); 'H NMR (270 MHz, 
CDCI3) 8  1.38 (3 H, t, J  = 7 Hz, CH2-CH3), 3.86 (3 H, s, OMe), 4.35 (2 H, q, 
7 = 7  Hz, CH2), 6.91 (2 H, d, J  = 8 . 8  Hz, Ph 3,5-H2), 8.00 (2 H, d, J  = 8.4 Hz, 
Ph 2,6-H2).
4-(2-(4-Nitrophenyl)-2-oxoethyl)thiophene-3-carboxylic acid (92a) and 
4-nitrobenzoic acid (89a). Sodium ethoxide was formed by dissolving sodium 




dione (85a) (1.2 g, 5.8 mmol) was added, followed by 4-bromothiophene-3- 
carboxylic acid (53) (0.10 g, 0.48 mmol) and copper powder (20 mg), and the 
mixture was heated under reflux for 24 h. The reaction was poured into water (7 ml) 
and filtered. The filtrate was acidified with 2 M hydrochloric acid and extracted with 
ethyl acetate. The extract was washed with brine and was dried. Evaporation and 
chromatography (hexane : ethyl acetate 10:1) yielded 4-(2-(4-nitrophenyl)-2- 
oxoethyl)thiophene-3-carboxylic acid (92a) (20 mg, 14%) as a yellow oil. Rf 0.46 
(hexane : ethyl acetate 4:1); *H NMR (270 MHz, CDCI3) 5 3.89 (2 H, s, CH2), 7.32 
(1 H, d, /  = 3.7 Hz, thiophene 5-H), 8.12 (1 H, d, J  = 3.5 Hz, thiophene 2-H), 8.22 
(2 H, d, J  = 8 . 8  Hz, Ph 2,6-H2), 8.29 (2 H, d, J  = 9 Hz, Ph 3,5-H2).
4-Nitrobenzoic acid (89a) (39 mg, 4%) was also isolated as a yellow solid. Rf 0.04 
(hexane : ethyl acetate 4:1); *H NMR (400 MHz, CDCI3) 5 8.26 (2 H, d, J -  8.5 Hz, 
Ph 2,6-H2), 8.32 (2 H, d, / =  8 . 6  Hz, Ph 3,5-H2).
OEt OH
OEt
(8 8 b) (89b)
Attempted Preparation of 4-(2-(4-Bromophenylacylthiophene-3-carboxylic acid 
(92b). Sodium ethoxide was formed by dissolving sodium (53 mg, 2.29 mmol) in 
ethanol (3 ml). To this solution, l-(4-bromophenyl)butane-l,3-dione (85b) (0.35 g,
1.5 mmol) was added, followed by 4-bromothiophene-3-carboxylic acid (53) (0.20 g, 
0.97 mmol) and copper powder (50 mg), and the reaction was heated under reflux for 
24 h. The mixture was poured into water (10 ml) and filtered. The filtrate was 
acidified with 2 M hydrochloric acid and extracted with ethyl acetate. The extract
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was washed with brine and was dried. Evaporation and chromatography (toluene : 
ether 3:1) furnished ethyl 4-bromobenzoate (91b) (37 mg, 11%) as a yellow oil. 
R f 0.79 (toluene : ether 2:1); *H NMR (270 MHz, CDC13) (5 1.39 (3 H, t, J  = 7.1 Hz, 
CH3), 4.37 (2 H, q, J  = 7.2 Hz, Clfc), 7.57 (2 H, d, J = 8 . 6  Hz, Ph 3,5-H2), 7.91 (2 H, 
d, 7=  8 . 6  Hz, Ph 2,6-H2).
Further elution yielded 1 -acetyl-4-bromobenzene (88b) (72 mg, 25%) as a pale 
yellow solid. Rf 0.63 (toluene : ether 3:1); mp 44-47°C (lit.272 mp 50-51°C); *H NMR 
(270 MHz, CDC13) 8  2.59 (3 H, s, COMe), 7.60 (2 H, d, J  = 8 . 8  Hz, Ph 3,5-H2), 7.82 
(2 H, d, J  = 8 . 6  Hz, Ph 2,6-H2).
4-Bromobenzoic acid (89b) (83 mg, 29%) was also isolated as a buff solid. Rf 0.16 
(10% methanol : chloroform); lH NMR (270 MHz, CDC13) 5 7.55 (2 H, d, 
7 = 8.4 Hz, Ph 3,5-H2), 7.89 (2 H, d, 7=8.4 Hz, Ph 2,6-H2).
Further elution furnished 4-ethoxythiophene-3-carboxylic acid (75) (17 mg, 10%) as 
a white solid. Rf 0.08 (10% methanol : chloroform); (compound reported by 
Press270); 'H NMR (270 MHz, CDC13) 8  1.53 (3 H, t, 7 = 7.1 Hz, CH3), 4.23 (2 H, q, 




Attempted Preparation of 4-(2-(4-Iodophenyl)-2-oxoethyl)thiophene-3- 
carboxylic acid (92c). Sodium ethoxide was formed by dissolving sodium (50 mg,
175
2.2 mmol) in ethanol (3.0 ml). To this solution, l-(4-iodophenyl)butane-l,3-dione 
(85c) (0.4 g, 1.4 mmol) was added, followed by 4-bromothiophene-3-carboxylic acid 
(53) (0.19 g, 0.92 mmol) and copper powder (40 mg), and the mixture was heated 
under reflux for 24 h. The mixture was poured into water (10 ml) and filtered. The 
filtrate was acidified with 2 M hydrochloric acid and extracted with ethyl acetate. 
The extract was washed with brine and was dried. Evaporation and chromatography 
(hexane : ethyl acetate 10:1) produced ethyl 4-iodobenzoate (91c) (60 mg, 16%) as a 
yellow oil. Rf 0.8 (hexane : ethyl acetate 4:1); (lit.277, oil); *H NMR (400 MHz, 
CDCls) 8  1.38 (3 H, t, J  = 7.3 Hz, CH3), 4.37 ( 2  H, q, J  = 7.3 Hz, CH2), 7.74 ( 2  H, d, 
J  = 8 . 8  Hz, Ph 3,5-H2), 7.79 (2 H, d, /  = 8.9 Hz, Ph 2,6-H2).
Further elution yielded l-acetyl-4-iodobenzene (8 8 c) (95 mg, 28%) as a yellow solid. 
Rf 0.58 (hexane : ethyl acetate 4:1); *H NMR (400 MHz, CDC13) 8  2.58 (3 H, s, 
COMe), 7.67 (2 H, d, J  = 8.6 Hz, Ph 3,5-H2), 7.83 (2 H, d, J = 8.5 Hz, Ph 2,6-H2). 
4-Iodobenzoic acid (89c) (18 mg, 5%) was also isolated as a white solid. Rf 0.11 
(hexane : ethyl acetate 4:1); *H NMR (270 MHz, (CD3)2SO) 8  7.69 (2 H, d, 














Attempted Preparation of 4-(2-(4-Methoxyphenyl)-2-oxoethyI)thiophene-3- 
carboxylic acid (92d). Sodium ethoxide was formed by dissolving sodium (0.13 g, 
5.72 mmol) in ethanol (7.5 ml). To this solution, l-(4-methoxyphenyl)butane-l,3- 
dione (85d) (0.70 g, 3.6 mmol) was added, followed by 4-bromothiophene-3- 
carboxylic acid (53) (0.50 g, 2.4 mmol) and copper powder (50 mg) and the mixture 
was heated under reflux for 24 h. The mixture was poured into water (25 ml) and 
filtered. The filtrate was acidified with 2M  hydrochloric acid and extracted with 
ethyl acetate. The extract was washed with brine and was dried. Evaporation and 
chromatography (hexane : ethyl acetate 10:1) produced ethyl 4-methoxybenzoate 
(91d) (0.15 g, 23%) as a yellow oil. Rf 0.56 (hexane : ethyl acetate 4:1); *H NMR 
(270 MHz, CDC13) 8  1.38 (3 H, t, 7 = 7 Hz, CH2-CH3), 3.86 (3 H, s, OMe), 4.35 
(2 H, q, 7 = 7.3 Hz, CH2-CH3), 6.92 (2 H, d, 7 = 9.2 Hz, Ph 3,5-H2), 8.00 (2 H, d, 
7=8.8 Hz, Ph 2,6-H2).
Further elution yielded l-acetyl-4-methoxybenzene (8 8 d) (0.31 g, 57%) as a yellow 
oil. Rf 0.35 (hexane : ethyl acetate 4:1); *H NMR (270 MHz, CDC13) 8  2.56 (3 H, s, 
COMe), 6.94 (2 H, d, 7 = 8 . 8  Hz, Ph 3,5-H2), 7.94 (2 H, d, 7 = 8 . 8  Hz, Ph 2,6-H2).
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4-Ethoxythiophene-3-carboxylic acid (75) ( 6 8  mg, 16%) was also isolated as a buff 
solid. Rf 0.24 (10% methanol: chloroform); ‘H NMR (400 MHz, CDC13) 1.53 (3 H, 
t, J  = 6.9 Hz, CH3). 4.35 (2 H, q, 7  = 6.9 Hz, CH2), 6.41 (1 H, d, J  = 3.6 Hz, 
thiophene 5-H), 8.20 (1 H, d, 7=  3.6 Hz, thiophene 2-H).
Further elution famished 4-methoxybenzoic acid (89d) (0.091 g, 17%) as a buff 
solid. Rf 0.01 (10% methanol: chloroform); ‘H NMR (270 MHz, CDC13) 8  3.88 (3 
H, s, OMe), 6.95 (2 H, d, J  = 9 Hz, Ph 3,5-H2), 8.06 (2 H, d, J  = 9 Hz, Ph 2,6-H2). 
4-(l,2-Dioxo-2-(4-methoxyphenyl)ethyl)thiophene-3-carboxylic acid (93) (94 mg, 
9%) was isolated as a buff solid. Rf 0.03 (hexane : ethyl acetate 4:1); mp 113-115°C; 
*H NMR (270 MHz, CDC13) 8  3.87 (3 H, s, OMe), 6.97 (2 H, d, 7 = 8 . 8  Hz, Ph 3,5- 
H2), 7.98 (2 H, d, 7=  8 . 8  Hz, Ph 2,6-H2), 8.18 (1 H, d, 7 = 3.3 Hz, thiophene 5-H),
8.27 (1 H, d, 7=  3.3 Hz, thiophene 2-H), 8.80 (1 H, br, C02H); 13C NMR (270 MHz, 
CDC13) 55.61 (OMe), 114.25 (Ph 3,5-C), 125.41 (Ph 1-C), 132.56 (thiophene 3-C), 
132.79 (Ph 2,6-C), 136.42 (thiophene 4-C), 137.75 (thiophene 2-C), 139.67 
(thiophene 5-C), 163.90 (Ph 4-C), 164.95 (C02H), 189.16, 190.49 (thiophene C=0, 
Ph-C=0); m/z (FAB*) 291.0362 (M + H) (C14H11O5S requires 291.0327), 259 (15), 






6-Methyl-7-nitrothieno[3,4-c]pyridin-4(5H)-one (97a) and 6 -Methyl-l-nitro- 
thieno-[3,4-c]pyridin-4(5H)-one (96a). Method A: Fuming nitric acid (90%,
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0.32 ml, 7.6 mmol) was added slowly to acetic anhydride (0.48 g, 7.6 mmol) at 
-10°C. 6  Methylthieno[3,4-c]pyridin-4(5H)-one (83a) (0.25 g, 1.5 mmol) and acetic 
acid (2 . 0  ml) were added and the reaction was stirred at ambient temperature for 
5 min. Water (3 ml) was added and the mixture was extracted with ethyl acetate. The 
extract was washed with saturated sodium hydrogen carbonate solution and with 
water, and was dried. Evaporation and chromatography (hexane : ethyl acetate 4:1) 
yielded 6-methyl-7-nitrothieno[3,4-c]-pyridin-4(5H)-one (97a) (0.12 g, 38%) as a 
yellow solid. Rf 0.26 (hexane : ethyl acetate 1:1); mp 278-279°C; *H NMR 
(270 MHz, (CD3)2SO) 8  2.64 (3 H, s, Me), 8.21 (1 H, d, 7=  3.3 Hz, 1-H), 8.65 (1 H, 
d, /  = 3.3 Hz, 3-H), 11.73 (1 H, br, N-H); m/z (FAB+) 211.0179 (M + H, 76) 
(C8H7N2 0 3S requires 211.0177).
Further elution yielded 6 -methyl-l-nitrothieno[3,4-c]pyridin-4(5H)-one (96a) 
(67 mg, 22%) as a yellow solid. Rf 0.016 (hexane : ethyl acetate 1:1); mp 290-293°C; 
*H NMR (270 MHz, (CD3)2SO) 8  2.27 (3 H, s, Me), 6.89 (1 H, s, 7-H), 8.87 (1 H, s,







6-Methyl-7-nitrothieno[3,4-c]pyridin-4(5H)-one (97a) and 6-Methyl-l,7-dinitro- 
thieno[3,4-c]pyridin-4(5H)-one (98a). Method B: Fuming nitric acid (90%, 0.12 ml,
3.0 mmol) was added slowly to acetic anhydride (0.31 g, 3.0 mmol) at -10°C.
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6  Methylthieno[3,4-c]pyridin-4(5H)-one (83a) (0.10 g, 0.61 mmol) and acetic acid 
(1 . 0  ml) were added and the reaction was stirred at ambient temperature for 1 0  min. 
Water (3 ml) was added and the mixture was extracted with ethyl acetate. The extract 
was washed thrice with saturated sodium hydrogen carbonate solution and once with 
water and was dried. Evaporation and chromatography (hexane : ethyl acetate 1:1) 
yielded 6-methyl-7-nitrothieno[3,4-c]-pyridin-4(5H)-one (97a) (0.012 g, 10%) as a 
yellow solid. Rf 0.22 (hexane : ethyl acetate 1:1); mp 276-278°C; !H NMR 
(400 MHz, CDCls) 8  2.78 (3 H, s, Me), 8.52 (1 H, d, J  = 3.1 Hz, 1-H), 8.58 (1 H, d, 
J  = 3.4 Hz, 3-H), 9.42 (1 H, br, N-H).
Further elution afforded 6 -methyl-l,7-dinitrothieno[3,4-c]pyridin-4(5H)-one (98a) 
(39 mg, 25%) as a yellow solid. Rf 0.13 (hexane : ethyl acetate 1:1); mp >350°C; *H 
NMR (400 MHz, (CD3)2SO) 8  2.43 (3 H, s, Me), 8.99 (1 H, s, 3-H), 12.23 (1 H, br, 






6-Phenyl-7-mtrotMeno[3,4-c]pyridin-4(5H)-one (97b) and 6-Phenyl-l-nitro- 
thieno[3,4-c]pyridin-4(5H)-one (96b). Method A: Fuming nitric acid (90%, 
0.016 ml, 0.38 mmol) was added very slowly to acetic anhydride (0.038 g, 
0.38 mmol) at -10°C. To this, 6-phenylthieno[3,4-c]pyridin-4(5H)-one (83b) 
(17.1 mg, 0.075 mmol) and acetic acid (2.0 ml) were added and stirred at ambient
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temperature for 5 min. Water (2.0 ml) was added and the mixture was extracted with 
ethyl acetate. The extract was washed with saturated sodium hydrogen carbonate 
solution and water, and was dried. Evaporation and chromatography (hexane : ethyl 
acetate 2:1) furnished 6-phenyl-7-nitrothieno[3,4-c]pyridin-4(5H)-one (97b) as a 
yellow solid (5.2 mg, 25%). Rf 0.33 (hexane : ethyl acetate 2:1); mp 233-235°C; 
‘H NMR (400 MHz, (CD3)2SO) 8  7.48 (5 H, s, Ph-H5), 8.16 (1 H, d, 7 = 3.4 Hz,
1-H), 8.67 (1-H, d, J  = 3.1 Hz, 3-H), 11.72 (1 H, br, N-H); m/z (FAB4) 273.0370 
(M + H, 100) (C13H9N2O3S requires 273.0334).
Further elution yielded 6 -phenyl-l-nitrothieno[3,4-c]pyridin-4(5H)-one (96b) 
(3.3 mg, 16%) as an orange solid. Rf 0.11 (hexane : ethyl acetate 2:1); mp 
270-272°C; 'HNMR (270 MHz, (CD3)2SO) 8  7.26 (1 H, s, 7-H), 7.56 (3 H, m, 






Method C: To a solution of 6-methylthieno[3,4-c]pyridin-4(5H)-one (83a) (0.25 g,
1.5 mmol) in trifluoroacetic acid (10 ml) at -15°C, potassium nitrate (0.31 g,
3.0 mmol) was added and the mixture was stirred for 5 min. The solvent was 
evaporated and the residue was partitioned between ethyl acetate and water. The
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extract again washed with brine and dried. Evaporation and chromatography 
(dichloromethane : methanol 40:1) produced 6 -methyl-1,7-dinitrothieno[3,4-c]- 
pyridin-4(5H)-one (98a) (0.14 g, 36%) as a yellow solid. Rf 0.1 (hexane : ethyl 
acetate 1:1); mp >350°C; *H NMR (270 MHz, (CD3)2SO) 8  2.43 (3 H, s, Me), 8.99 






Method B: To 6-phenylthieno[3,4-c]pyridin-4(5H)-one (83b) (0.22 g, 0.97 mmol) in 
trifluoroacetic acid (10 ml) at -15°C, potassium nitrate (0.20 g, 1.9 mmol) was added 
and the mixture was stirred for 5 min. The solvent was evaporated and the residue 
was partitioned between ethyl acetate and water. The extract was washed with brine 
and was dried. Evaporation and chromatography (dichloromethane : methanol 100:1) 
produced 6 -phenyl-l,7-dinitrothieno[3,4-c]-pyridin-4(5H)-one (98b) (0.11 g, 36%) as 
a yellow crystalline solid. Rf 0.48 (dichloromethane : methanol 20:1 ); mp 
294-295°C; 'H NMR (270 MHz, (CD3)2SO) 8  7.53 (5 H, s, Ph-H5), 9.05 (1 H, s,




To methyl mercaptoacetate (106) (26.5 g, 0.25 mol) and piperidine (0.25 ml), methyl 
propenoate (107) (22.5 g, 0.26 mol) was added during the period of 40 min. The 
temperature was maintained at 40-50°C by external cooling and piperidine (0.5 ml) 
was added in aliquots. The mixture was warmed to 50°C for a 5 min. Ether was 
added and the solution was washed with water and with brine, and was dried. The 
solvent was evaporated to yield methyl 3-(methoxycarbonylmethylthio)propanoate 
(105) (43.9g, 92%) as a pale yellow oil. Rf 0.18 (hexane : ethyl acetate 5:1); 
bp20142°C, (lit.238 bp2 111-112°C); *H NMR (270 MHz, CDC13) 5 2.66 (2 H, t, 
J  = 7.1 Hz, Me0 2C-CH2-CH2), 2.92 (2 H, t, J  = 7.1 Hz, CH^Qfc-S), 3.27 (2 H, s, 








(1 1 0 a)
Ethyl (±)-4-oxotetrahydrothiophene-3-carboxylate (110) and ethyl (±)-4-oxo- 
tetrahydrothiophene-3-carboxylate (111). Sodium (0.14 g, 6.2 mmol) was allowed 
to dissolve in ethanol (20 ml) at 0°C under nitrogen. Methyl 3-(methoxycarbonyl- 
methylthio)propanoate (1.0 g, 5.2 mmol) was added slowly and the mixture was
heated under reflux for 16 h.. The solvent was evaporated. The residue was brought 
to pH 5 with 2 M aqueous hydrochloric acid and was extracted with ethyl acetate. 
The extract was dried (MgSCU). Evaporation and chromatography (hexane : ethyl 
acetate 40 : 1) yielded ethyl (±)-4-oxotetrahydrothiophene-3-carboxylate (110) 
(0.13 g, 14%) as a pale yellow oil. Rf 0.39 (hexane : ethyl acetate 10 : 1); (compound 
reported by Duus239); *H NMR (270 MHz, CDC13) 6  1.30 (1 H, t, J  = 6 . 8  Hz, CH3 
keto), 1.31 (2 H, t, /  = 6 . 8  Hz, CH3 enol), 3.21 (0.3 H, dd, J  = 11.7, 7.8 Hz, 2a-H 
keto), 3.32 (0.3 H, d, J  = 17.6 Hz, 5a-H, keto), 3.39 (0.3 H, d, J  = 20 Hz, 5b-H, keto),
3.54 (0.3 H, dd, J = 9.3, 7.8 Hz, 2b-H, keto), 3.77 (1.4 H, t, /  = 2.91 Hz, 5-H2, enol), 
3.82 (1.4 H, t, J = 2.9 Hz, 2-H2, enol), 4.26 (0.7 H, q, /  = 6 . 8  Hz, OCH2, keto), 4.26 
(1.4 H, q, J  = 6 . 8  Hz, OCH2, enol), 4.37 (0.3 H, m, 3-H, keto), 11.03 (0.7 H, br, OH 
enol); m/z (El) 174.0351 (M, 100) (C7Hi0O3S requires 174.0351); a w  (film, cm-1) 
3500-3100 (O-H), 1748 (C=0, ketone), 1724 (C=0, ester, enol), 1665 (C=0, enol), 
1618 (C=C, enol).
Ethyl (±)-3-oxotetrahydrothiophene-2-carboxylate (111) (0.088 g, 10%) was also 
isolated as a pale yellow oil. Rf 0.28 (hexane : ethyl acetate 10: 1); (compound 
reported by Duus239); 'H NMR (270 MHz, CDC13) 8  1.27 ( 2  H, t, 7  = 7.0 Hz, CH3 
keto), 1.27 (1 H, t, J  = 7.0 Hz, CH3 enol), 2.02-2.54 ( 8  H, m, 4 ,5 -H2 for enol and 
keto), 3.68-3.71 (0.3 H, m, 2-H keto), 4.13 (1.4 H, q, J  = 7.0 Hz, CH2CH3 keto), 4.26 
(0.7 H, q, 7 = 7.0 Hz, ClfcCHs enol), 11.05 (0.7 H, br, OH enol); \ w  (film, cm'1) 




To ethyl (±)-4-oxotetrahydrothiophene-3-carboxylate (110) (1.32 g, 7.6 mmol) in 
methanol (20 ml), barium carbonate (3.43 g, 17.4 mmol) and hydroxylamine 
hydrochloride (1.21 g, 17.4 mmol) were added and the mixture was heated under 
reflux for 16 h. Barium carbonate was removed by filtration and the filtrate was 
concentrated. A solution of the residue in ethyl acetate was washed with water and 
was dried. Evaporation of the solvent furnished ethyl (±)-4-oximinotetrahydro- 
thiophene-3-carboxylate (104) (1.36 g, 95%) as a pale yellow oil. Rf 0.27 (hexane : 
ethyl acetate 2:1); !H NMR for geometrical isomers I and II (270 MHz, CDCI3) 
6  1.28 (0.6 H, t, 7 = 7.1 Hz, CH3 (II)), 1.29 (2.4 H, t, 7 = 7.1 Hz, CH3 (I)), 3.10 
(0.8 H, dd, 7 = 11.5, 7.0 Hz, 2a-H (I)), 3.15 (0.2 H, dd, 7 = 14, 7.1 Hz, 2a-H (II)), 
3.26 (0.2 H, dd, 7 = 13, 7.9 Hz, 2b-H (II)), 3.27 (0.8 H, dd, 7 = 11.5, 6 . 6  Hz, 2b-H 
(I)), 3.55 (0.2 H, d, 7 = 16 Hz, 5a-H (II)), 3.65 (0.8 H, dd, 7 = 16, 1.5 Hz, 5b-H (I)), 
3.67 (0.2 H, dd, 7 = 16, 1.5 Hz, 5b-H (II)), 3.75 (0.8 H, d, 7 = 17 Hz, 5a-H (I)), 3.81 
(0.8 H, t, 7 = ca. 7 Hz, 3-H (I)), 4.06 (0.2 H, ddd, 7=  7.9, 7.1, 1.5 Hz, 3-H (II)), 4.21 
(0.4 H, q, 7 = 7.1 Hz, OCH2CH3 (II)), 4.23 (1.6 H, q, 7 = 7.2 Hz, OCIfcCHs (I)), 8.45 
(0.2 H, br, OH (II)), 8.65 (0.8 H, br, OH (I)); m/z 189 (M, 43), 116 (100); i w  (film, 




Ethyl 4-aminothiophene-3-carboxylate hydrochloride (103).
To ethyl (±)-4-oximinotetrahydrothiophene-3-carboxylate (104) (1.30 g, 6.9 mmol) 
in dry ether (6.4 ml) and methanol (1.3 ml), hydrogen chloride in ether (1.0 M, 
7.9 ml, 7.9 mmol) was added and the mixture stirred for 24 h. Evaporation gave ethyl 
4-aminothiophene-3-carboxylate hydrochloride (103) (1.36 g, 95%) as a hydroscopic 
brown semi-solid. Rf 0.13 (ethyl acetate); *H NMR (270 MHz, (CD3)2SO) 8  1.32 
(3 H, t, 7 = 7.0 Hz, CH3), 4.30 (2 H, q, J  = 7.3 Hz, CH2), 7.73 (1 H, d, J  = 3.7 Hz, 
thiophene 5H), 8.45 (1 H, d, / =  3.3 Hz, thiophene 2-H); m/z (FAB+) 172.0437 
(M - Cl, 100) (C7HioN02S requires 172.0432).
NHCOMe
(1 1 2 a)
Ethyl 4-acetamidothiophene-3-carboxylate (112a). Ethyl 4-aminothiophene-3- 
carboxylate hydrochloride (103) (0.11 g, 5.3 mmol) in chloroform (1.5 ml) was 
stirred with acetyl chloride (0.05 g, 0.64 mmol), triethylamine (0.13 g, 1.3 mmol) and 
4-(dimethylamino)pyridine (20 mg) for 16 h. Chloroform (20 ml) was added and the 
solution was washed with 2 M hydrochloric acid, 10% sodium carbonate solution and 
water, and was dried. Evaporation and chromatography (hexane : ethyl acetate 10:1)
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afforded ethyl 4-acetamidothiophene-3-carboxylate (112a) (0.09 g, 80%) as a white 
crystalline solid. Rf 0.69 (hexane : ethyl acetate 4:1); mp 57-59°C; *H NMR 
(270 MHz, CDC13) 6  1.40 (3 H, t, /  = 7.2 Hz, CH3), 2.21 (3 H, s, COMe), 4.36 (2 H, 
q, /  = 7.2 Hz, CH2), 8.01 (1 H, d, J  =3.7 Hz) and 8.04 (1 H, d, J  = 3.5 Hz) 
(thiophene 2,5-H2), 11.05 (1 H, br, NH); m/z (El) 213 (M, 43), 125 (100); Calcd. for 
C9H11NO3S: C, 50.68; H, 5.21; N, 6.57. Found: C, 50.70; H, 5.19; N, 6.36.
C 02Et
NHCOPh 
(1 1 2 b)
Ethyl 4-benzamidothiophene-3-carboxylate (112b). To benzoyl chloride (0.12 g,
8.7 mmol) in chloroform (2.0 ml), ethyl 4-aminothiophene-3-carboxylate 
hydrochloride (103) (0.15 g, 7.2 mmol) was added, followed by triethylamine 
(0.18 g, 1.8 mmol) and 4-(dimethylamino)pyridine (20 mg). The mixture was stirred 
for 16 h. Chloroform (20 ml) was added and the mixture was washed with 2 M 
aqueous hydrochloric acid, 1 0 % sodium carbonate solution and with water, before 
being dried. Evaporation and column chromatography (hexane : ethyl acetate 20:1) 
gave ethyl 4-benzamidothiophene-3-carboxylate (112b) (0.15 g, 75%) as a white 
crystalline solid. Rf 0.16 (hexane : ethyl acetate 4:1); mp 106-108°C; *H NMR 
(270 MHz, CDCI3) 8  1.43 (3 H, t, /  = 7.0 Hz, CH3), 4.41 (2 H, q, /  = 7.0 Hz, CH2), 
7.52 (3 H, m, Ph 3,4,5-H3), 8.0 (2 H, dd, J  = 7.7, 1.5 Hz, Ph 2,6-H2), 8.11 (1 H, d, 
J  = 3.7 Hz, thiophene 5-H), 8.21 (1 H, d ,J=  3.7 Hz, thiophene 2-H), 11.05 (1 H, br,
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NH); m/z (El) 275 (M, 36), 105 (100); Calcd. for C14H13NO3S: C, 61.07; H, 4.77; 





4-Acetamidothiophene-3-carboxylic acid (113a). Ethyl 4-acetamidothiophene-3- 
carboxylate (112a) (54 mg, 0.25 mmol) in ethanol (0.6 ml), was heated under reflux 
with aqueous sodium hydroxide (1.0 M, 0.57 ml, 0.57 mmol) for 1 h. The solvent 
was evaporated and the residue was dissolved in water (10 ml), acidified with 2 M 
hydrochloric acid and extracted with ethyl acetate. The extract was dried and 
evaporated to furnish 4-acetamidothiophene-3-carboxylic acid (113a) (40.3 mg, 
8 6 %) as a pale yellow solid. Rf 0.13 (methanol : chloroform 1 : 9); mp 203-205°C 
(lit. 278 mp 207-208°C); ‘H NMR (270 MHz, CDC13) 8  2.24 (3 H, s, Me), 8.07 (1 H, 
d, J=  3.6 Hz, thiophene 5-H), 8.19 (1 H, d, J=  3.6 Hz, thiophene 2-H), 9.85 (1 H, br, 
NH); m/z (FAB+) 186.0257 (M + H, 100) (C7H8N 03S requires 186.0225).
2-Methylthieno[3,4-d][l,3]oxazin-4-one (114a). 4-Acetamidothiophene-3- 
carboxylic acid (113a) (34 mg, 0.18 mmol) was heated under reflux in acetic 
anhydride (3.4 ml) for 24 h. The solvent was evaporated to produce
O
(114a)
2-methylthieno [3,4-J] [ 1 ,3] oxazin-4-one (114a) (29 mg, 94%) as a white crystalline 
solid. Rf 0.8 (methanol : chloroform 1 : 9); mp 121-123°C (lit.278 mp 121-122°C); 
*H NMR (270 MHz, CDC13) 8  2.24 (3 H, s, Me), 8.07 (1 H, d, /  = 3.3 Hz, 7-H), 8 . 6 6  
(1 H, d, /  = 3.7 Hz, 5-H); m/z (Cl) 168 (M + H, 29).
4-Acetamidothiophene-3-carboxamide (115a). Ammonia was passed through 
2-methylthieno[3,4-d][l,3]oxazin-4-one (114a) (31 mg, 0.18 mmol) in 1,4-dioxane 
(4.0 ml) for 30 min. The mixture was filtered, washed with 1,4-dioxane and the 
filtrate was concentrated to produce ethyl 4-acetamidothiophene-3-carboxamide 
(115a) (24 mg, 71%) as a white solid, mp 185-187°C; Rf 0.30 (methanol : 
chloroform 1 : 9); 'H NMR (270 MHz, CDCI3) 8  2.20 (3 H, s, Me), 5.7 (2 H, br, 
NH2), 7.64 (1 H, d, 7 = 3.3 Hz, thiophene 5-H), 8.07 (1 H, d, J  = 3.3 Hz, thiophene 
2-H), 10.5 (1 H, br, NH); m/z (FAB*) 185.0375 (M + H, 33) (C7H9N2O2S requires 
185.0385), 149 (100).
The precipitate was collected and dried to produce 4-acetamidothiophene-3- 
carboxylic acid (113a) (7 mg, 21%) as a pale brown solid. Rf 0.05 (methanol ; 
chloroform 1 : 9); mp 189-191°C (lit.278 mp 207-208°C); *H NMR (270 MHz, 
(CD3)2SO) 8  2.03 (3 H, s, Me), 7.61 (1 H, d, J  = 3.3 Hz, thiophene 5-H), 7.71 (1 H, 










2-Methylthieno[3,4-J]pyrimidin-4(3H)-one (103a). Aqueous sodium hydroxide 
solution (10%, 0.10 ml, 0.26 mmol) was added to 4-acetamidothiophene-3- 
carboxamide (115a) (0.009 g, 0.0049 mmol) in water (0.1 ml) and the mixture stirred 
at 100°C for 30 min. The mixture was acidified with acetic acid and extracted with 
ethyl acetate. The extract was washed with water and was dried. Evaporation and 
chromatography (methanol : chloroform 1 : 49) afforded 2 -methylthieno [3,4-<i] - 
pyrimidin-4(5H)-one (103a) (0.0041 g, 57%) as a white solid. Rf 0.27 (5% methanol 
: chloroform); mp 232-233°C; *H NMR (270MHz, CDC13) 8  2.45 (3 H, s, Me), 7.48 
(1 H, d, /  = 3.3 Hz, 7-H), 8.28 (1 H, d, J  = 3.3 Hz, 5-H), 9.5 (1 H, br, N-H); m/z 




4-Benzamidothiophene-3-carboxylic acid (113b). Ethyl 4-benzamidothiophene-3- 
carboxylate (112b) (63 mg, 0.23 mmol) in ethanol (0.5 ml) was heated with sodium 
hydroxide (1.0 M, 0.51 ml, 0.51 mol) under reflux for 1 h. The solvent was 
evaporated and the residue was dissolved in water ( 1 0  ml), acidified with 2 M 
hydrochloric acid and extracted with ethyl acetate. The extract was dried and the
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solvent was evaporated to furnish 4-benzamidothiophene-3-carboxylic acid (113b) 
(52 mg, 92%) as a cream solid. Rf 0.078 (hexane : ethyl acetate 2:1); mp 199-202°C 
(lit.278 mp 215-216°C); *H NMR (270 MHz, CDCI3) 8  7.56 (3 H, m, Ph 3,4,5-H3), 
7.97 (2 H, d, /  = 7.2 Hz, Ph 2,6-H2), 8.26 (1 H, d, /  = 3.6 Hz) and 8.27 (1  H, d, 






2-Phenylthieno[3,4-d][l,3]oxazin-4-one (114b). 4-Benzamidothiophene-3- 
carboxylic acid (113b) (48 mg, 0.2 mmol) was heated under reflux in acetic 
anhydride (5.0 ml) for 16 h. The solvent was evaporated to yield 2-phenylthieno- 
[3,4-d] [ 1,3])oxazin-4-one (114b) (42 mg, 95%) as an off-white solid Rf 0.9 
(methanol : chloroform 1 : 9); mp 172-174°C (lit.278 mp 172-173°C); *H NMR 
(270 MHz, CDCI3) 8  7.52 (3 H, m, Ph 3,4,5-H3), 7.59 (1 H, d, J  = 3.3 Hz, 7-H), 8.27 
(2 H, dd, J  = 8.4, 1.5 Hz, Ph 2,6-H2), 8.43 (1 H, d, /  = 3.3 Hz, 5-H); m/z (El) 
229.0200 (M, 100) (Ci2H7N02S requires 229.0198).
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(115b)
4-Benzamidothiophene-3-carboxamide (115b). Ammonia was passed through 
2-phenylthieno[3,4-d][l,3]oxazin-4-one (114b) (41 mg, 0.18 mmol) in 1,4-dioxane 
(5.0 ml) for 10 min and the mixture was stirred for 16 h. Ammonia was passed 
through the mixture for a further 20 min. The solvent and excess reagent were 
evaporated to furnish 4-benzamidothiophene-3-carboxamide (115b) (42 mg, 97%) as 
a pale yellow solid. RfO.ll (methanol: chloroform 1 : 19); mp 180-182°C; *H NMR 
(270 MHz, CDC13) 8  5.8 (2 H, br, NH2), 7.52 (3 H, m, Ph 3,4,5-H3), 7.73 (1 H, d, 
J  = 3.3 Hz, thiophene 5-H), 8.0 (2 H, dd, /  = 7.7, 1.5 Hz, Ph 2,6-H2), 8.25 (1 H, d, 
J  = 3.3 Hz, thiophene 2-H), 11.64 (1 H, br, N-H); m/z (El) 246.0462 (M, 67) 
(Ci2HioN20 3 S requires 246.04630).
1
(103b)
2-Phenylthieno[3,4-d]pyrimidin-4(3H)-one (103b). To 4-benzamidothiophene-3- 
carboxamide (115b) (0.020 g, 0.081 mmol) in water (0.2 ml), aqueous sodium 
hydroxide solution (10%, 0.20 ml, 0.49 mmol) was added. The mixture was heated to 
90-100°C for 30 min, acidified with acetic acid and extracted with ethyl acetate. The 
extract was washed with water and dried. Evaporation and chromatography
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(methanol : chloroform 1 : 19) furnished 2-phenylthieno [3,4-J]pyrimidin-4(5H)-one 
(103b) (0.008 g, 43%) as a white solid. Rf 0.76 (10% methanol : chloroform); 
mp 242-243°C; 'H NMR (270MHz, CDCI3) 8  7.56 (3 H, m, Ph 3,4,5-Hj), 7.69 (1 H, 
d, J  = 3.3 Hz, 7-H), 8.05 (2 H, dd, J  = 7.7, 1.8 Hz, Ph 2,6-H2), 8.34 (1 H, d, 




7,8-Dihydroimidazo[l,5-c]pyrimidin-5(6H)-one (116a). Imidazole-4-eth an amine 
(118) (2.60 g, 23.4 mmol) in dichloromethane ( 8  ml) was added to a solution of 
bis(4-nitrophenyl) carbonate (7.84 g, 26 mmol) in chloroform (130 ml) at 40°C. The 
mixture was heated under reflux for 48 h. The solvent was evaporated to produce a 
yellow residue which was washed with ether (3 x 100 ml) to remove 4-nitrophenol. 
The remaining solid residue was suspended in warm dimethylformamide (3 ml) to 
remove any unreacted carbonate. The suspension was filtered and the solid was 
washed with cold propan-2-ol and was dried to yield 7,8-dihydroimidazo-[l,5-c]- 
pyrimidin-5(6H)-one (116a) (2.5 g, 78%) as a very pale yellow solid. Rf 0.61 (hexane 
: ethyl acetate 1:1); mp 217-219°C Git-243 mp 220-222°C); ‘H NMR (270 MHz, 
(CD3)2SO) 8  2.88 (2 H, t, 7 = 6 . 6  Hz, 2-H2), 3.34 (2 H, td, J  = 6 .6 , 2.6 Hz, 3-H2),
6.79 (1 H, s, 1-H), 8.06 (1 H, s, 6 -H), 8.23 (1 H, br, NH); m/z (El) 137 (M, 56); t w  




l-Nitro-7,8-dihydroimidazo[l,5-c]pyrimidin-5(6H)-one (116b). Method A: 
Potassium nitrate (0.22 g, 2.2 mmol) was added slowly to a stirred solution of
7,8-dihydroimidazo-[ 1,5-c]-pyrimidin-5(6H)-one (116a) (0.3 g, 2.2 mmol) in 
concentrated sulphuric acid (4.0 ml). The mixture was stirred for 16 h at ambient 
temperature, poured onto crushed ice and extracted with ethyl acetate. The extract 
was washed with water and with 10% sodium carbonate solution and was dried. 
Evaporation produced l-nitro-7,8-dihydroimidazo[l,5-c]pyrimidin-5(6H)-one (116b) 
(0.040 g, 10%) as a yellow solid. Rf 0.45 (ethyl acetate); mp 195-197°C; *H NMR 
(270 MHz, (CD3)2SO) 5 3.32 (2 H, t, J  = 6.6 Hz, 2-H2), 3.49 (2 H, td, J  = 6.6, 2.4 Hz,
3-H2), 8.28 (1 H, s, 6-H), 8.68 (1 H, br, NH); m/z (FAB+) 183 (M + H, 100).
l-Nitro-7,8-dihydroimidazo[l,5-c]pyrimidin-5(6H)-one (116b). Method B: 
Concentrated nitric acid (0.11 ml) was added to 7,8-dihydroimidazo- 
[l,5-c]pyrimidin-5(6H)-one (116a) (0.10 g, 0.73 mmol) in concentrated sulphuric 
acid (0.32 ml) at a rate to maintain the temperature at 40-45°C. The mixture was 
stirred at 40°C for 2 h, poured onto ice and extracted with ethyl acetate. The extract 
was washed with brine and dried. Evaporation furnished 1 -nitro-7,8-dihydroimidazo- 
[l,5-c]pyrimidin-5(6H)-one (116b) (0.050 g. 38%) as a yellow solid. Rf 0.25 (ethyl 
acetate); mp 194-196°C; 'H NMR (270 MHz, (CD3)2SO) 8 3.32 (2 H, t, 7 = 7 Hz,
194
2-H2), 3.48 (2 H, m, 3-H2), 8.28 (1 H, s, 6 -H), 8.67 (1 H, br, NH); m/z (FAB+) 
183.0529 (M + H, 100) (C6H7N4O3 requires 183.0518).
(121)
4-(2-Acetamidoethyl)imidazole (121). Acetic anhydride (6.20 g, 60.7 mmol) was 
added to a warmed solution of imidazole-4-ethanamine (118) (2.52 g, 20.2 mmol) in 
pyridine (70 ml) and the mixture was heated under reflux for 24 h. Pyridine was 
evaporated and the residue was boiled under reflux in methanol (150 ml) for 3 h. The 
solvent was evaporated to produce 4-(2-acetamidoethyl)imidazole (121) (2.97 g, 
96%) as a yellow oil which formed small white cubes. Rf 0.25 (15% methanol : 
chloroform); mp 142-144°C (lit.279 mp 143°C); 'H NMR (270 MHz, (CD3)2SO) 
5 1.79 (3 H, s, COCH3), 2.61 (2 H, t, J  = 7.3 Hz, CHz-OD-NHCOMe), 3.24 (2 H, q, 
J  = 7.7 Hz, CHj-NHCOMe), 6.79 (1H, s, imidazole 5-H), 7.54 (1 H, s, imidazole
2-H), 7.93 (1 H, br, NH); m/z (CD 154 (M + H, 100); t),,** (KBr, cm'1) 3468, 3365 
(NH), 1623 (amide D, 1586 (amide H).
/f^ N H  NH2
o 2n
(122)
5-Nitroimidazole-4-ethanamine (122). To a cooled solution of 4-(2-acetamido- 
ethyl)imidazole (121) (4.2 g, 27 mmol) in concentrated sulphuric acid (12.2 ml),
195
fuming nitric acid (6 . 6  ml, 94 mmol) was added at a rate to maintain the temperature 
at 40-45°C. The solution was stirred at 40°C for 2 h., poured onto ice (85 g), and 
adjusted to pH 2 with 10% sodium carbonate solution. The white solid was collected 
and dried to furnish 5-nitroimidazole-4-ethanamine (122) (3.85 g, 90%). Rf 0.33 
(ethyl acetate); mp 163-165°C; ‘H NMR (270 MHz, (CD3)2SO) 8  3.41 (4 H, brt, 
J  = 5.9 Hz, imidazole-CHj and 2 x NH), 4.82 (2 H, t, J  = 5.9 Hz, CH2NH2), 7.8 (1 H, 
s, 2-H), 13.28 (1 H, br, NH); m/z (El) 126 (M - NO, 6 8 ), 110 (10), 94 (100)..
Imidazole-4-propanoic acid (126). Imidazole-4-propenoic acid (125) (6.10 g,
44.2 mmol) was dissolved in hot acetic acid (130 ml) at 120°C. A slurry of 10% 
palladium on charcoal (305 mg) in acetic acid (3 ml) was added and the mixture was 
stirred under hydrogen for 6  d. The suspension was filtered through a pad of Celite® 
and washed with hot acetic acid. Evaporation of the solvent gave imidazole-4- 
propanoic acid (126) (3.4 g, 55%) as a white solid. Rf 0.58 (ethyl acetate); mp 
203-205°C (lit.247 mp 203-204°C); 'H NMR (270 MHz, CD3C02D) 2.81 (2 H, t;
, / ^ N H
(126)
7 = 7 Hz, CHzCOjH), 3.06 (2 H, t, J  = 7 Hz, CH2-CH2-C0 2H), 7.31 (1 H, s, 2-H),
8.79 (1 H, s, 5-H); m/z (CD 140 (M + H, 100); v w  (KBr, cm'1) 3000-2400 (O-H),
1710(0 0 ).
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(127)
5-Nitroimidazole-4-propanoic acid (127). To a solution of imidazole-4-propanoic 
acid (126) (1.69 g, 12.1 mmol) in concentrated sulphuric acid (6.5 ml), concentrated 
nitric acid (1.87 ml) was added at a rate to maintain the temperature at 40-45°C. The 
reaction was stirred at 40°C for 2 h. The mixture was poured onto ice and extracted 
with ethyl acetate. The extracts were dried and the solvent was evaporated to produce
5-nitroimidazole-5-propanoic acid (127) (0.60 g, 27%) as a pale yellow solid. 
Rf 0.034 (methanol : chloroform 1 : 9); mp 216-218°C (compound reported by 
Dennis et al.2S0 but no mp given); *H NMR (270 MHz, ( d ^ S O )  8  2.64 (2 H, t, 
J = 13  Hz, CH2-CO2H), 3.17 (2 H, t, J  = 7.3 Hz, CH2-CH2-CO2H), 7.74 (1 H, s,
2-H), 10.0 (1 H, br, C02H); m/z (Cl) 186 (M + H, 80); a w  (KBr, cm'1) 3100-2400 
(O-H), 1740 (C=C>) 1550,1390 (C-N02).
2 n
(116b)
l-Nitro-7,8-dihydroimidazo[l,5-c]pyrimidin-5(6H)-one (116b). 5-Nitroimidazole- 
4-propanoic acid (0.15 g, 0.81 mmol) was stirred with thionyl chloride (2.0 ml) and 
dimethylformamide (500 |il) for 16 h. The excess reagent was evaporated. 
Dichloromethane (10 ml) was added and evaporated. This process was repeated to 
produce 5-nitroimidazole-4-propanoyl chloride as a bright yellow solid. A solution of
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this material in acetone (1.5 ml) was stirred with sodium azide (0.18 g, 2.8 mmol) in 
water (1.5 ml) at 0°C under nitrogen for 1.5 h. The solvent was evaporated and the 
residue was extracted with dichloromethane. The organic extracts were washed with 
water and dried, and the solvent was evaporated. The residue was stirred in toluene 
(2 ml) and stirred for 24 h at 100°C. The solvent was evaporated to produce 1-nitro-
7,8-dihydroimidazo[l,5-c]-pyrimidin-5(6H)-one (116b) (22 mg, 15%) as a pale buff 
solid. Rf 0.26 (10% methanol : chloroform); mp 191-194°C; *H NMR (270 MHz, 
(CD3)2SO) 5 3.47 (2 H, t, / =  6 . 6  Hz, 2-H2), 3.74 (2 H, m, 3-H2), 8.10 (1 H, s, 6 -H); 
m/z (FAB+) 183.0434 (M + H, 71) (QH7N4O3 requires 183.0518); t)max (KBr, cm'1) 
3140 (NH), 1740 (C=0), 1520,1360 (C-N02).
O
(131)
Piperazinone (131). Method A: Ethyl chloroacetate (6.80 g, 55.5 mmol) in ethanol 
(30 ml), was added slowly to ethane-1,2-diamine (20.0 g, 0.33 mol) in ethanol 
(100 ml) during 3 h and the mixture was stirred for further 2 h. Sodium ethoxide 
(3.78 g, 55 mmol) was added and the precipitate was removed by filtration. The 
excess ethanol and ethane-1,2-diamine were removed by distillation at 20 torr. The 
residual mass was heated to 200°C at 0.5 torr and the distillate was collected to give 
piperazinone (131) (0.17 g, 3%) as a pale yellow oil. bpo.5 65°C (lit.250 bp76o 165°C); 
Rf 0.05 (methanol: chloroform 1 : 9); *H NMR (270 MHz, CDCI3) 5 1.91 (1 H, br,
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4-H2), 3.00 (2 H, t, J  = 5.7 Hz, 5-H2), 3.34 (2 H, m, 6 -H2), 3.49 (2 H, s, 3-H2), 6.89 






To a solution of 2-chloroethylamine hydrochloride (10.2 g, 8 8  mmol) in water 
(50 ml), ethyl acetate (100 ml) was added, followed by potassium carbonate 
(ca. 10 g). The mixture was shaken for 10 min and was filtered. N-( 1,1-Dimethyl- 
ethoxycarbonyl)glycine pentaflurophenyl ester (132)281 (5.00 g, 14.7 mmol) in ethyl 
acetate (50 ml) was added and the solution was stirred for 16 h. The organic layer 
was washed with dilute sulphuric acid, 1 0 % sodium carbonate solution (thrice), water 
and brine before being dried. The solvent was evaporated to furnish 
N-(2-chloroethyl)-N'-(l,l-dimethylethoxycarbonyl)glycinamide (133) (2.84 g, 82%) 
as a colourless oil. Rf 0.23 (hexane : ethyl acetate 1:1); *H NMR (270 MHz, 
(CD3)2SO) 5 1.37 (9 H, s, C(CH3)3), 3.38 (2 H, q, /  = 6.2 Hz, NH-CHzCHzCl), 3.52 
(2 H, d, J  = 5.9 Hz, Gly-H2), 3.56 (2 H, t, J  = 6.2 Hz, CH rCfib-C l), 6.99 (1 H, t, 
J=ca. 5.6 Hz, NH), 8.10 (1 H, t,J=ca. 5.6 Hz, CONH).
199









Attempted Preparation of 4-(Phenylmethoxycarbonyl)piperazin-2-one (135).
N-(2-Chloroethyl)-N'-( 1,1 -dimethylethoxycarbonyl)glycinamide (133) (4.2 g,
17.7 mmol) in dichloromethane (150 ml) was treated with excess hydrogen chloride 
for 3 h. The solvent and excess reagent were evaporated to produce a pale yellow 
residue (3.06 g). The residue (134) was dissolved in dichloromethane (300 ml) and 
was stirred with N,N-diisopropylethylamine (6.86 g, 53 mmol) for 16 h. 
N,N-Diisopropylethylamine (2.29 g, 17.7 mmol) and phenylmethyl chloroformate 
(3.02 g, 17.7 mmol) were added and the mixture was stirred for 6 h. The solution was 
washed thrice with 2 M sulphuric acid, saturated sodium hydrogen carbonate solution 
(twice) and once with water, and was dried. Evaporation and chromatography (ethyl 
acetate) yielded N'-(phenylmethoxycarbonyl)-N-(2-chloroethyl)glycinamide (136) 
(2.25 g, 47%) as a white solid. Rf 0.17 (methanol: chloroform 1 : 19); mp 111-113°C 
Git282 mp 115-116°C); 'H NMR (270 MHz, (CD3)2SO) 8 3.39 (2 H, q, 7 = 5.9 Hz, 
NH -CH 2CH2CI ), 3.60 (4 H, t, /  = 6 Hz, Gly-H2 and C H r O L -C l) , 5.03 (2 H, s, 
CJLPh), 7.35 (5 H, s, Ph-H5), 7.50 (1 H, t, J  = 6.2 Hz, NH), 8.16 (1 H, t, J  = ca. 
6 Hz, NH); m/z (Cl) 271, 273 (M + H, 18), 91 (100); i w  (KBr, cm'1) 3340, 3300 
(NH2), 1695 (C=0, carbamate), 1660 (amide I), 1550 (carbamate and amide II).
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N-Trifluoroacetylglycinamide (137). Potassium r-butoxide (5.33 g, 47.5 mmol) was 
stirred with glycinamide hydrochloride (5.00 g, 45.2 mmol) in methanol (500 ml) and 
ethyl trifluoroacetate (33.5 g, 0.34 mol) for 48 h. Filtration and evaporation of the 
solvent furnished N-trifluoroacetylglycinamide (137) (8.25 g, 91%) as white crystals. 
Rr 0.43 (ethyl acetate); mp 102-104°C (lit.283 mp 114-115°C); ‘H NMR (270 MHz,
(KBr, cm'1) 3400, 3205 (N-H), 1740 (amide I, CF3C=0), 1685 (amide I, CONH2), 
1635 (amide H, CF3C=0), 1580 (amide D, CONH2).
O
N-(2,2,-Dimethoxyethyl)trifluoroacetamide (138). Potassium carbonate (1.00 g,
7.2 mmol) was stirred with 2,2-dimethoxyethylamine (3.67 g, 35 mmol) in ethanol 
(50 ml) and ethyl trifluoroacetate (10.8 g, 76 mmol) for 16 h. Filtration and 
evaporation of the solvent yielded a colourless viscous oil. The oil was dissolved in 
ethyl acetate and was washed with water and was dried. The solvent was evaporated 
to furnish N-(2,2-dimethoxyethyl)trifluoroacetamide (138) (5.8 g, 83%) as a yellow 
oil. Rf 0.53 (methanol : chloroform 1 : 19); *H NMR (270 MHz, (CD3)2SO) 6  3.28 
(8 H, m, (2 x OMe), and HN-CH2-CH-(OMe)2), 4.47 (1 H, t, /  = 5.9 Hz,
(CD3)2SO) 5 3.75 (2 H, d, J  = 5.9 Hz, Gly-H2), 7.16 (1 H, br, NH), 7.56 (1 H, br,




CH2-CH-(OMe)2), 9.56 (1 H, br, NH); m/z (FAB+) 224.0817 (M+ Na, 13) 
(C6H10F3NO3S requires 224.0589), 170 (100); Umax (film, cm'1) 2860 (Me-O), 1720 




Ethyl (2,2-dimethoxyethylamino)acetate (141). To a stirred mixture of sodium 
carbonate (2.83 g, 27 mmol) and 2,2-dimethoxyethylamine (140) (1.86 g, 25 mmol) 
in ethanol (40 ml) at 0°C, ethyl iodoacetate (2.2 g, 10 mmol) was added dropwise 
during 30 min. The mixture was stirred vigorously for 2 h at 0°C and then for 16 h at 
ambient temperature. Filtration, concentration and distillation furnished ethyl 
(2,2-dimethoxyethylamino)acetate (141) (1.21 g, 63%) as a pale yellow oil. Rf 0.54 
(methanol: chloroform 1 : 9); bp0.i 60°C (lit.251 bpo.r 58-60°C); 'H NMR (270 MHz, 
CDCI3) 8  1.19 (3 H, t, J  = 7.1 Hz, CH2CH3), 2.55 (2 H, d, 7 = 5.5 Hz; (CH-CH2-N),
3.54 (2 H, s, CH2CO), 3.26 ( 6  H, s, 2  x OCH3), 4.07 (2 H, q, J  = 7.1 Hz, OCH2CH3), 
4.21 (1 H, t, J  = 5.5 Hz, CH-CH2); m/z (El) 160 (M - OMe,); t w  (film, cm'1) 3451, 
3425 (NH2), 1737 (C=0), 1536 (N-H).
N-(Cyanomethyl)-2,2-dimethoxyethylamine (143) and N,N-bis(cyanomethyl)- 
2,2-dimethoxyethyl)amine (144). Bromoacetonitrile (1.24 g, 10 mmol) was added 





carbonate (3.18 g, 30 mmol) in ethanol (40 ml). The mixture was stirred for 16 h. 
Filtration, concentration and chromatography (hexane : ethyl acetate 1:1) produced 
N-(cyanomethyl)-2,2-dimethoxyethylamine (143) (1.42 g, 99%) as a yellow oil. 
Rf 0.52 (ethyl acetate); ‘HNMR (270 MHz, CDClj) 8 2.87 (2 H, d, 7 = 5.1 Hz, 
CH-CHj-NH), 3.39 (6 H, s, 2 x OCH3), 3.64 (2 H, s, CH2CN), 4.48 (1 H, t, 
J  = 5.1 Hz, CH-CH2); m/z (FAB*) 145.0987 (M + H, 69) (QHi3N20 2 requires 
145.0977); (film, cm'1) 3577,3362 (NH), 2260 (C=N).
N,N-Bis(cyanomethyl)-2,2-dimethoxyethyl)amine (144) (27 mg, 1%) was also 
isolated as a yellow oil. Rf 0.79 (ethyl acetate); *H NMR (270 MHz, CDCI3) 6 2.82 
(2 H, d, 7 = 4.9 Hz, CH-CH2-NH), 3.41 (6 H, s, 2 x OCH3), 3.74 (4 H, s, 2 x 
CH2CN), 4.50 (1 H, t, J  = 4.9 Hz, CH-CH2); m/z (FAB+) 184.1102 (M + H, 19) 





N-(2,2-Dimethoxyethyl)glycinamide (145). To sodium carbonate (1.6 g, 15 mmol) 
and 2,2-dimethoxyethylamine (140) (1.05 g, 10 mmol) in ethanol (20 ml) at 0°C, 
iodoacetamide (1.90 g, 10 mmol) was added during 30 min. The mixture was stirred 
vigorously for 2 h at 0°C and at ambient temperature for 16 h. Filtration, 
concentration and chromatography (methanol ; chloroform 1 : 9) yielded N-(2,2- 
dimethoxyethyl)glycinamide (145) (0.84 g, 52%) as a yellow oil. Rf 0.02 (methanol: 
chloroform 3 : 17); ‘H NMR (270 MHz, (CD3)2SO) 8 2.76 (2 H, d, J  = 5.1 Hz; 
CH-CH2), 3.30 (2 H, s, QLCONH;.), 3.39 (6 H, s, 2 x OCH3), 4.43 (1 H, t,
203
/  = 5.1 Hz, CH-CH2-N), 6.21 (1 H, br, NH), 7.15 (1 H, br, NH); m/z (FAB+) 
163.1070 (M + H, 49) (C6H15N2O3 requires 163.1083); Umax (film, cm*1) 3496, 3238 
(NH2), 1728 (amide I), 1585 (amide II).
(146)
Phenylmethyl N-(cyanomethyl)-N-(2,2-dimethoxyethyl) carbamate (146).
N-(Cyanomethyl)-2,2-dimethoxyethylamine (143) (1.5 g, 11 mmol) was stirred with 
phenylmethyl chloroformate (1.88 g, 11 mmol), triethylamine (2.23 g, 22 mmol) and 
4-pyrrolidinopyridine (10 mg) in dichloromethane (17 ml) for 16 h. The mixture was 
washed with water, 5% aqueous citric acid (thrice) and was dried. Evaporation and 
chromatography (hexane : ethyl acetate 2 :1) furnished phenylmethyl
N-(cyanomethyl)-N-(2,2-dimethoxyethyl)carbamate (146) (1.54 g, 50%) as a yellow 
oil. Rf 0.68 (hexane : ethyl acetate 2:1); !H NMR (270 MHz, (CD3)2SO) 6 3.36 (3 H, 
s) and 3.44 (3 H, s) (2 x OCH3), 3.45-3.50 (2 H, m, CH-CIfc), 4.24 (1 H, s) and 4.32 
(1 H, s) (CHz-CN), 4.36 (0.5 H, t, /  = ca. 5 Hz) and 4.44 (0.5 H, t, J  = ca. 5 Hz) 
(CH:CH2), 5.20 (2 H, s, -CHrPh), 7.35-7.45 (5 H, m, Ph-H5); m/z (FAB+) 279.1353 
(M + H, 13) (Ci4Hi9N20 4 requires 279.1345), 91 (100); (film, cm*1) 3601, 3530 
(NH2), 2249 (C=N), 1716 (C=0).
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To phenylmethyl N-(cyanomethyl)-N-(2,2-dimethoxyethyl)carbamate (146) (1.2 g,
4.3 mmol) in ethanol (12 ml), aqueous sodium hydroxide solution (15%, 0.29 ml,
1.1 mmol) and hydrogen peroxide solution (27.5%, 0.51 g, 15 mmol) were added. 
The mixture was stirred at room temperature for 2 h and was neutralised with 10% 
sulphuric acid. The solvent was evaporated to produce a colourless oil, which was 
partitioned between ethyl acetate and water. The organic layer was washed with 2 M 
sodium hydroxide and was dried. The solvent was evaporated to produce N-(2,2- 
dimethoxyethyl)-N-(phenylmethoxycarbonyl)-glycinamide (147) (1.06 g, 83%) as a 
pale yellow oil. Rf 0.4 (methanol: chloroform 1 : 9); *H NMR (270 MHz, (CDs^SO)
(1.2 H, s) and 3.99 (0.8 H, s) (CH2-CONH2), 4.45 (0.4 H, t, J  = ca. 5 Hz) and 4.59
6.45 (0.4 H, br) (NH), 7.34-7.36 (5 H, m, Ph-H5); m/z (FAB+) 297.1436 (M + H) 
(C14H21N2O5 requires 297.1450).
N-(2,2-Dimethoxyethyl)-N-(phenylmethoxycarbonyl)glycinamide (147). N-(2,2- 
Dimethoxyethyl)glycinamide (145) (0.1 g, 0.61 mmol) was stirred with phenylmethyl
6  3.31 (2.4 H, s) and 3.40 (3.6 H, s) ( 2  x OCH3), 3.47-3.52 ( 2  H, m, CH-CH2), 3.95




chloroformate (0.13 g, 0.74 mmol), triethylamine (0.16 g, 1.5 mmol) and 
4-pyrrolidinopyridine (10 mg) in dichloromethane (1 ml) for 16 h. The mixture was 
washed once with water, thrice with 5% citric acid solution and dried. Evaporation 
and chromatography (methanol : chloroform 1 : 19) furnished N-(2,2-dimethoxy- 
ethyI)-N-(phenylmethoxycarbonyl)glycinamide (147) (0.13 g, 71%) as a pale yellow 
oil. Rf 0.34 (methanol ; chloroform 1 : 9); *H NMR (400 MHz, (CD3)2SO, 20°C) 
8  3.23 (3 H, s) and 3.28 (3 H, s) (2 x OCH3), 3.31-3.36 (2 H, m, CH-Cfih), 3.84 (1 H, 
s) and 3.86 (1 H, s) (CH2-CONH2), 4.42 (0.5 H, t, J  = 5.2 Hz) and 4.47 (0.5 H, t, 
J  = 5.2 Hz) (CH-CHj-N), 5.06 (1 H, s) and 5.10 (1 H, s) (Clfc-Ph), 7.05 (1 H, br, 
NH), 7.34-7.38 ( 6  H, m, Ph-H5 and NH); 'H NMR (400 MHz, (CD3)2SO, 80°C) 
83.29 ( 6  H, s, 2 x OCH3), 3.36 (2 H, d, J  = 5.2 Hz CH-CIfc), 3.88 (2 H, s, 
CH2-CONH2), 4.47 (1 H, t, 7 = 4.9 Hz, CH-CH2-N), 5.28 (2 H, s, Clfc-Ph), 6.90 
(2 H, br, 2 x NH), 7.28-7.37 (5 H, m, Ph-H5); m/z (FAB*) 297.1452 (M + H) 





4-(Phenylmethoxycarbonyl)piperazin-2-one (150). Method A: 
N-(2,2-Dimethoxyethyl)-N-(phenylmethoxycarbonyl)glycinamide (147) (3.41 g, 
12 mmol) in tetrahydrofuran (55 ml) and water (55 ml) was heated under reflux with 
Dowex 50X4 (4.1 g, H+ form) for 16 h. The resin was filtered off and was washed
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with tetrahydrofuran. The solvent was evaporated to produce a brown oil. Sodium 
cyanoborohydride (1.48 g, 24 mmol) was added to the residue in trifluoroacetic acid 
(30 ml) and the mixture was stirred for 16 h. The solvent was evaporated. The 
residue was dissolved in sodium hydrogen carbonate solution and was extracted with 
ethyl acetate. The extract was washed with water and dried. Evaporation and 
chromatography (dichloromethane : methanol 20:1) furnished 4-(phenylmethoxy- 
carbonyl)piperazinone (150) (0.51 g, 18%) as a white solid. Rf 0.12 (dichloromethane 
: methanol 20:1); mp 114-116°C; !H NMR (270 MHz, (CD3)2SO) 5 3.40 (2 H, br,
6 -H2), 3.70 (2 H, t, J  = 5 Hz, 5-H2), 4.16 (2 H, s, 2-H2), 5.16 (2 H, s, CHrPh), 6 . 6 8  
(1 H, br, NH), 7.36 (5 H, m, Ph-H5); m/z (El) 234 (M, 15), 91 (100); Calcd. for 
Ci2Hi4N20 3: C, 61.52; H, 6.04; N, 11.96; Found: C, 61.3; H, 5.94; N, 11.6; \ w  
(KBr, cm*1) 3200, 3160 (NH), 1715 (C=0, carbamate), 1675 (C=0, lactam).
4-(Phenylmethoxycarbonyl)piperazin-2-one (150). Method B: N-(2,2-
Dimethoxyethyl)-N-(phenylmethoxycarbonyl)glycinamide (147) (2.76 g, 9.3 mmol) 
in tetrahydrofuran (43 ml) and water (43 ml) was heated under reflux with Dowex 
50X4 (3.21 g, H+ form) for 16 h. The resin was filtered off, washed with 
tetrahydrofuran and the solvent was evaporated to produce a brown oil. A solution of 
the residue in trifluoroacetic acid (25 ml) was stirred with triethylsilane (3.0 ml, 
19 mmol) for 48 h. The solvent was evaporated and ethyl acetate was added. The 
solution and excess reagent were evaporated. A solution of the residue was washed 
with water, sodium hydrogen carbonate solution, water and was dried. Evaporation 
and chromatography (dichloromethane : methanol 40:1) yielded 4-(phenylmethoxy- 
carbonyl)piperazinone (150) (0.68 g, 31%) as a white solid. Rf0.19 (dichloromethane
207
: methanol 20:1); mp 111-113°C; ‘H NMR (270 MHz, (CD3)2SO) 8  3.40 (2 H, br,
6 -H2), 3.70 (2 H, t, J  = 6  Hz, 5-H2), 4.17 (2 H, s, 2-H2), 5.16 (2 H, s, Cfib-Ph), 6 . 6 8  
(1 H, br, NH), 7.36 (5 H, m, Ph-Hs); m/z (Cl) 235 (M + H, 50), 91 (100).
(131)
Piperazinone (131). Method B: A slurry of 10% palladium on charcoal (100 mg) in 
tetrahydrofuran (1.0 ml) was added to 4-(phenylmethoxycarbonyl)piperazin-2-one
(150) (0.18 g, 7.7 mmol) in methanol (2.0 ml). The mixture was stirred in an 
atmosphere of hydrogen for 16 h. The suspension filtered through a pad of Celite® 
and washed with methanol. Concentration produced piperazinone (131) (43 mg, 
56%) as a white semi-solid. Rf 0.09 (15% methanol : chloroform); (lit.250 
bpveo 165°C); lH NMR (270 MHz, CF3CO2D) 6  3.87 (2 H, m, 5-H2), 3.95 (2 H, t, 
/  = 4 Hz, 6 -H2), 4.40 (2 H, s, 3-H2); m/z (El) 100 (M, 35), 42 (100); t w  (film, cm'1) 




4-(Aminoiminomethyl)piperazinone (151). Aqueous cyanamide solution (50%, 
0.08 ml, 0.04 g, 0.95 mmol) was added to a stirred solution of piperazinone (131)
208
(0.087 g, 0.87 mmol) in acetic acid (20%, 1.0 ml), and the mixture was stirred for 
48 h. The solvents were evaporated to produce 4-(aminoiminomethyl)piperazinone
(151) (0.069 g, 56%) as a yellow semi-solid. Rf 0.04 (15% methanol : chloroform); 
m/z (FAB+) 143.0870 (M + H, 90) (C5H11N4O requires 143.0933); a w  (film, cm'1) 
3468,3365 (N-H), 1623 (amide I), 1586 (amide II).
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APPENDIX
PARP activity in the presence of these test compounds was examined using an assay 
system in vitro. PARP was extracted with 0.4 M aqueous sodium chloride from
Ar*7
nuclei isolated from EAhy 926 ceils (human hybrid cells from huvecs and human 
lung carcinoma A929). Enzyme activity was estimated by the rate of incorporation of 
radioactivity from adenine-[3H]NAD+ into acid-insoluble material. Here follows the 
graphs of PARP activity over a 4 min time course in the presence of the test 
compounds.
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Figure 24 PARP activity in the presence of thiophene-2-carboxamide (36) 
[11.8 pM].
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Figure 26 PARP activity in the presence of 5-aminothiophene-2-carboxamide
hydrobromide (29b) [10.3 fiM],
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Figure 27 PARP activity in the presence of 4-nitrothiophene-2-carboxamide 
(30a) [8.9 jiM].
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Figure 28 PARP activity in the presence of 4-aminothiophene-2-carboxamide
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Figure 29 PARP activity in the presence of 5-nitrothiophene-3-carboxamide
(31a) [9.3 |iM].
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Figure 30 PARP activity in the presence of 5-aminothiophene-3-carboxamide
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Figure 31 PARP activity in the presence of 6-methylthieno-[3,4-c]pyridin- 
4(5H)-one (83a) [9.7 jiM].
Control
Figure 32 PARP activity in the presence of 6-methyl-l-nitrothieno[3,4-c]-
pyridin-4(5H)-one (96a) [10.0 jiM].
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Figure 33 PARP activity in the presence of 6-methyl-7-nitrothieno[3,4-c]- 
pyridin-4(5H)-one (97a) [9.5 pM].
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Figure 34 PARP activity in the presence of 6-phenylthieno[3,4-c]pyridin-
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Figure 35 PARP activity in the presence of 6-pheny-l-nitrothieno[3,4-c] 
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Figure 36 PARP activity in the presence of 6-phenyl-7-nitrothieno[3,4-c]
pyridin-4(5H)-one (97b) [8.8 pM].
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Figure 37 PARP activity in the presence of 2-methylthieno[3,4-d]pyrimidin- 
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Figure 38 PARP activity in the presence of 2-methylthieno[3,4-d]pyrimidin- 
4(5H)-one (103b) [8.8 pM].
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Figure 39 PARP activity in the presence of 7,8-dihydroimidazo[l,5-c]pyrimidin- 
5(6H)-one (116a) [0.4 |xM].
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Figure 40 PARP activity in the presence of l-nitro-7,8-dihydroimidazo- 
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ISOTOPICALLY EFFICIENT SYNTHESES OF 
(,sNl-NITROTHIOPHENECARBOXAMIDES
Anne E. Shinkwin and Michael D. Threadgill*
School o f Pharmacy & Pharmacology, University o f Bath,
Clover ton Down, Bath BA2 7AY, U. K.
SU M M A RY
Reaction o f  3-cyanothiophene with one equivalent o f  potassium nitrate in concentrated 
sulphuric acid causes nitration, concurrent with hydrolysis o f  the nitrile, to give 5-nitro- 
thiophene-3-carboxamide in high yield. Similarly, 2-cyanothiophene gives 4-nitro- 
thiophene-2-carboxamide and 5-nitrothiophene-2-carboxamide, benzonitrile gives 3- 
nitrobenzamide and 4-methylbenzonitrile gives 4-methyl-3-nitrobenzamide. Extension o f 
this process to  use o f  potassium [I5N]-nitrate, formed from [lsN]-nitric acid (95% 
isotopic enrichment), enables preparation o f  the corresponding [ ,5N]-nitrothiophene- 
carboxamides in high isotopic yield.
In troduction
As part o f  a programme o f  synthesis and evaluation o f nitro-heterocycles as radiosensitisers, 
bioreductively-activated cytotoxins and inhibitors o f  repair o f  DNA2-6, we required the three possible 
isomeric nitro-thiophene-carboxamides with the functional groups in the ‘meta’ relationship. These 
compounds can be regarded as heterocyclic analogues o f  3-nitrobenzamide. We also required the 
corresponding [lsN]-nitro compounds for metabolic and other studies. Thiophenes are usually 
nitrated using acetyl nitrate in acetic acid or acetic anhydride7'9, the nitric acid required for the 
formation o f  the reagent being taken in excess. Excess nitric acid in concentrated sulphuric acid has 
been used by Campaigne and M onroe10 to form 5-nitrothiophene-3-carboxamide 2c from thiophene-
3-carboxamide. Both processes would be inefficient if applied to a 15N-labelled synthesis. However, 
nitration o f  thiophene-2-carboxamide to form solely 4-nitrothiophene-2-carboxamide 2c in high
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CONH-CN
CONH2CN 0 ,N '
2b
.CONH,.CN K N 0 j /H 2S 0 4
NOz
Scheme 1. Concurrent nitration and hydrolysis 
of cyanothiophenes and benzonitriles.
2d: R = H 
21 : R = Me
Id: R = H 
le: R * Me
yield, using only one equivalent o f  potassium nitrate, has been reported by Dell’Erba et a l 7 Similarly, 
Ostm an" has described efficient nitration o f  3-cyanothiophene la  and 2 -cyanothiophene lb  with one 
equivalent o f nitric acid in trifluoroacetic acid, although mixtures o f isomers o f  the corresponding 
cyanonitrothiophenes were produced. In this paper, we report our development o f  a method for 
direct conversion o f  cyano(hetero)arenes to  nitro(hetero)arenecarboxamides.
Results and  Discussion
The initial approach to  development o f  potential isotopically efficient syntheses o f  the isomeric nitro- 
thiophene-carboxamides was to investigate a two-step sequence from 3-cyanothiophene la  and 2- 
cyanothiophene lb ,  involving nitration, followed by hydrolysis o f  the nitrile. However, since the 
method o f Ostman11 (HNO3 /  CF3CO2H) gives mixtures o f  isomers o f cyanonitrothiophenes, the 
method o f  Dell’Erba7 was applied to the cyanothiophenes la ,b . Unexpectedly, treatment o f  3- 
cyanothiophene l a  in concentrated sulphuric acid with one equivalent o f potassium nitrate gave 5- 
nitrothiophene-3-carboxamide 2a in 91% yield, rather than the corresponding nitrile, as shown in 
Scheme 1. No cyanonitrothiophenes were isolated. Clearly, the vigorously acidic conditions had been 
sufficient to hydrolyse the nitrile to the carboxamide. Application o f  this process to 2-cyano­
thiophene lb  gave a mixture o f  5-nitrothiophene-2-carboxamide 2b and 4-nitrothiophene-2- 
carboxamide 2c in good yield in ca. 4:3 ratio. These were easily separable by chromatography. No 
cyanonitrothiophenes were evident in the product mixture. The process was extended to the benzene 
series by high-yielding direct conversions o f  benzonitrile Id  to 3-nitrobenzamide 2d and 4-methyl- 
benzonitrile le  to 4-methyl-3-nitrobenzamide 2e.
For the syntheses introducing 1SN, potassium [ lsN]-nitrate was prepared by neutralisation o f [ l5N]- 
nitric acid (95 atom %) with the calculated amount o f potassium carbonate in water, followed by 
removal o f  the solvent by freeze-drying. Addition o f  this material to 3 -cyanothiophene la  in 
concentrated sulphuric acid gave 5-[ISN]-nitrothiophene-3-carboxamide 3a in excellent chemical and
[,sNJ-Nitrothiophene Carboxamides 1017
isotopic yields (82%), as shown in 
Scheme 2. Similar [ ISN]-nitration 
of lb  gave satisfactory chemical 
yields o f the isomeric [I5N]-nitro- 
thiophene-carboxamides 3b,c, after 
chromatographic separation. The 
total isotopic yield for this process 
was 52%.
The lsN-labelled isotopomers 3a-c 
were characterised by comparison 
o f  spectra and mpts with those o f  the unlabelled materials 2a-c. In addition, lsN  NM R and mass 
spectrometry demonstrated that each product contained only one 15N, as required. The ,5N NMR 
signals all appeared in the range 8 365 to 8 368, as appropriate for A r'5N02. No coupling of ,5N to 
other nuclei was seen in the 1SN  spectra, probably owing to  insufficient digital resolution. However, 
couplings to ,5N w ere observed through lH and 13C spectra. In the 5-nitrothiophene-3-carboxamide 
3a, ,SN coupled to protons on the thiophene ring with the three-bond coupling constant 3J  = 1.1 Hz. 
In contrast, l5N-*H coupling was only evident to the 3-H in 3c and to the 4-H in 3c, with 3J  = 1.1 Hz 
in both cases. One-bond I5N -13C coupling was clearly seen for all three compounds, with 
XJ  = ca. 20 Hz. The only three-bond ,SN -,3C coupling was in the spectrum of 3a, between ISN  in the 
nitro group and the quaternary carbon 3-C bearing the carboxamide; 3J  = 3.7 Hz.
CN CONH2
r i  r iV  O ^ N - V
la 3a
<V*N
^  k '’n < v h 2s o 4
\ s^ c n  o 2« N '< s> 'C onh2+  \ s^ ~ oonh2
lb 3b 3c
Scheme 2. Synthesis of 
[ 15N]-nitrothiophene-carboxamides.
Conclusion
Direct rapid one-pot conversions o f cyanothiophenes to nitrothiophene-carboxamides and o f  
benzonitriles to 3-nitrobenzamides have been developed. In the thiophene cases, these have been 
extended to provide highly isotopically efficient syntheses o f  [ ,5N]-nitrothiophene-carboxamides. The 
source of ISN is potassium [ lsN]-nitrate, which is derived from the readily available and inexpensive 
[ l5N]-nitric acid. This technique may have more general applications in introduction of lsN in 
syntheses using stoichiometric amounts o f [ ,JN]-reagents.
Experim ental
[ ,5N]-Nitric acid (95 atom % , ca. 5 M) was purchased from MSD Isotopes. Infra-red spectra were 
obtained using potassium bromide discs. Jeol GX270 and EX400 instruments furnished the NMR 
spectra o f  solutions in (CD3)2SO. The l5N chemical shifts are referenced externally to  [ l5NJ- 
ammonium nitrate (2.9 M in 1.0 M aqueous hydrochloric acid: 8n +24.90)’2. Mass spectra were
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obtained in the electron impact (E l) mode, except where noted. Melting points are uncorrected. 
Solvents were evaporated under reduced pressure. The chromatographic stationary phase was silica 
gel.
5-N itrothiophene-3-carboxam ide (2a). Potassium nitrate (1.85 g, 18.3 mmol) was added to 3- 
cyanothiophene la  (2.00 g, 18.3 mmol) in concentrated sulphuric acid (20 ml). The mixture w as 
stirred at ambient temperature for 16 h before being poured onto ice and extracted with ethyl 
acetate. The extract was washed with water and with 10% aqueous sodium carbonate and was dried 
(MgSO«). Evaporation and recrystallisation (ethanol) gave 5-nitrothiophene-3-carboxamide 2a 
(2.86 g, 91%) as a pale buff solid: mp 161-162°C (lit.13 mp 162-163°C); vM  3450, 3300, 1700, 
1670 c rn 1; 6H 7.63 (1 H, s, NH), 8.11 (1 H, s, NH), 8.47 (1 H, d, J  -  0.8 Hz, 2-H), 8.51 (1 H, d, 
. /=  0.8 Hz, 4-H); 8c 128.11, 136.66, 136.90, 151.19, 161.85; m/z 172 (M).
5-N itrothiophene-2-carboxam ide (2b) and 4-nitrothiophene-2-carboxam ide (2c). 2-Cyano- 
thiophene lb  was treated w ith potassium nitrate and concentrated sulphuric acid, as for the synthesis 
of 2a. Chromatography (hexane /  ethyl acetate 3:2) gave 4-nitrothiophene-2-carboxamide 2c (41% ) 
as a white solid: mp 151-152°C (lit.7 mp 152-153°C); 3480, 1715, 1620 cm*1; 8H 7.82 (1 H, s,
NH), 8.33 (1 H, s, NH), 8.42 (1 H, d , / =  1.5 Hz, 5-H), 8.94 (I H, d , / =  1.5 Hz, 3-H);m/z 172 (M). 
From later fractions was obtained 5-nitrothiophene-2-carboxamide 2b (32%) as a white solid: 
mp 191-193°C (compound reported by Occhipinti et al.u  and by Johnson et a / .15 but no mp given); 
Vmax 3460, 1660, 1620 cm*1; 8H 7.79 (1 H, d, J  = 4.4 Hz, 3-H), 7.99 (1 H, s, NH), 8.14 (1 H, d, 
J = 4.4 Hz, 4-H), 8.45 (1 H, s, N-H); m/z 172 (M).
3-N itrobenzaraide (2d). Benzonitrile Id  was treated with potassium nitrate and concentrated 
sulphuric acid, as for the synthesis of 2a, to give 3-nitrobenzamide 2d (73%) as an pale orange solid: 
mp 136-138°C (lit.16 mp I42-I43°C ); w  3460, 3350, 1695, 1625 cm*1; 8H 7.75 (1 H, s, NH), 7.78 
(1 H, t, J=  7.7 Hz, 5-H), 8.32 (1 H, dd, J  8.8, 1.1 Hz, 6-H), 8.37 (1 H, s, NH), 8.39 (1 H, ddd, 
7 =  1.1, 1.5, 8.6 Hz, 4-H), 8.70 (1 H, ca. t ,J c a .  1.5 Hz, 2-H); 5c 122.24, 125.89, 130.06, 133.81, 
135.77, 147.80, 165.71; m/z 166 (M).
4-M ethyl-3-nitrobenzam ide (2e). 4-Methylbenzonitrile le  was treated with potassium nitrate and 
concentrated sulphuric acid, as for the synthesis of 2a, to give 4-methyl-3-nitrobenzamide 2e (96%) 
as an off-white solid: mp 161-163°C (lit.17 mp 168-169°C); v™* 3450, 1685, 1615 cm '1; 5h 2.57 
(3 H, s, Me), 7.61 (1 H, d , / =  8.1 Hz, 5-H), 7.65 (I H, s, NH), 8.13 (I H, dd, 7  = 7.7, 1.8 Hz, 6-H), 
8.24(1 H, s, NH), 8.47(1 H , d , y =  1.8 Hz, 2-H); 8C 19.54, 123.45, 131.89, 133.03, 133.44, 135.95, 
148.84, 165.69; m/z (C l) 181 (M + H).
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5-[l5N]-Nitrothiophene-3-carboxamide (3a). Potassium [l5N]-nitrate (79 mg, 0.77 mmol, 
95 atom % ) was added to 3-cyanothiophene la  (840 mg, 0.77 mmol) in concentrated sulphuric acid 
(1.0 ml). Isolation, as for the synthesis of 2a, gave 5-[,5N]-nitrothiophene-3-carboxamide 3a 
(110 mg, 82%) as a pale buff solid: mp 158-160°C (lit.13 mp 162-163°C for 2a); 5H 7.62 (1 H, s, 
NH), 8.10 (1 H, s, NH), 8.46 (1 H, dd, J H.h =  18  Hz, «/h>n -  1.1 Hz, 4-H), 8.51 (1 H, dd, 
JH.H= 1.8 Hz, J h.n -  1.1 Hz, 2-H); 6c 128.05, 136.59 (d, l / C-N = 3.7 Hz, 3-C), 136.85, 151.10 (d, 
Vc-n -  20.3 Hz, 5-C), 161.79; 6N +365.07; m/z (El) 173 (M).
5-[lsN)-Nitrothiophene-2-carboxamide (3b) and 4-[>sNl-nitrothiophene-2-carboxamide (3c). 
Potassium [ lsN]-nitrate (280 mg, 2.75 mmol, 95 atom % ) was added to 2-cyanothiophene lb  
(840 mg, 0.77 mmol) in concentrated sulphuric acid (1.0 ml). Isolation and purification, as for the 
synthesis of 2b,c, gave 4-[l5N]-nitrothiophene-2-carboxamide 3c (180 mg, 38%) as a pale buff solid, 
mp 151-152°C (lit.7 mp 152-153°C for 2c), 6H 7.80 (1 H, s, NH), 8.32 (1 H, s, NH), 8.40 (1 H, d, 
7 =  1.5 Hz, 5-H), 8.93 (1 H, dd, Jh.h *  1 5  Hz, Jh-n = 11  Hz, 3-H); 6c 122.49, 133.16, 141.48, 
147.07 (d, 1 J c.n = 18.4 Hz, 4-C), 161.32; 6N +367.48; m/z (E l) 173 (M). Further elution gave
5-[,sN]-nitrothiophene-2-carboxamide 3b (69 mg, 14%) as an off-white solid: mp 188-190°C; 
8 h  7.78 (1 H, d, J  =  4.4 Hz, 3-H), 7.98 (1 H, s, NH), 8.14 (1 H, dd, JH*  =  4.4 Hz, N =  1.1 Hz,
4-H), 8.44 (1 H, s, NH); 6C 127.87 (d, VC-n = 3.7 Hz, 2-C), 130.27, 146.93, 152.93 (d,
lJc-n -  ca. 20 Hz, 5-C), 161.30; 6N +367.52; m/z (El) 173 (M).
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